CA2148713A1 - Allergenic proteins and peptides from japanese cedar pollen - Google Patents
Allergenic proteins and peptides from japanese cedar pollenInfo
- Publication number
- CA2148713A1 CA2148713A1 CA002148713A CA2148713A CA2148713A1 CA 2148713 A1 CA2148713 A1 CA 2148713A1 CA 002148713 A CA002148713 A CA 002148713A CA 2148713 A CA2148713 A CA 2148713A CA 2148713 A1 CA2148713 A1 CA 2148713A1
- Authority
- CA
- Canada
- Prior art keywords
- cry
- protein
- seq
- fragment
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 137
- 102000004169 proteins and genes Human genes 0.000 title claims description 130
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 112
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 54
- 240000005109 Cryptomeria japonica Species 0.000 title abstract description 74
- 230000002009 allergenic effect Effects 0.000 title description 6
- 239000012634 fragment Substances 0.000 claims abstract description 112
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 80
- 239000013573 pollen allergen Substances 0.000 claims abstract description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 101000692312 Cryptomeria japonica Polygalacturonase Proteins 0.000 claims abstract description 10
- 241000218692 Cryptomeria Species 0.000 claims abstract 15
- 239000002773 nucleotide Substances 0.000 claims description 92
- 125000003729 nucleotide group Chemical group 0.000 claims description 91
- 239000013566 allergen Substances 0.000 claims description 75
- 239000002299 complementary DNA Substances 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 45
- 108020004414 DNA Proteins 0.000 claims description 35
- 208000026935 allergic disease Diseases 0.000 claims description 33
- 230000004044 response Effects 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 230000000890 antigenic effect Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 230000005867 T cell response Effects 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 210000003630 histaminocyte Anatomy 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 210000003651 basophil Anatomy 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 229960001340 histamine Drugs 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 12
- 206010048908 Seasonal allergy Diseases 0.000 abstract description 11
- 235000018102 proteins Nutrition 0.000 description 97
- 235000001014 amino acid Nutrition 0.000 description 91
- 229940024606 amino acid Drugs 0.000 description 91
- 150000001413 amino acids Chemical class 0.000 description 88
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 108091034117 Oligonucleotide Proteins 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 31
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 28
- 206010020751 Hypersensitivity Diseases 0.000 description 24
- 238000012163 sequencing technique Methods 0.000 description 22
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 229960004784 allergens Drugs 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 108091033380 Coding strand Proteins 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 230000003321 amplification Effects 0.000 description 15
- 208000010668 atopic eczema Diseases 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 230000000172 allergic effect Effects 0.000 description 14
- 230000007815 allergy Effects 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000012286 ELISA Assay Methods 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241000218645 Cedrus Species 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000001632 sodium acetate Substances 0.000 description 9
- 235000017281 sodium acetate Nutrition 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 8
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
- 229960005542 ethidium bromide Drugs 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- OTSVBELRDMSPKY-PCBIJLKTSA-N Ile-Phe-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OTSVBELRDMSPKY-PCBIJLKTSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 235000011089 carbon dioxide Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 4
- 244000184734 Pyrus japonica Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000017274 T cell anergy Effects 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 108010051242 phenylalanylserine Proteins 0.000 description 4
- -1 promoters Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 101000641574 Apis mellifera Venom dipeptidyl peptidase 4 Proteins 0.000 description 3
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 3
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 3
- DZQKLNLLWFQONU-LKXGYXEUSA-N Asp-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N)O DZQKLNLLWFQONU-LKXGYXEUSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WVTIBGWZUMJBFY-GUBZILKMSA-N Glu-His-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O WVTIBGWZUMJBFY-GUBZILKMSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 3
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- QQQHYJFKDLDUNK-CIUDSAMLSA-N His-Asp-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N QQQHYJFKDLDUNK-CIUDSAMLSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010027338 isoleucylcysteine Proteins 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- GSHKMNKPMLXSQW-KBIXCLLPSA-N Ala-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C)N GSHKMNKPMLXSQW-KBIXCLLPSA-N 0.000 description 2
- IEAUDUOCWNPZBR-LKTVYLICSA-N Ala-Trp-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N IEAUDUOCWNPZBR-LKTVYLICSA-N 0.000 description 2
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 2
- BMNVSPMWMICFRV-DCAQKATOSA-N Arg-His-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CN=CN1 BMNVSPMWMICFRV-DCAQKATOSA-N 0.000 description 2
- LKDHUGLXOHYINY-XUXIUFHCSA-N Arg-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LKDHUGLXOHYINY-XUXIUFHCSA-N 0.000 description 2
- MEFGKQUUYZOLHM-GMOBBJLQSA-N Asn-Arg-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MEFGKQUUYZOLHM-GMOBBJLQSA-N 0.000 description 2
- LUVODTFFSXVOAG-ACZMJKKPSA-N Asn-Cys-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N LUVODTFFSXVOAG-ACZMJKKPSA-N 0.000 description 2
- XLZCLJRGGMBKLR-PCBIJLKTSA-N Asn-Ile-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XLZCLJRGGMBKLR-PCBIJLKTSA-N 0.000 description 2
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 2
- OOXUBGLNDRGOKT-FXQIFTODSA-N Asn-Ser-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OOXUBGLNDRGOKT-FXQIFTODSA-N 0.000 description 2
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 2
- PSLSTUMPZILTAH-BYULHYEWSA-N Asp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PSLSTUMPZILTAH-BYULHYEWSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 101001123585 Cryptomeria japonica Pectate lyase 1 Proteins 0.000 description 2
- SBDVXRYCOIEYNV-YUMQZZPRSA-N Cys-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N SBDVXRYCOIEYNV-YUMQZZPRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 2
- LXAUHIRMWXQRKI-XHNCKOQMSA-N Glu-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O LXAUHIRMWXQRKI-XHNCKOQMSA-N 0.000 description 2
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 2
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 2
- DBJYVKDPGIFXFO-BQBZGAKWSA-N Gly-Met-Ala Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O DBJYVKDPGIFXFO-BQBZGAKWSA-N 0.000 description 2
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 2
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 2
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 2
- OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 2
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- QLBXWYXMLHAREM-PYJNHQTQSA-N His-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N QLBXWYXMLHAREM-PYJNHQTQSA-N 0.000 description 2
- GYAFMRQGWHXMII-IUKAMOBKSA-N Ile-Asp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N GYAFMRQGWHXMII-IUKAMOBKSA-N 0.000 description 2
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- DCGXHWINSHEPIR-SRVKXCTJSA-N Leu-Lys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N DCGXHWINSHEPIR-SRVKXCTJSA-N 0.000 description 2
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 2
- QFGVDCBPDGLVTA-SZMVWBNQSA-N Lys-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 QFGVDCBPDGLVTA-SZMVWBNQSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- VTKPSXWRUGCOAC-GUBZILKMSA-N Met-Ala-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCSC VTKPSXWRUGCOAC-GUBZILKMSA-N 0.000 description 2
- FSTWDRPCQQUJIT-NHCYSSNCSA-N Met-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCSC)N FSTWDRPCQQUJIT-NHCYSSNCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108090000709 Phakinin Proteins 0.000 description 2
- 102100035832 Phakinin Human genes 0.000 description 2
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 2
- JIYJYFIXQTYDNF-YDHLFZDLSA-N Phe-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N JIYJYFIXQTYDNF-YDHLFZDLSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 2
- 102100037681 Protein FEV Human genes 0.000 description 2
- 101710198166 Protein FEV Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 2
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 2
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 2
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 2
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 2
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- SOUPNXUJAJENFU-SWRJLBSHSA-N Thr-Trp-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O SOUPNXUJAJENFU-SWRJLBSHSA-N 0.000 description 2
- CZSMNLQMRWPGQF-XEGUGMAKSA-N Trp-Gln-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CZSMNLQMRWPGQF-XEGUGMAKSA-N 0.000 description 2
- YVXIAOOYAKBAAI-SZMVWBNQSA-N Trp-Leu-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 YVXIAOOYAKBAAI-SZMVWBNQSA-N 0.000 description 2
- YPBYQWFZAAQMGW-XIRDDKMYSA-N Trp-Lys-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N YPBYQWFZAAQMGW-XIRDDKMYSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 2
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 2
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 201000004338 pollen allergy Diseases 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 108010071207 serylmethionine Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 108010045269 tryptophyltryptophan Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- FRFDXQWNDZMREB-ACZMJKKPSA-N Ala-Cys-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRFDXQWNDZMREB-ACZMJKKPSA-N 0.000 description 1
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 1
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 1
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- PMQXMXAASGFUDX-SRVKXCTJSA-N Ala-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCCN PMQXMXAASGFUDX-SRVKXCTJSA-N 0.000 description 1
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 1
- PVQLRJRPUTXFFX-CIUDSAMLSA-N Ala-Met-Gln Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PVQLRJRPUTXFFX-CIUDSAMLSA-N 0.000 description 1
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- BHTBAVZSZCQZPT-GUBZILKMSA-N Ala-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N BHTBAVZSZCQZPT-GUBZILKMSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- AUFACLFHBAGZEN-ZLUOBGJFSA-N Ala-Ser-Cys Chemical compound N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O AUFACLFHBAGZEN-ZLUOBGJFSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- YCTIYBUTCKNOTI-UWJYBYFXSA-N Ala-Tyr-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCTIYBUTCKNOTI-UWJYBYFXSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- 101100245453 Arabidopsis thaliana psbC gene Proteins 0.000 description 1
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 1
- OHYQKYUTLIPFOX-ZPFDUUQYSA-N Arg-Glu-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OHYQKYUTLIPFOX-ZPFDUUQYSA-N 0.000 description 1
- CVXXSWQORBZAAA-SRVKXCTJSA-N Arg-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N CVXXSWQORBZAAA-SRVKXCTJSA-N 0.000 description 1
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 1
- AWMAZIIEFPFHCP-RCWTZXSCSA-N Arg-Pro-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWMAZIIEFPFHCP-RCWTZXSCSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- POZKLUIXMHIULG-FDARSICLSA-N Arg-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCCN=C(N)N)N POZKLUIXMHIULG-FDARSICLSA-N 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- POOCJCRBHHMAOS-FXQIFTODSA-N Asn-Arg-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O POOCJCRBHHMAOS-FXQIFTODSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- PIWWUBYJNONVTJ-ZLUOBGJFSA-N Asn-Asp-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N PIWWUBYJNONVTJ-ZLUOBGJFSA-N 0.000 description 1
- QRHYAUYXBVVDSB-LKXGYXEUSA-N Asn-Cys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QRHYAUYXBVVDSB-LKXGYXEUSA-N 0.000 description 1
- XWFPGQVLOVGSLU-CIUDSAMLSA-N Asn-Gln-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XWFPGQVLOVGSLU-CIUDSAMLSA-N 0.000 description 1
- QPTAGIPWARILES-AVGNSLFASA-N Asn-Gln-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QPTAGIPWARILES-AVGNSLFASA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- GJFYPBDMUGGLFR-NKWVEPMBSA-N Asn-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O GJFYPBDMUGGLFR-NKWVEPMBSA-N 0.000 description 1
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 1
- OLISTMZJGQUOGS-GMOBBJLQSA-N Asn-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N OLISTMZJGQUOGS-GMOBBJLQSA-N 0.000 description 1
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 1
- FODVBOKTYKYRFJ-CIUDSAMLSA-N Asn-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N FODVBOKTYKYRFJ-CIUDSAMLSA-N 0.000 description 1
- ICDDSTLEMLGSTB-GUBZILKMSA-N Asn-Met-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ICDDSTLEMLGSTB-GUBZILKMSA-N 0.000 description 1
- BKZFBJYIVSBXCO-KKUMJFAQSA-N Asn-Phe-His Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O BKZFBJYIVSBXCO-KKUMJFAQSA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- DBWYWXNMZZYIRY-LPEHRKFASA-N Asp-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O DBWYWXNMZZYIRY-LPEHRKFASA-N 0.000 description 1
- AKPLMZMNJGNUKT-ZLUOBGJFSA-N Asp-Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AKPLMZMNJGNUKT-ZLUOBGJFSA-N 0.000 description 1
- DXQOQMCLWWADMU-ACZMJKKPSA-N Asp-Gln-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DXQOQMCLWWADMU-ACZMJKKPSA-N 0.000 description 1
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 1
- YFSLJHLQOALGSY-ZPFDUUQYSA-N Asp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N YFSLJHLQOALGSY-ZPFDUUQYSA-N 0.000 description 1
- PYXXJFRXIYAESU-PCBIJLKTSA-N Asp-Ile-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PYXXJFRXIYAESU-PCBIJLKTSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 1
- HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 description 1
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723198 Cupressus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- DEVDFMRWZASYOF-ZLUOBGJFSA-N Cys-Asn-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DEVDFMRWZASYOF-ZLUOBGJFSA-N 0.000 description 1
- QADHATDBZXHRCA-ACZMJKKPSA-N Cys-Gln-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N QADHATDBZXHRCA-ACZMJKKPSA-N 0.000 description 1
- PORWNQWEEIOIRH-XHNCKOQMSA-N Cys-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N)C(=O)O PORWNQWEEIOIRH-XHNCKOQMSA-N 0.000 description 1
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 1
- CWHKESLHINPNBX-XIRDDKMYSA-N Cys-Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CS)CCCCN)C(O)=O)=CNC2=C1 CWHKESLHINPNBX-XIRDDKMYSA-N 0.000 description 1
- BCWIFCLVCRAIQK-ZLUOBGJFSA-N Cys-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O BCWIFCLVCRAIQK-ZLUOBGJFSA-N 0.000 description 1
- JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 1
- FCXJJTRGVAZDER-FXQIFTODSA-N Cys-Val-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O FCXJJTRGVAZDER-FXQIFTODSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- SSWAFVQFQWOJIJ-XIRDDKMYSA-N Gln-Arg-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N SSWAFVQFQWOJIJ-XIRDDKMYSA-N 0.000 description 1
- ZPDVKYLJTOFQJV-WDSKDSINSA-N Gln-Asn-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ZPDVKYLJTOFQJV-WDSKDSINSA-N 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- VNCLJDOTEPPBBD-GUBZILKMSA-N Gln-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N VNCLJDOTEPPBBD-GUBZILKMSA-N 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- GQZDDFRXSDGUNG-YVNDNENWSA-N Gln-Ile-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O GQZDDFRXSDGUNG-YVNDNENWSA-N 0.000 description 1
- FYAULIGIFPPOAA-ZPFDUUQYSA-N Gln-Ile-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(O)=O FYAULIGIFPPOAA-ZPFDUUQYSA-N 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- ZVQZXPADLZIQFF-FHWLQOOXSA-N Gln-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 ZVQZXPADLZIQFF-FHWLQOOXSA-N 0.000 description 1
- NPMFDZGLKBNFOO-SRVKXCTJSA-N Gln-Pro-His Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NPMFDZGLKBNFOO-SRVKXCTJSA-N 0.000 description 1
- KUBFPYIMAGXGBT-ACZMJKKPSA-N Gln-Ser-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KUBFPYIMAGXGBT-ACZMJKKPSA-N 0.000 description 1
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 1
- LSYFGBRDBIQYAQ-FHWLQOOXSA-N Glu-Tyr-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LSYFGBRDBIQYAQ-FHWLQOOXSA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 1
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 1
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- JBJNKUOMNZGQIM-PYJNHQTQSA-N His-Arg-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JBJNKUOMNZGQIM-PYJNHQTQSA-N 0.000 description 1
- VOEGKUNRHYKYSU-XVYDVKMFSA-N His-Asp-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O VOEGKUNRHYKYSU-XVYDVKMFSA-N 0.000 description 1
- CZXKZMQKXQZDEX-YUMQZZPRSA-N His-Gly-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N CZXKZMQKXQZDEX-YUMQZZPRSA-N 0.000 description 1
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 1
- MLZVJIREOKTDAR-SIGLWIIPSA-N His-Ile-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MLZVJIREOKTDAR-SIGLWIIPSA-N 0.000 description 1
- UROVZOUMHNXPLZ-AVGNSLFASA-N His-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 UROVZOUMHNXPLZ-AVGNSLFASA-N 0.000 description 1
- JSQIXEHORHLQEE-MEYUZBJRSA-N His-Phe-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JSQIXEHORHLQEE-MEYUZBJRSA-N 0.000 description 1
- LNCFUHAPNTYMJB-IUCAKERBSA-N His-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNCFUHAPNTYMJB-IUCAKERBSA-N 0.000 description 1
- GYXDQXPCPASCNR-NHCYSSNCSA-N His-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N GYXDQXPCPASCNR-NHCYSSNCSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000880588 Homo sapiens CCAAT/enhancer-binding protein zeta Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- QLRMMMQNCWBNPQ-QXEWZRGKSA-N Ile-Arg-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N QLRMMMQNCWBNPQ-QXEWZRGKSA-N 0.000 description 1
- YPQDTQJBOFOTJQ-SXTJYALSSA-N Ile-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N YPQDTQJBOFOTJQ-SXTJYALSSA-N 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- FADXGVVLSPPEQY-GHCJXIJMSA-N Ile-Cys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FADXGVVLSPPEQY-GHCJXIJMSA-N 0.000 description 1
- PFTFEWHJSAXGED-ZKWXMUAHSA-N Ile-Cys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N PFTFEWHJSAXGED-ZKWXMUAHSA-N 0.000 description 1
- DURWCDDDAWVPOP-JBDRJPRFSA-N Ile-Cys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N DURWCDDDAWVPOP-JBDRJPRFSA-N 0.000 description 1
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 1
- DFFTXLCCDFYRKD-MBLNEYKQSA-N Ile-Gly-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N DFFTXLCCDFYRKD-MBLNEYKQSA-N 0.000 description 1
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
- WIZPFZKOFZXDQG-HTFCKZLJSA-N Ile-Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O WIZPFZKOFZXDQG-HTFCKZLJSA-N 0.000 description 1
- MTONDYJJCIBZTK-PEDHHIEDSA-N Ile-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)O)N MTONDYJJCIBZTK-PEDHHIEDSA-N 0.000 description 1
- GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 1
- FTUZWJVSNZMLPI-RVMXOQNASA-N Ile-Met-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N FTUZWJVSNZMLPI-RVMXOQNASA-N 0.000 description 1
- HQEPKOFULQTSFV-JURCDPSOSA-N Ile-Phe-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N HQEPKOFULQTSFV-JURCDPSOSA-N 0.000 description 1
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 1
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 1
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 1
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- FMFNIDICDKEMOE-XUXIUFHCSA-N Leu-Val-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMFNIDICDKEMOE-XUXIUFHCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- QZONCCHVHCOBSK-YUMQZZPRSA-N Lys-Gly-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O QZONCCHVHCOBSK-YUMQZZPRSA-N 0.000 description 1
- DAOSYIZXRCOKII-SRVKXCTJSA-N Lys-His-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O DAOSYIZXRCOKII-SRVKXCTJSA-N 0.000 description 1
- GNLJXWBNLAIPEP-MELADBBJSA-N Lys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCN)N)C(=O)O GNLJXWBNLAIPEP-MELADBBJSA-N 0.000 description 1
- XREQQOATSMMAJP-MGHWNKPDSA-N Lys-Ile-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XREQQOATSMMAJP-MGHWNKPDSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- ORVFEGYUJITPGI-IHRRRGAJSA-N Lys-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN ORVFEGYUJITPGI-IHRRRGAJSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- WLXGMVVHTIUPHE-ULQDDVLXSA-N Lys-Phe-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O WLXGMVVHTIUPHE-ULQDDVLXSA-N 0.000 description 1
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 1
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- DLAFCQWUMFMZSN-GUBZILKMSA-N Met-Arg-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N DLAFCQWUMFMZSN-GUBZILKMSA-N 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- JACAKCWAOHKQBV-UWVGGRQHSA-N Met-Gly-Lys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN JACAKCWAOHKQBV-UWVGGRQHSA-N 0.000 description 1
- DJBCKVNHEIJLQA-GMOBBJLQSA-N Met-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCSC)N DJBCKVNHEIJLQA-GMOBBJLQSA-N 0.000 description 1
- UROWNMBTQGGTHB-DCAQKATOSA-N Met-Leu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UROWNMBTQGGTHB-DCAQKATOSA-N 0.000 description 1
- ZGVYWHODYWRPLK-GUBZILKMSA-N Met-Pro-Cys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O ZGVYWHODYWRPLK-GUBZILKMSA-N 0.000 description 1
- QEDGNYFHLXXIDC-DCAQKATOSA-N Met-Pro-Gln Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O QEDGNYFHLXXIDC-DCAQKATOSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 101710109612 Neurofilament medium polypeptide Proteins 0.000 description 1
- 102100023055 Neurofilament medium polypeptide Human genes 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 101150005926 Pc gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- DJPXNKUDJKGQEE-BZSNNMDCSA-N Phe-Asp-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DJPXNKUDJKGQEE-BZSNNMDCSA-N 0.000 description 1
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 1
- GPSMLZQVIIYLDK-ULQDDVLXSA-N Phe-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O GPSMLZQVIIYLDK-ULQDDVLXSA-N 0.000 description 1
- OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- APZNYJFGVAGFCF-JYJNAYRXSA-N Phe-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(O)=O APZNYJFGVAGFCF-JYJNAYRXSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- WECYCNFPGZLOOU-FXQIFTODSA-N Pro-Asn-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O WECYCNFPGZLOOU-FXQIFTODSA-N 0.000 description 1
- SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 1
- WFHYFCWBLSKEMS-KKUMJFAQSA-N Pro-Glu-Phe Chemical compound N([C@@H](CCC(=O)O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 WFHYFCWBLSKEMS-KKUMJFAQSA-N 0.000 description 1
- HBBBLSVBQGZKOZ-GUBZILKMSA-N Pro-Met-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O HBBBLSVBQGZKOZ-GUBZILKMSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- IYCBDVBJWDXQRR-FXQIFTODSA-N Ser-Ala-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O IYCBDVBJWDXQRR-FXQIFTODSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 1
- YMEXHZTVKDAKIY-GHCJXIJMSA-N Ser-Asn-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O YMEXHZTVKDAKIY-GHCJXIJMSA-N 0.000 description 1
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- UGHCUDLCCVVIJR-VGDYDELISA-N Ser-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)N UGHCUDLCCVVIJR-VGDYDELISA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000942680 Sus scrofa Clusterin Proteins 0.000 description 1
- PXQUBKWZENPDGE-CIQUZCHMSA-N Thr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N PXQUBKWZENPDGE-CIQUZCHMSA-N 0.000 description 1
- MQBTXMPQNCGSSZ-OSUNSFLBSA-N Thr-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N MQBTXMPQNCGSSZ-OSUNSFLBSA-N 0.000 description 1
- JTEICXDKGWKRRV-HJGDQZAQSA-N Thr-Asn-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JTEICXDKGWKRRV-HJGDQZAQSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- CJEHCEOXPLASCK-MEYUZBJRSA-N Thr-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=C(O)C=C1 CJEHCEOXPLASCK-MEYUZBJRSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- CXUFDWZBHKUGKK-CABZTGNLSA-N Trp-Ala-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O)=CNC2=C1 CXUFDWZBHKUGKK-CABZTGNLSA-N 0.000 description 1
- XKTWZYNTLXITCY-QRTARXTBSA-N Trp-Val-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 XKTWZYNTLXITCY-QRTARXTBSA-N 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- JFDGVHXRCKEBAU-KKUMJFAQSA-N Tyr-Asp-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JFDGVHXRCKEBAU-KKUMJFAQSA-N 0.000 description 1
- UMXSDHPSMROQRB-YJRXYDGGSA-N Tyr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O UMXSDHPSMROQRB-YJRXYDGGSA-N 0.000 description 1
- CRHFOYCJGVJPLE-AVGNSLFASA-N Tyr-Gln-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CRHFOYCJGVJPLE-AVGNSLFASA-N 0.000 description 1
- LOOCQRRBKZTPKO-AVGNSLFASA-N Tyr-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LOOCQRRBKZTPKO-AVGNSLFASA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- GITNQBVCEQBDQC-KKUMJFAQSA-N Tyr-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O GITNQBVCEQBDQC-KKUMJFAQSA-N 0.000 description 1
- ARMNWLJYHCOSHE-KKUMJFAQSA-N Tyr-Pro-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O ARMNWLJYHCOSHE-KKUMJFAQSA-N 0.000 description 1
- NXPDPYYCIRDUHO-ULQDDVLXSA-N Tyr-Val-His Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 NXPDPYYCIRDUHO-ULQDDVLXSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- CPTQYHDSVGVGDZ-UKJIMTQDSA-N Val-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N CPTQYHDSVGVGDZ-UKJIMTQDSA-N 0.000 description 1
- YDPFWRVQHFWBKI-GVXVVHGQSA-N Val-Glu-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YDPFWRVQHFWBKI-GVXVVHGQSA-N 0.000 description 1
- MHAHQDBEIDPFQS-NHCYSSNCSA-N Val-Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C MHAHQDBEIDPFQS-NHCYSSNCSA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- OPGWZDIYEYJVRX-AVGNSLFASA-N Val-His-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N OPGWZDIYEYJVRX-AVGNSLFASA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000003678 bronchial smooth muscle cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002402 nanowire electron scattering Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j II
and fragments thereof. The present invention also provides purified Cry j II and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j II or at least one fragment thereof and fragments of Cry j) prepared synthetically. Cry j II and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis.
and fragments thereof. The present invention also provides purified Cry j II and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j II or at least one fragment thereof and fragments of Cry j) prepared synthetically. Cry j II and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis.
Description
W094/11512 2~71~ PCr/US93/11000 AI.LERGENIC PROTEINS AND PEPTIDES
FROM JAPANESE CEDAR POLLEN
.
Back~round of the Invention Genetically predisposed individuals, who make up about 10% of the population, become hypersensitized (allergic) to antigens from a variety of ~` environmental sources to which they are exposed. Those antigens that can induce immediate and/or delayed types of hypersensitivity are known as allergens. ~King, - T.P., Adv. Immunol. 23: 77-105, (1976)). Anaphylaxis or atopy, which includes the - symptoms of hay fever, asthma, and hives, is one form of immediate allergy. It can be caused by a variety of atopic allergens, such as products of grasses, trees. weeds, animal dander, insects, food, drugs, and chemicals.
The antibodies involved in atopic allergy belong primarily to the IgE class of immunoglobulins. IgE binds to mast cells and basophils. Upon combination of a - ~ ~; specific allergen with IgE bound to mast cells or basophils, the IgE may be cross-link~ed on the cell surface, resulting in the physiological effects of IgE-antigen interaction. These physiological effects include the release of, among other substances, histamine, serotonin, heparin, a chemotactic factor for eosinophilicleukocytes and/or the leukotrienes, C4, D4, and E4, which cause prolonged constriction of bronchial smooth muscle cells (Hood, L.E. et al. Immunology (2nded.), The Benjamin/Cumming Publishing Co., Inc. (1984)). These released substances are the mediators which result in allergic symptoms caused by a combination of IgE with a specific allergen. Through them. the effects of an allergen are manifested. Such effects may be systemic or local in nature, depending on the route by which the antigen entered the body and the pattern of deposition of IgE on mast cells or basophils. Local manifestations generally occur on epithelial surfaces at the location at which the allergen entered the body. Systemic effects can ~, include anaphylaxis (anaphylac~ic shock), which is the result of an IgE-basophilresponse to circulating (intravascular) antigen.
Japanese cedar (Sugi; C yptomeria japonica) pollinosis is one of the most r important allergic diseases in Japan. The number of patients suffering from thisdisease is on the increase and in some areas, more than 10% of the population are affected. Treatment of Japanese cedar pollinosis by administration of Japanese cedar pollen extract to effect hyposensitization to the allergen has been attempted.
Hyposensitization using Japanese cedar pollen extract, however, has drawbacks in WO 94/l1~12 ~ 1 1 8 71 c~ PCI/US93/11000 ~t that it can elicit anaphylaxis if high doses are used, whereas when low doses are used to avoid anaphylaxis, treatment must be continued for several years to build up a tolerance for the extract.
The major allergen from Japanese cedar pollen has been purified and s designated as Sugi basic protein (SBP) or Cry j I. This protein is reported to be a basic protein with a molecular weight of 41-S0 kDa and a pI of 8.8. There appear tO
be multiple isoforms of the allergen, apparently due in part to differential glycosylation (Yasueda et al. (1983) J. Allergy Clin. Immunol. 71: 77-86; and Taniai et al . (1988) FEBS Letters 239: 329-332 . The sequence of the first twenty amino lo acids at the N-terrninal end of Cry j I and a sixteen amino acid internal sequence have been determined (Taniai supra).
A second allergen has recently been isolated from the pollen of Cryptomeria japonica (Japanese cedar) (Sakaguchi et al. (1990) Allergy 45:309-312). This allergen, designated Cry j II, has been reported to have a molecular weight of s approximately 37 kl~a and 45 kDa when assayed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing and reducing conditions, respectively (Sukaguchi et al., supra). Cry j II was found to have no immunological cross-reactivity with Cly j I (Sakaguchi (1990) supra; Kawashima et ~`:
al. (1992) Int. Arch. Allergy Immunol. 98:110-117). Most patients with Japanese ;~ 20 cedar pollinosis were found to have IgE antibodies to both C~y j I and C~y j II.
- however, 29% of allergic patients had IgE that only reacted with Cry; I and 14% of ~ allergic patients had IgE that only reacted with C~y j II (Sakaguchi (1990) supra).
J Isoelectric focusing of Cry j II indicated that this protein has a pI above 9.5. as ~, compared to pI 8.6-8.8 for C)y; I (Sakaguchi (1990) supra). Further, the reported 2s NH2-terminal sequence for Cry j II, NH2-AlaIleAsnIlePheAsnValGluLysTyr-COOH, did not match that reported for C~y j I (Sakaguchi (1990) ~E~) Despite the attention Japanese cedar pollinosis allergens have received, definition or characteri~ation of the allergens responsible for its adverse effects on people is far from complete. Current desensitization therapy involves treatment with pollen extract with its attendant risks of anaphylaxis if high doses of pollen exlract are administered, or long desensitization times when low doses of pollen extract are ~-administered~ ,~
J
Sun~nar~ of the Invention The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j II and fragments thereof. The present invention also provides purified Cly j II and at least one fragment thereof /094/11512 21'1~713 Pcr/uss3/llooo produced in a host cell transformed with a nucleic acid sequence coding for C~y j II i or at least one fragment thereof and fra~ments of C y j II prepared synthetically.
~; ~ As used herein, a fragment of the nucleic acid sequence coding for the entire amin~o acid sequence of C~y j II refers to a nucleotide sequence having fewer bases than the 1-nucleotide sequence coding for the entire amino acid sequence of Cry j II and/ormature CrY J; II. Cry j II and fragments thereof are useful for diagnosing, treating~
and preventing Japanese cedar pollinosis. This invention is more particularly described in the appended claims and is described in its preferred embodiments in the following description.
Description of the Drawin~s Fig. la shows an SDS-PAGE (12%) analysis of C~yj II under non-reducing conditions.
Fig. lb shows an SDS-PAGE (12%) analysis of Cry j II under reducing conditions.
- Fig~ 2 shows the results of mono S column chromatography of Cry j II eluted with a step gradient of NaCI in 10mM sodium acetate buffer, pH 5Ø
Fig. 3 shows an SDS-PAGE (12%) of purified subfractions of C~yj II
analyzed under reducing conditions.
20 ~ ~ ~ Fig. 4 shows the nucleic acid sequence (SEQ ID N0: 1) and the deduced amino acid (SEQ ID N0: 2) coding for C~y j II.
Fig. S shows the deduced amino acid sequence of C~y j II (SEQ ID N0: 2).
Fig. 6 shows the long form (SEQ ID N0: 4) and short forrn (SEQ ID N0: 5) NH2-terrninii amino acid sequences of C~y j II deterrnined by protein sequence ;25 analysis as discussed in Example 2 aligned with the ten amino acid sequence of C~y j II (SEQ ID N0: 3) defined by Sakaguchi et al., supra (SEQ ID N0: 6).
Fig. 7 is a graphic representation of the results of a direct ELISA assay showing the binding response of the monoclonal antibody 4Bl l and seven patients' (Batch l) plasma IgE to purified Cry j I as the coating antigen.
Fig. 8 is a graphic representation of a direct ELISA assay showing the - ~ binding response of the monoclonal antibody 4Bl l, and seven patients' (Batch 1) plasma IgE to purified native Cry j II as the coating antigen. ~-Fig. 9 is a graphic representation of a direct ELISA assay showing the ~ binding response of the monoclonal antibody, 4Bll, and seven patients' (Batch 1) - ~ 3S plasma IgE to recombinant Cry j II (rCry j II) as the coating antigen.
Fig. lO is a graphic representation of a direct ELISA assay showing the binding response of eight patients' (Batch 2) plasma IgE to purified native C~y j E
~:
. : .
'~
~,~ ..... ". . . . .- . .. .. ~.. . . . .
WO 94/l 1512 ~ 1 4 ~ ~ 1 3 4 Pcr/us93/
Fig. 11 is a graphic representation of a direct ELISA assay showing the ' binding response of eight patients' (Batch 2) plasma IgE to purified native Cry j II.
Fig. 12 is a graphic representation of a direct ELISA assay showing the binding response of eight patients' (Batch 2) plasma IgE to recombinant Cry j II.
s Fig. 13 is a graphic representation of a direct ELISA assay showing the ~, binding response of eight patients' (Batch 3) plasma IgE to purified natilve Cr),~ j I.
Fig. 14 is a graphic representation of a direct ELISA assay showing the ` binding response of eight patients' (Batch 3) plasma IgE to purified na~ive Crv j II.
Fig. 15 is a graphic representation of a direct ELISA assay showing the 0 binding response of eight patients' (Batch 3) plasma IgE to recombinant Cry j II.
Fig. 16 is a table which summarizes both the MAST scores performed on patient's plasma samples (Batch 1-3) and the direct ~LISA results shown in Figs. 7-15; a positive response is indicated by a (+) sign and the number of positive responses for each antigen is shown at the bottom of each column.
Detailed Description of the Invention The present invention provides nucleic acid sequences coding for C~ j II, an allergen found in Japanese cedar pollen. The nucleic acid sequence coding for Cry j II shown in Fig. 4 (SEQ ID NO: 1) encodes a protein of 514 amino acids. The deduced C7y j II amino acid sequence is shown in Figs. 4 and 5 (SEQ ID NO: 2) .
Direct protein sequence analysis of native purified Cry j II resulted in two separate overlapping NH2-termini sequences, designated Long and Short, corresponding respectively to amino acids 46 through 89 (SEQ ID NO: 4) and 51 through 89 (SEQ
l ID NO: 5) of Figs. 4, 5 and 6. The ten amino acid sequence NH2-AlaIleAsnIlePhe-2s AsnValGluLysTry-COOH (SEQ ID NO: 6) previously defined by Sakaguchi et al, su~ra for c~y j II corresponds to amino acids 55 through 64 of Figs. 4 and 6. The full-length cry j II sequence contains 20 cysteine residues and three potential N-linked glycosylation sites with the consensus sequence of Asn-Xxx-Ser/Thr.
According to the program contained in PC Gene, Intelligenetics (Mountain View, CA) the proteins with the NH2-termini defined by the Long and Short forms of C~y j II would contain 469 and 464 amino acids, respectively, and have predicted molecular weights of 51.5 kDa (long) and 50.9 kDa (short). The amino acid sequence representing the long form of C~y j II is encoded by the nucleotide sequence extending from bases 177-1586 (SEQ ID NO: 7) as shown in Fig. 4, and the arnino acid sequence representing the short form of Cry j II is encoded by the nucleotide sequence extending from 192-1586 (SEQ ID NO: 8) as shown in Fig. 4.
A host cell transformed with a vector containing the cDNA insert coding for full-"~
: . . . .
~;-r~t ~ 1 4 ~ 7 1 3 2 ~ ~Cr/uss3/1 1000 1 --i --length C~y j II has been deposited with the American Type Culture Collection, ATCC No. 69105 .
Fragments of the nucleic acid sequence coding for fragments of Cry j II are~
also within the scope of the invention. Fragments within the scope of the invention mclude those coding for parts of Cry j II which induce an immune respanse in 1.
!- mammals, preferably humans, such as stimulation of minimal amounts of IgE;
;~ bindlng of IgE; eliciting the production of IgG and IgM antibodies; or the eliciting ~t: of a T cell response such as proliferation and/or Iymphokine secretion and/or the 1 ~ induction of T cell anergy. The foregoing fragments of Cry j II are referred to herein i ~lo as antigenic fragments. Fragments within the scope of the invention also include those capable of hybridizing with nucleic acid from other plant species for use in screening protocols to detect allergens that are cross-reactive with Cry j II. As used herein, a fragment of the nucleic acid sequence coding for Cry j II refers to a nucleotide sequence having fewer bases than the nucleotide sequence coding ~or the entire amino acid sequence of C~y j II and/or mature Cry j II. Generally, the nucleic acid sequence coding for the fragment or fragments of Cry j II will be selected from the bases coding for the mature protein, however, in some instances it may be desirable to select all or a part of a fragment or fragments from the leader sequence ; ponion of the nucleic acid sequence of the invention. The nucleic acid sequence of t he invention may also contain linker sequences, modified restriction endonuclease sites and other sequences useful for cloning, expression or purification of C~y j II or fragments thereof.
A nucleic acid sequence coding for Cry j II may be obtained from Cryptomeria japonica plants. Applicants have found that fresh pollen and staminate 2s cones are a good source of Cry j II mRNA. It may also be possible tO obtain the nucleic acid sequence coding for Cry j II from genomic DNA. C~yptomeria japonica is a well-known species of cedar, and plant material may be obtained from wild, cultivated, or ornamental plants. The nucleic acid sequence coding for Cry j II
~ may be obtained using the method disclosed herein or any other suitable techniques for isolation and cloning of genes. The nucleic acid sequence of the invention may be DNA or RNA.
The present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention. Nucleic acid coding for Cry j II, or at least one fragment thereof may be expressed in bacterial cells such as E.
3s coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. Molecular Cloning: A
. .
~1~8713 wo s4t l l 512 PCr/ US93/ 11000 Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art.
Expression in mammalian, yeast or insect cells leads to partial or complete glycosylation of the recombinant material and formation of any inter- or intra-chain disulfide bonds. ~Suitable vectors for expression in yeast include ~epSecl (Baldari et al. (1987) Embo J. 6: 229-234); pMFa (Kurjan and Herskowitz (1982~ Cell 30: 933-943); JRY88 (Schultz et al. (1987) Gene 54: 113-123) and pYES2 (lnvitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and0 mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego, CA) for expression in insect cells while the pMSG vector is commerically available (Pharmacia, ~, Piscataway, NJ) for expression in mammalian cells.
For expression in E. coli. suitable expression vectors include, among others, pTRC (Amann et al. (1988) Gene 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRlT5 (Pharmacia, Piscataway, NJ); pET-lld (Novagen, Madison, WI) Jameel et al., (1990) J. Virol. 64:3963-3966; and pSEM (Knapp et al. (1990) BioTechniques 8: 280-281). The use of pTRC, and pET-l ld, for example, will lead to the expression of unfused protein.The use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of allergen fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated B-galactosidase (PSEM), or glutathione S-transferase (pGEX). When Cry j II, fragment, or fragments thereof is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and Cly j II or fragment thereof. C~y j II or fragment thereof may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from for example Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann et al., (1988) supra; pET-lld, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, 3s NJ) . It may also be appropriate to express recombinant C~y j II in different E. coli hosts that have an aleered capacity to degrade recombinantly expressed proleins (e.g.
U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic WO 94/11512 2 1 4 8 7 1 3 PC~`~US93/t 1000 ~;
acid sequence to use codons preferentially utilized by E. coli, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.
Host cells can be transformed to express the nucleic- acid sequences of the invention using conventional techniques such as calcium phosphate or calcium ~5 chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation.
Suitable methods for transforrning the host cells may be found in Sambrook et al.
supra, and other laboratory textbooks. The nucleic acid sequences of the invention may also be synthesized using standard techniques.
The present invention also provides a method of producing purified Japanese 0~ ~ cedar pollen allergen C~y j II or at least one fragment thereof comprising the steps of culturing a host cell transformed with a DNA sequence encoding Japanese cedar pollen allergen C)y j II or at least one fragment thereof in an appropriate medium to produce a mixture of cells and medium containing said Japanese cedar pollen allergen Cry j II or at least one fragment thereof; and purifying the mixture toi5 ~ produce substantially pure Japanese cedar pollen allergen Cry j II or at least one fragment thereof. Host cells transformed with an expression vector containing DNA
coding ~for Cly j II or at least one fragment thereof are cultured in a suitable medium for the host cell. Cry j II protein and peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for Cly j II or fragments thereof. The terms isolated and purified are used interchangeably herein and refer to peptides, protein, protein fragments, and nucleic acid sequences substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors~
Cr~ j II protein may also be isolated from lapanese cedar pollen as described in Exarnple l . C~y j II isolated directly from Japanese cedar pollen is referred to herein as "purif~ed native" C~y j II. It is preferable that purified native C~y j II of ~
the invention be at least 80% pure, and more preferably at least 90% pure and even ' more preferably be purified to homogeneity (at least 99% pure).
Another aspect of the invention provides preparations comprising lapanese cedar pollen allergen Cry j II or at least one fragment thereof synthesized in a host cell transformed with a DNA sequence encoding all or a portion of Japanese cedarpollen allergen Cry j II, or chemically synthesued, and purified Japanese cedar pollen allergen Cry j II protein, or at least one aMigenic fragment thereof produced ~`
in a host cell transformed with a nucleic acid sequence of the invention, or chemically synthesized. In preferred embodiments of the invention the Cr~ j II
~__, WO 94/11512 2 1 1 g 7 1 3 PCr/US93/1 1000 ~;
8 . -protein is produced in a host cell transformed with the nucleic acid sequence coding for at least the mature C~y j II protein. t Fragments of an allergen from Cry j II, eliciting a desired antigenic response ', (referred to herein as antigenic fragments) are defined herein as any protein fragment ' s or peptide which can be derived from the Cry j II proteins, but does not include the ,.
ten amino acid fragments which extends from amino acid residues 55-64~ as shown in Figs. 4, 5 and 6, but may include any portion of that ten amino acid fragment in conjunction with another fragment derived from C)y j Il. Antigenic fragments of ~ ; C~y j Il may be obtained, for example, by screening peptides recombinantly ! ~ o produced from the corresponding fragment of the nucleic acid sequence of the invention coding for such peptides, or by screening peptides which have been synthesized chemically using techniques known in the art, or by screening peptides ;~ produced by chemical cleavage of the allergen. The allergen may be arbitrarily divided into fragments of a desired length with no overlap of the peptides, or preferably divided into fragments of a desired length with no overlap of the peptides, or preferably divided into overlapping fragments of a desired length.~ The fragments . are tested to determine their antigenicity (e.g. the ability of the fragment tO induce an immune response such as T cell proliferation as discussed in Example 7).
Antigenic fragments may also be predicted using an algorithm such as that discussed in a paper by Hill et al, ~ournal of Immunology, 147:184-197 (199l).
Algorithms for predicting peptides which elicit T cell activity such as the algorithm discussed by Hill et al. are based on the protein's sequence wherein certain patterns within the sequence are likely to bind MHC and therefore may contain T cell epitopes. The peptides predicted by the algorithm such as Cry j IIA and Cry j IIB
discussed in Example 7 may be produced recombinantly or synthetically and testedfor T cell activity as discussed in Example 7.
If fragments of Japanese cedar pollen allergen, e.g. C)y j Il are to be used fortherapeutic purposes, then the fragments of Japanese cedar pollen allergen which are capable of eliciting a T cell response such as stimulation (i.e., proliferation or '.
lymphokine secretion) and/or are capable of inducing T cell anergy are particularly desirable and fragments of Japanese cedar pollen which have min~mal IgE
stimulating activity are also desirable. Additionally, for therapeutic purposes, ~ -purified Japanese cedar pollen allergens, e.g. Cly j Il, and fragments thereof preferably do not bind IgE specific for Japanese cedar pollen or bind such IgE to a substantially lesser extent than the purified native Japanese cedar pollen allergen binds such IgE. If the purified Japanese cedar pollen allergen or fragment or fragments thereof bind IgE, it is preferable that such binding does not result in the ;~ W094/11~12 2 1 4 8 ~ 1 3 PCr/US93/11000 9 1:~
release of mediators (e.g. histamines) from mast cells or basophils. Minimal IgEstimulating activity refers to IgE stimulating activity that is less than the amount of IgE production stimulated by the native Cry j II protein.
"r~ Isolated antigenic fragments or peptides of the present invention which have s ~ T~ cell stimulating activity, and thus comprise at least one T cell epitope are particularb desirable. T cell epitopes are believed to be involved in initiation and "`'t~ perpetuation of the imrnune response to a protein allergen which is responsible for the ~linicàl~symptoms of allergy. These T cell epitopes are thought to trigger early ` ~ events ~at the level of the T helper cell by binding to an appropriate HLA molecule ~l0 ~ ~ on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulatlon. These events lead to T cell proliferation, Iymphokine secretion, local inflammatory reactions, recruitrnent of additional immune cells to the site, andactivation of the B cell cascade leading to production of antibodies. One isotype of - ~ ~ these~ antibodies, IgE, is fundamentally important to the development of allergic ~15~ symptoms and its production is influenced early in the cascade of events, at the level of ~the T:helper cell, by the nature of the Iymphokines secreted. An epitope is the ; ~ basic~elem~nt or smallest unit of recognition by a receptor, particularly immunoglobulins, histocompatibility antigens and T cell receptors, where the epitope comprises ~amino acids essential to receptor recognition. Amino acid sequences 20 ~ which mimic those of the epitopes particularly T cell epitopes and which modify the allergic response to protein allergens including those capable of down regulating allergic response to Cry j II, are within the scope of this invention.
As discussed in Example 7, human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to Japanese cedar pollenS ~ allergen, (i.e., an individual who has an IgE mediated immune response to Japanese cedar~ pollen allergen) with a peptide derived from the allergen and determining. ~ whether proliferation of T cells occurs in response to the peptide as measured, e.g., it by cellular uptake of tritiated thymidine. Stimulation indices for responses by T t cells to peptides can be c?lculated as the maximum CPM in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background level is considered "positive" . Positive results are used to L `
calculate the mean stimulation index for each peptide tested. Preferred peptides of ~ `
this invention comprise at least one T cell epitope and have a mean T cell stimulation index of greater than or equal to 2Ø A peptide having a mean T cell stimulation 3S ~ index of greater than or equal to 2.0 is considered useful as a therapeutic agent. As shown in Fig. 17 Cr~ j Il peptides Cry j IIA and Cry j IIB have mean stirnulation - ~ indexes of at least two and therefore comprise at least one T cell epitope as 8~ WO 94/1 1512 1 ~ 7 1 3 Pcr/us93/l lO00 3 lo predicted.
Purified protein allergens from Japanese cedar pollen or preferred antigenic ;
fragments thereof, when administered to a Japanese cedar pollen-sensitive individual, or an individual allergic to an allergen cross-reactive with Japanese cedar pollen ' l -5 ~ ` allergen, are capable of modifying the allergic response of the individual to Japanese cedar poilen or such cross-reactive allergen of the individual, and preferably are capable ~of modifying the B-cell response, T-cell response or both the B-cell and the T-cell response of the individual to the allergen. As used herein, modification of the~allergic response of an individual sensitive to a Japanese cedar pollen allergen o ~ can be defined as wn-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See e.g. Varney et al, British Medical Jou~nal, 302:265-269 (1990)) including dirninution in Japanese cedarpollen induced asthmatic symptoms. As referred to herein, a diminution in symptoms includes any reduction in allergic response of an individual to the allergen after the 15 ~ individual has completed a treatment regimen with a peptide or protein of the invention. This diminution may be subjective (i.e. the patient feels more comforta'ole in the presence of the allergen). Diminution in symptoms can be deterrnined clinically as well, using standard skin tests as is known in the art.
The purified C~y j II protein or fragments thereof are preferably tested in 20 mammalian models of Japanese cedar pollinosis such as the mouse model disclosed i n Tamura et al. (1986) Microbiol. Immunol. 30: 883-896, or U.S. patent 4,939,239; or the primate model disclosed in Chiba et al. (1990) Int. Arch. Allergy mmunol. 93: 83-88. Initial screening for IgE binding to the protein or fragmentsthereof may be perforrned by scratch tests or intradermal skin tests on laboratory 2S ~ animals or human vo!unteers, or in in vitro systems such as RAST
(radioallergosorbent test), RAST inhibition, ELISA assay, radioimmunoassay (RIA), or histamine release.
Exposure of allergic individuals to purified protein allergens of the present invention or to the antigenic fragments of the present invention which comprise at 30 least one T cell epitope and are derived from protein allergens may tolerize or anergize appropriate T cell subpopulations such that they become unresponsive to the protein allergen and do not participate in stimulating an immune response upon such exposure. In addition, administration of the protein allergen of the invention or an antigenic fragment of the preseM invention which comprises at least one T cell 35~ epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring protein allergen or portion thereof (e.g. result in a decrease of IL4 and/or an increase in IL-2). Furthermore, exposure to such antigenic :: .
~ :
_ . . . . . . . . . . . . . . .
~ 214~713 ; WO 94/11~12 ~ Pcr/uS93/llOOO
11 f-.
- ~ fragment or protein allergen may influence T cell subpopulations which norrnally participate in the response to the allergen such that these T cells are drawn away ¦ ~ from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and~ !
lung) towards the site(s) of therapeutic administration of the fragment or protein 5; ~ ~ allergen. This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate thc usual irmIlune response at the site of normal exposure to the allergen, resulting in a dirnunution in allergic symptoms.
The isolated Cry j II protein, and fragments or portions derived therefrom can 10 ~ ~ be used in methods of diagnosing, treating and preventing allergic reactions to Japanese cedar pollen allergen or a cross reactive protein allergen. Thus the present invention provides therapeutic compositions comprising purified Japanese cedar `~ ~ pollen allergen Cly j II or at least one fragment thereof produced in a host cell transformed to express C~y j II or at least one fragment thereof, and a ~15 ~ ~ pharmaceutically acceptable carrier or diluent. The therapeutic compositions of the mvention may also comprise synthetically prepared Cry j II or at least one fragment thereof and a pha~naceutically acceptable carrier or diluent. Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. C~ j II protein or at least one fragment thereof may be administered to an individual in combination with, for example, an appropriate diluent, a carrier and/or an adjuvant. Pharmaceutically acceptable - ~ diluents include saline and aqueous buffer solutions. Pharrnaceutically acceptable carriers include polyethylene glycol (Wie et al. (1981) Int. Arch. Allergy Appl.Immunol. 64~ 99) and liposomes (Strejan et al. (1984) J. Neuroimmunol 7: 27).
2 5 For purposes of inducing T cell anergy, the therapeutic composition is preferably administered in nonimmunogenic form, e.g. it does not contain adjuvant. Such compositions will generally be administered by injection (subcutaneous, intravenous, ~ . ~
etc.), oral administration, inhalation, transdermal application or rectal administration. The therapeutic compositions of the invention are administered to 3 0 Japanese cedar pollen-sensitive individuals at dosages and for lengths of time effective to reduce sensitivity (i.e, reduce the allergic response~ of the individual to Japanese cedar pollen. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to Japanese ; - cedar pollen, the age, sex, and weight of the individual, and the ability of the Cty j t.
II protein or fragment thereof to elicit an antigenic response in the individual.
The Cty j II cDNA (or the mRNA from which it was transcribed) or a portion thereof can be used to identify similar sequences in any variety or type of ,~
WO 94/1 1512 2 1 ~ 8 7 1 3 ~ PCr/US93/1 1000 plant and thus, to identify or "pull out" sequences which have sufficient homology to hybridize to the Cry j II cDNA or mRNA or portion thereof, for exarnple, DNA
~ ;~ from allergens of Cupressus sempervirens, Juniperus sabinoides etc., under ~ ~
conditions of low stringency. Those sequences which have sufficient homology ~ .
5~ (generally greater than 40%) can be selected for further assessment using the method described herein Alternatively, high stringency conditiolls can be used. In thismarmer, DNA of the present invention can be used to identify, in other types of - ~ plants, preferably related families, genera, or species such as Juniperus, or Cupressus, sequences encoding polypeptides having amino acid sequences similar to lo~ that of ~Japanese cedar pollen allergen Cry j II, and thus to identify allergens in other species. Thus, the present invention includes not only Cry j II, but also other allergens~ encoded~ by DNA which hybridizes to DNA of the present invention. Theinvention further includes previously unidentified isolated allergenic proteins or fragments thereof that are irnmunologically related to Crv j II or fragments thereof, 15 ~ such~as by antibody cross-reactivity wherein the isolated allergenic proteins or f~ments~ therèof are capable of binding to antibodies specific for the protein and peptides of ~the invention, or by T cell cross-reactivity wherein the isolated al!ergenic proteins or fragments thereof are capable of stimulating T cells specific for the protein and peptides of this invention.
20 ~ ~`Proteins or peptides~ encoded by the cDNA of the present invention can be used,~ for example as "purified" allergens. Such purified allergens aro useful in the standardization of allergen extracts which are key reagents for the diagnosis and treatment of Jàpanese cedar pollinosis~ Furthermore, by using peptides based on the nucleic acid sequences of Cry j II, antl-peptide antisera or monoclonal antibodies can 2s ~ be ~made using standard methods. These sera or monoclonal antibodies can be used to standardize~allergen extracts.
Through use of the peptides and protein of the present invention, preparations of consistent, well-de~med composition and biological activity can be made and administered for therapeutic purposes (e.g. to modify the allergic response of a- ~ 30 Japanese cedar sensitive individual to pollen of such trees). Administration of such peptides or protein may, for example, modify B-cell response to Cry j II allergen, modify T-cell response to C~y j II allergen or modify both B-cell and T-cell 1 -~
responses. Purified peptides can also be used to study the mechanism of immunotherapy of C~yptomeria japonica allergy and to design modified derivatives, ~ ~ t 35 ~ ~ or analogues useful in immunotherapy.
Work by others has shown that high doses of allergens generally produce the best results (i.e., best symptom relief). However, many people are unable to s'~
-~?~ :
WO 94/1 ISI 2 ~ 1 4 ~ 7 ~ 3 pcrtus93J1 1000 tolerate large doses of allergens because of allergic reactions to the allergens.
Modification of naturally-occurring allergens can be designed in such a manner that modified peptides or modified allergens which have the same or enhanced therapeutic properties as the corresponding naturally-occurring allergen but have ~: s ~ reduced side effects (especially anaphylactic reactions) can be produced. These can be, for example, a protein or peptide of the present invention (e.g., one having all or a portion of the amino acid sequence of Cry j II), or a modified protein or peptide, or protein or peptide analogue.
It is possible to modify the structure of a protein or peptide of the invention lo ~ ~ for such purposes as increasing solubility, enhancing therapeutic or preventive efficacy, or stability (e.g., shelf life ex vivo, and resistance to proteolytic degradadon in vivo). ~ A modified protein or peptide can be produced in which the ~; amino acid sequence has been altered, such as by amino acid substitution. deletion, or addition, to modify imrnuno~enicity and/or reduce allergenicity, or to which a component has been added for the same purpose. For example, the arnino acid residues essential to T cell epitope function can be determined using known techniques ~e.g., substitution of each residue and determination of the presence or absence of T cell re?ctivity).
For example, a peptide can be modified so that it maintains the ability to induce T cell anergy and bind MHC proteins without the ability to induce a strong proliferative response or possibly any proliferative response when administered in unmunogenic forrn. In this instance, critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue anddetermination of the presence or absence of T cell reactivity). Those residues shown 2s to be essential to interact with the T cell receptor can be modified by replacing the essential amino acid with another, preferably similar amino acid residue (a . ~.
conservative substitution) whose presence is shown to enhance, diminish but not eliminate binding to relevant MHC.
Additionally, peptides of the invention can be modified by replacing an amino acid shown to be essential to interact with the MHC protein complex with another, preferably sirnilar amino acid residue (conservative substitution) whose ` ~ ~ ~ presence is shown to enhance, diminish but not elirninate or not effect T cell ~r .
activity. In addition, amino acid residues which are not essential for interaction with the MHC protein complex but which still bind the MHC protein complex can be 3 5 modified by being replaced by another amino acid whose incorporation may enhance, not effect, or diminish but not eliminate T cell reactivity. Preferred amino - acid substitutions for non-essential amino acids include, but are not limited to ,;
., `' wos4/ll5l2 21~8713 Pcr/US93/llOOO ~ ``
substiNtions with alanine, glutamic acid, or a methyl amino acid.
Another example of a modification of protein or peptides is substitution of cysteine residues preferably with alanine, serine, threonine, leucine or glutamic acid to mini nize dimerization via disulfide linkages. Another example of modification of s the peptides of the invention is by chemical modification of amino acid side chains or cyclization of the peptide.
In order to enhance stability and/or reactivity, the protein or peptides of the invention Gan also be modified to incorporate one or more polymorphisms in the àrnino acid sequence of the protein allergen resulting from natural allelic variation.
o~; Addltionally, D-amino acids, non-natural amino acids or non-amino acid analogues can~be substituted or added to produce a modified protein or peptide within the scope of lhis lnvention. Furthermore, proteins or peptides of the present invention can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers ~; (Wie et al. supra) to produce a protein or peptide conjugated with PEG. In addition, 5 ~ PEG~ can be added during chemical synthesis of a protein or peptide of the invention.
M~ifications~ of proteins or peptides or portions thereof can also include reduction/
abklation (Tarr in: Methods of Protein Microcharacterization, J.E. Silver ed.
Hurnana Press, ~Clifton, NJ, pp 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an appropriate`carrier (Mishell and Shiigi, eds, Selected Methods inCellular Immunology, WH Freeman, San Francisco, CA (1980); U.S. Patent 4,939,239; or mild formalin treatment (Marsh International Archives of Allergy and Applied :lmmunology, 41:199-215 (1971)).
` To facilitate purification and potentially increase solubility of proteins or peptldes of the invention, it is possible to add reporter group(s) to the peptide 25~ backbone. For example, poly-histidine can be added to a peptide to purify the peptide on~immobilized metal ion affinity chromatography (Hochuli, E. et al., io/lechnology, 6:1321^1325 (1988)). In addition, specific endoprotease cleavage sitès can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences.
In order to successfully desensitize an individual to a protein antigen, it may be necessary to increase the solubility of a protein or peptide by adding functional :~
~ ~ ~ groups to the peptide or by not including hydrophobic T cell epitopes or regions containing hydrophobic epitopes in the peptides or hydrophobic regions of the protein or peptide.
3S~ To potentially aid proper antigen processing of T cell epitopes within a peptide, canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope. For ,~
,,., .','.~-~ ' .
~ !' W094/11512 2I~713 PCI`/US93/11000 1:
example, charged amino acid pairs, SUC~I as KK or RR, can be introduced between regions within a peptide during recombinant construction of the peptide. The resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell s epitopes. In addition, such charged arnino acid residues can result in an increase in ;- ~ solubility of a peptide.
Site-directed mutagenesis of DNA encoding a peptide or protein of the invention (e.g. Cry j II or a fragment thereof) can be used to modify the structure of the peptide or protein by methods known in the art. Such methods may, among o~ others, include PCR withdegenerate oliganucleotides (Ho et al., Gene, 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z. et al., Biochem. Biophvs, Res. Comm., 161:1056-1063 (1989)). Toenhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to chan~e ~- the eucaryotic codons in I;)NA constructs encoding protein or peptides of the l5 ~ invention to ones preferentially used in E. coli, yeast, marnmalian cells, or other `` ~ eukaryotic cells.
Using the structural information now available, it is possible to design Cr~
II peptides which, when administered to a Japanese cedar pollen sensitive individual in s~ufficient quantities, will modify the individual's allergic response to Japanese ~20~ cedar~pollen. This can be done, for example, by examining the structure of C~yj II, producing~peptides (via an expression system, synthetically or otherwise) to be ex`amined for their ability to influence B-cell and/or T-cell responses in Japanese cedar pollen sensitive individuals and selecting appropriate peptides which contain ~ epitopes recogr~ized by the cells. It is now also possible to design an agent or a drug ;~ 25 ~ ~ ~ capable of blocking or inhibiting the ability of Japanese cedar pollen allergen to induce an allergic reaction in Japanese cedar pollen sensitive individuals. Suchagents could be designed, for example, in such a maMer that they would bind to relevant anti-Cry j II IgEs, thus preventing IgE-allergen binding and subsequent mast cell degranulation. Alternatively, such agents could bind to cellular components of the imrnune system, resulting in suppression or desensitization of the allergic response to Cryptomeria japonica pollen allergens. A non-restrictive exarnple of~;~ ~is is the use of appropriate B- and T-cell epitope peptides, or modifications ~ `
thereof, based on the cDNA/protein structures of the present invention to suppress the allergic response to Japanese cedar pollen. This can be carried out by defining 35 ~ the strucmres of B- and T-cell epitope peptides which affect B- and T-cell function in - in vitro studies with blood components from Japanese cedar pollen sensitive individuals .
:
:
' ~ ! .
WO 94/11512 2 1 4 8 71 3 pcr/us93/11000 16 ~`
Protein, peptides or antibodies of the present invention can also be used for detecting and diagnosing Japanese cedar pollinosis. For example, this could be done by combining blood or blood products obtained from an individual to be assessed^ for sensitivity to Japanese cedar pollen with an isolated antigenic peptide or peptides of Cly j II, or isolated Cry j II protein, under conditions appropriate for binding of t components in the blood (e.g., antibodies, T-cells, B-cells) with the peptide(s) or i! protein and determining the extent to which such binding occurs. Other diagnostic ~- methods for allergic diseases which the protein, peptides or antibodies of the present invention can be used include radio-allergosorbent test (RAST), paper j 10 radioimmunosorbent test (PRIST), enzyme linked immunosorbent assay (ELISA), 1 radioimrnunoassays (RIA), immuno-radiometric assays (IRMA), luminescence ¦ immunoassays (LIA), histamine release assays and IgE imrnunoblots.
In another diagnostic test, the presence in individuals of IgE specific for Cry j II at least one protein allergen and the abilitv of T cells of the individuals to respond to T cell epitope(s) of C~y j Il protein allergen can be determined by adminis~ering to the individuals an Irnmediate Type Hypersensitivity test and a Delayed Type Hypersensitivity test. The individuals are administered an Immediate Type Hypersensitivity test (see e.g. Immunology (1985) Roitt, I.M., Brostoff, J., Male, D.K. (eds), C.V. Mosby Co., Gower Medical Publishing, London, NY, pp.
~ 20 19.2-19.18; pp. 22.1-22.10) utilizing the Cry i II protein allergen or a portion `-~ ~ thereof, or a modified form of the Cry j Il protein allergen or a portion thereof, each of which binds IgE specific for the allergen. The same individuals are administered a Delayed Type Hypersensitivity test prior to, simultaneously with, or subsequent to administraiton of the Imrnediate Type Hypersensitivity test. Of course, if the Irnmediate Type Hypersensitivity test is administered prior to the Delayed Type Hypersensitivity test, the Delayed Type Hypersensitivity test would be given to those individuals exhibiting a specific Immediate Type Hypersensitivityreaction. The Delayed Type Hypersensitivity test utilizes a modified form of theprotein allergen or a portion thereof, the protein allergen produced recombinantly, or a recombitope peptide derived from the protein allergen, each of which has human T
cell stimulating activity and each of which does not bind IgE specific for the allergen in a substantial percentage of the population of individuals sensitive to the allergen 7 "
(e.g., at least about 75 %). Based on the results of the above diagnostic tests, those individuals found to have both a specific lmmediate Type Hypersensitivity reaction 3s and a specific Delayed Type Hypersensitivity reaction are suitable candidates for administration of a therapeutically effective amount of a therapeutic composition The thFrapeutic composition comprises the modified forrn of the protein or portion WO94tllS12 21 4 ~, ~1 3 pcr/uss3/1looo thereof, the recombinantly produced protein allergen, or the recombitope peptide~
each as used in the Delayed Type Hypersensitivity test, and a pharmaceutically acceptable carrier or diluent. ~ 3 The present invention also provides a method of producing C~y j II or fragment thereof comprising culturing a host cell containing an expression vector which contains DNA encoding all or at least one fiagnient of C~yJ II under conditions appropriate for expression of C~y j II or at least one fragment. The expressed product is then récovered, using known techniques. Alternatively, Cry j II
or fragment thereof can be synthesized using known mechanical or chemical techniques.
;~ The DNA used in any embodiment of this invention can be cDNA obtained as described herein, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or ls ~ enzymatically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which is 1) a sequence capable of hybridizing to a complemeMary oligonucleotide to which the sequence (or corresponding sequence ~portions) of Cry j II or fragments thereof hybridizes, or 2) the sequence (or corresponding sequence portion) complementary to C~y j II? and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or correspondin~ sequence portion) of C~y j II. Whether a functional equivalent must meet one or both criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first or second criteria and if it is to be used to produce a Cty j II allergen, ~25 it need only meet the third criterion).
The invention is further illustrated by the following non-limiting examples.
Example 1 Purification of Native Japanese Cedar Pollen Aller~en (CrY i II) :
The following purification of native C~y j II from Japanese cedar pollen was ~, modified from previously published reports (Yasueda et al, J. Allergy Ctin.
Immunol. 71:77 (1983); Sukaguchi et al., Allergy, 45:309 (l990)).
100g of Japanese cedar pollen obtained from Japan (Hollister-Stier, Spokane, WA) was defatted in lL diethyl ether three times, the pollen was collected afterfiltration and the ether was dried off in a vacuum.
The defatted pollen was extracted at 4C overnight in 2L extraction buffer :
.
~,.. .~ .. , - . . . ~ -,. .:
WO 94/11512 Pcr/uss3/1looo ~ '~!~ ~,','' 2148713 1~ :
containing 50 mM tris-HCl, pH 7.~, 0.2 M NaCl and protease inhibitors in final .~; concentrations: soybean trypsin inhibitor (2 !lg/mL), leupeptin (1 ,ug/mL), pepstatin A (1 ~Lg/mL) and phenyl methyl sulfonyl fluoride (0.17 mg/mL). The insoluble~
material was re-extrated with 1.2L extraction buffer at 4C overnight and both ~,1 s extracts were combined together and depigmented by batch absorption with 'J
Whatman DE-52 (200g dry weight) equilibrated wilh the extraction buffer.
,~ The depigmented material was then fractionated by ammonium sulfate precipitation at 80% saturation (4C), which removed much of the lower molecularweight material. The resulting pellet was resuspended in 0.4 L of 50 mM Na-3 lo acetate, pH 5.0 containing protease inhibitors and was dialyzed extensively against the same buffer.
The sample was further subjected to purification by either one of the two methods described below.
Method A
The sample was applied to a 100 rnL DEAE cellulose column (Whatman DE-52) equilibrated at 4C with 50 mM Na-acetate, pH 5.0 with protease inhibitors.
The unbound material (basic proteins) from the DEAE cellulose column was then applied to a 50 ml cation exchange column (Whatman CM-52) which was equilibrated with 10 rnM Na-acetate, pH 5.0 at 4C with protease inhibitors. A
linear gradient of 0-0.3 M NaCI was used to elute the proteins. The early fractions were enriched in C~y j I whereas the later fractions were enriched in Cly j II.
Fractions containing Cr,v j II were pooled and next applied to an 1 mL Mono S HR5/5 column (Pharmacia, Piscataway, NJ) in 10 mM Na-acetate, pH 5.0, and proteinswere eluted with a linear gradient of NaCI at room temperature. Residual Cry j Iwas eluted at -0.2 M NaCI and Cry j II was eluted between 0.3 to 0.4 M NaCI.
The C~ j II peak was pooled and concentrated to twofold by Iyophilization and subjected to gel filtration chromatography.
The sample was applied to FPLC Superdex 75 16/60 column (Pharmacia, Piscataway, NJ) in 10 mM acetate buffer, pH 5.0 and 0.15 M NaCI at a flow rate of 30 ml/min. at room temperature. Purified Cr,v j II was recovered in the 35-30 kDregion. Cr,v j II migrated as ~wo broad bands lower than Cry j I under non-reducing j conditions (Fig. la) but both bands shifted upward and migrated as C~y j I under '1 reducing condition (Fig. lb) when analyzed by silver-stained SDS-PAGE. This 3s highly puri~led C~y j II still contained a small amount (~5 %) of Cry j I as detected by Western blot using MAb CBF2, which has been shown to bind to C~y j I and by N-terminal protein sequencing. This C~y j II preparation was used to generate primary ;~, . ~ ... . . .;
WO94/11512 21'1~ 713 pcr/us93/llooo 19 !`
protein sequence of Cry J II as described below.
Method B ~ j The dialyzed sample from the amrnonium sulfate precipitation was applied at ~-1 ml/min to an 5.0 ml Q-Sepharose Econapac anion exchange cartridge (BioRad, Richmond, CA) equilibrated with 50 mM Na-acetate, pH 5.0 with protease inhibitors at 4C. Elution was performed with the above buffer containing 0.5 M
NaCI. The basic unbound material was then applied to a 5.0 ml CM-Sepharose Econopac cation exchange cartridge (BioRad, Richmond, CA) equilibrated in 50 rnM~10 `~ ~ sodium~acetate pH 5.0 with protease inhibitors. Basic proteins were eluted with a linear gradient up to 0.1 M sodium phosphate pH 7.0, 0.3 M NaCI at 1 ml/min at 4C. A CtyJ II -enriched peak was collected late in the gradient and further purified by gel filtration chromatography.
FPLC gel filtration was performed using a 320 mL Superdex 75 26/60 15~ (Pharmacia, Piscataway, NJ) column at 0.5 ml/min in 20 mM sodium acetate, pH
5.0, in~the presence of 0.15 M NaCI. The major peak containing mostly Cry j II
eluted between 160 and 190 ml. Contaminating Cry j I was next removed by FPLC
using a 1.0 ml Mono S 515 (Pharmacia, Piscataway, NJ) cation exchaIlge column ; equilibrated with 10 mM sodium acetate pH 5Ø A stepwise gradient of 0^1 M
~o ~ NaCl was~utilized by~holding isocratically at 0.2 M, 0.3 M, 0.4 M and 1 M salt concenttation.
Multiple peaks (up to nine peaks) were obtained (Fig. 2) and analyzed by silver stained SDS-PAGE under reducing conditions (Fig 3). Cry j I with a ~ reported pI of 8.6-8.9 (Yasueda et al, J. Allergy Clin. Immunol., vol. 17 (1983)), 25 ~ ~eluted in the earlier peaks and displayed a molecular weight of about 40 kD. Cry j II
was purified to homogeneity as two bands (Fig. 3) and eluted in the later multiple peaks, suggesting the existence of isofor ns. ELlSA analysis using the mouse monoclonal 8Bl I IgG antibody which was raised against biochemically purified Cry ~ j I confirmed the absence of Cry j I in these purified Cry j II preparation. This ¦ 30 purified C~ j Il was used in the human IgE reactivity studies (Example 6).
Phvsical properties of Cns j II ~`~
The physiochemical properties of Cr~ j II were studied and sumrnarized as ¦ ~ ~ below. Under non-reducing SDS-PAGE conditions Cr~ j II consists of two bands with molecular weights ranged 34000-32000. The molecular weights of both bands ~- are shifted higher to about 38-36 kD under reducing conditions (Fig. lb). This shift in SDS-polyacrylamide gel has also been observed by others (Sakaguchi et al, Wo 94/l 1512 2 1 4 ~ 7 1 3 Pcr/uss3/l 1000 `!` ~
Aller~45:309-312 (1990)). These results suggest that intra-disulfide bonds are probably present in the protein, and it is supported by the present findings that cloned Cry j II contains 20 cysteines deduced from the nucleotide sequence (Example ~ 3). The pI of Cry j II estimated from IEF gel is about 10. The purifled Cry j II
- ~ ~ s binds human IgE of some allergic patients.
The two moleeular weight bands of Cr~ j II wele ~eparated on a 12~ SDS-polyacrylamide gel and was then electroblotted onto PVDF membrane (Applied Biosystems, Foster City, CA). The blot was stained with coomassie brilliant blueand was cut and subjected to N-terrninal amino acid sequencing. (Example 2). Theo results showed that the upper and lower molecular weight bands had identical N-terminal sequences except the lower molecular weight band missed the first five arnino acids. The estimated molecular weight of the upper band based on the cDNAsequence is about 52,000, which is significantly higher than the molecular weight estimated from SDS-polyacrylamide gel either in the presence or absence of reducing ls ~ ~ reagent. It is also higher than that obtained from gel filtration and preliminary mass spectroscopy analysis. These are several possibilities to account for this difference.
One possibility is that C~y j II protein is processed. It is probable that the N-terminal and C-terminal of the protein are cleaved. It is not clear at the present time whether this processing occurs in the cell or due to proteolysis during purification even though four different protease inhibitors were added in most of the purification steps. Nevertheless, the two N-terminal sequences obtained from the purified Cry j II (Example 2) also contained the N-terminal sequence (10 amino acid) published by Sakaguchi et al (Allergy, 45:309-312(1990)) suggesting that the N-terminal of C~II is probably hydrolyzed. Since Sakaguchi et al. (supra), did not use any protease inhibitors in their purification, a higher degree of hydrolysis might have occurred.
This could explain why the N-terminal amino acid sequence that Sakaguchi et al.
obtained was downstream of the N-terminal sequences as discussed in Example 2.
Another approach which may be used to purify native C~ j II or recombinant Cry j II is in~nunoaf~mity chromatography. This technique provides a very selective protein purification due to the speci~lcity of the interaction between monoclonal antibodies and antigen. Murine polyclonal and monoclonal antibodies are generated against purified C~y j II. These antibodies are used for purification, characterization, analysis and diagnosis of the allergen C~y j II. `
: :
Example 2 Protein Sequencing of Purified CJY j II
C.Yi II protein was isolated as in Exarnple l . The doublet band shown on ~: ' ~ WO 94/11512 2 1 4 ~ 7 1 3 PCr/USs3/1 1000 SDS-PAGE (Fig. la) was electroblotted onto ProBlott (Applied Biosystems, Foster City, CA). Sequencing was performed with the Beckman/Porton Microsequencer (model LF3000, Beckman Instruments, Carlsbad, CA), a Programmable Solvent Module (Beckman System Gold Model 126, Beckman Instuments, Carlsbad, CA) and a Diode Array Detector Module for PTH-amino acid detection (Beckman System Gold Model 168, Beckman Inslruments, Carlsbad, CA) foliowing manufacturers specifications.
A~single N-terrninal sequence analysis of the upper doublet band and multiple N-tèrminal sequence analyses of the lower doublet band showed that both bands o ~ contained two N-termini, designated "long" and "short". The lower doublet band contained~approximately 3.3 picomoles of the long form and 8.3 picomoles of the shon~form. This difference in yields was sufficient to make sequence assignmentsaccording to the quantitation at each sequencer cycle. The upper doublet band contained approximatelyl8.3 picomoles of both sequences. The revealed long ,~ s- ~ sequence~wasNH2-RKVEHSRHDAINIFNVEKYGAVGDGKH-DCTEAFSTAW(Q) ) ( ) KNP ( ) -COOH, (SEQ ID NO: 4) where (Q) indicates a tentative i dent~ication of glutarnine at position 38 and () indicated unknown residues atpositions 39~1 and 45. The revealed "short" sequence was NH2-; SRHDA:tNIFNVE~YGAVGDGKHDCTEAFSTAWS-COOH (SEQ ID NO: 5).
Thus ~the ~ long Cry j II sequence had five additional amino terminal residues than the short~for n~and the sequence of the short form exactly matched that of the long form.
In addition,~both the long and short forms of Cry j II contained the ten amino acids, NH2-AINIFNVEKY-COOH (SEQ ID NO 6), previously described for Crv j II
(Sakaguchi et al. 1990t ~). The previously published ten amino acids ~: 25 ~ (Sal~aguchi et al. 1990, suora) correspond to amino acids ten through 19 of the long form described above.
` Example3 ; , ~ Extraction of RNA From Japanese Cedar Pollen and Staminate Cones and '.
Clonin~ of Crv iII
Fresh pollen and staminate cone samples, collected from a single ~yptomena japonica (Japanese Cedar) tree at the Arnold Arboretum (Boston, MA), were frozen ~mmediately on dry ice. RNA was prepared from 500 mg of each ; sample, essentially as described by Frankis and Mascarhenas (1980) Ann. Bot~ 45:
595-599. The samples were ground by mortar and pestle on dry ice and suspended in 5 ml of 50 mM Tris pH 9.0 with 0.2 M NaCI, 1 mM EDTA, 0.1~ SDS that had been treated overnight with 0.1~ diethyl pyrocarbonate (DEPC). After five . ~ .
':
WO 94/~ 1512 2 1 4 ~ 7 1 3 Pcr/uS93/~ lOoo extractions with phenol/chloroform/isoamyl alcohol (mixed 25:24:1), the RNA was precipitated from the aqueous phase with 0.1 volume 3M sodium acetate and 2 volumes ethanol. The pellets were recovered by centrifugation, resuspended in 2~ml dH2O and heated to 65C for 5 minutes. Two ml 4M lithium chloride was added to s the preparation and the RNA was precipitated overnight at 0C. The RNA pellets .`
were rècovered by centrifugation, resuspended in 1 ml dH2O~ and again preeipitated with 3M sodium acetate and ethanol on dry ice for one hour. The final pellet waswashed with 70% ethanol, air dried and resuspended in 100 ~I DEPC-treated dH2O
;~ ~ and stored at -80C.
lo ~ Double stranded cDNA was synthesized from 4 ~g pollen RNA or 8 ,ug flowerhead RNA using a commercially available kit (cDNA Synthesis System kit, BRL, Gaithersburg, MD). The double-stranded cDNA was phenol extracted, ethanol precipitated, blunted with T4 DNA polymerase (Promega, Madison, WI), and then ligated to ethanol precipitated, self annealed, AT and AL oligonucleotides for use in a modified Anchored PCR reaction, according to the method of Rafnar et al. (1990) J. Biol. Chem. 266: 1229-1236; Frohman et al. (1990) Proc. Natl.
Acad~. Sci. USA 85: 8998-9002; and Roux et al. (1990) BioTech. 8: 48-57.
~; Oligonucleotide AT has the sequence (SEQ ID NO: 10) 5'-GGGTCTAGAGGTACCG-TCCGTCCGATCGATCATT-3' (Rafnar et al.
- 20 su~ra). Oligonucleotide AL has the sequence (SEQ ID NO: 11) 5'-AATGATCGATGCT (Rafnar et al. supra).
d ~ -~ The first attempts at amplifying the amino terminus of Cry j II from the linkered cDNA (2 ~l of a 20 ~l reaction) was made using the degenerate.
oligonucleotide CP-11 and oligonucleotide AP. CP-11 has the sequence (SEQ ID
- ~ 25 NO: 12) 5'-ATACTTCTCIACGI~GAA-3', wherein A at positon 1 can be G, C at position 4 can be T, C at position 7 can be T, I at position 10 is inosine to reduce degeneracy (Knoth et al. (1988) Nucleic Acids Res. I6: 10932), G at position 13 can be A, and G at position 16 can be A). AP, which has the sequence (SEQ ID NO:
13) 5'-GGGTCTAGAGGTA-CCGTCCG-3', corresponds to nucleotides 1 through 20 of the oligonucleotide AT. CP-11 is the degenerate oligonucleotide sequence that is complementary to the coding strand sequence substantially encoding amino acids PheAsnValGluLysTyr (SEQ ID NO: 14) (amino acids 59 to 64 of Fig. 4), which ~:
correspond to the carboxy terminus of the previously published Cry j II sequence(Sakaguchi et al., supra) shown in Fig. 4. All oligonucleotides were synthesized by Research Genetics Inc., Huntsville, AL.
Polymerase chain reactions (PCR) were carried out using a commercially available kit (GeneAmp DNA Arnplification kit, Perkin Elmer Cetus, Norwalk, CT) :; .
:
`` W 0 94/11512 21~1~713 PCr/US93/11000 ~ 23 t~
,~ J
whereby 10 ,ul 10x buffer contair~ing dNTPs was mixed with 100 pmoles of each oligonucleotide, cDNA (3-5 ,ul of a 20 ~l first strand cDNA reaction mix), 0.5 ,ul Amplitaq DNA polymerase, and distilled water to 100 ~
The samples were amplified with a programmable thermal controller (MJ
s Research, Inc., Cambridge, MA). The first ~ rounds of amplification consisted of denaturation at 94C for 1 min, annealing of primers to tlle t~mplate at 45C for 1 min, and chain elongation at 72C for 1 min. The final 20 rounds of amplification consisted of denaturation as above, annealing at 55C for 1 min~ and elongation as above. The-primary PCR reaction was carried out with 100 pmol each of the 0 oligonucleotides AP and CP-11. Five percent (S ,ul) of this initial amplification was then used in a secondary amplification with 100 pmoles each of AP and CP-12. CP-12 has the sequence (SEQ ID NO: 15) 5'-CCTGCAGTACTTCT-CIACGTTGAAIAT-3', wherein C at position 10 can be T, C at position 13 can be T, I at positions 16 and 25 are inosines to reduce degeneracy as above, G at position 19 can 've A, and G at position 22 can be A. The sequence (SEQ ID NO: 16) 5'-CCTGCAG-3' (bases 1 through 7 of CP-12) represents a Pst I site added for cloning pulposes; the remaining degenerate oligonucleotide sequence is complementary to the coding strand sequence that substantially encodes the amino -acids IlePheAsnValGluLysTyr (SEQ ID NO: 17) (amino acids 58-64 of Fig. 4).
Ampli~led DNA was recovered by sequential chloroforrn, phenol, and chlorofo~n extractions, followed by precipitation on dry ice with 0.5 volumes of 7.5M
ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washing `
with 70% ethanol, the DNA was simultaneously digested with Xba I and Pst I in a 50 ~l reaction, precipitated to reduce the volume to 10 ~1, and electrophoresed through a preparative 2% GTG NuSeive low melt gel (EMC, Rockport, ME). The appropriate sized DNA area was visualized by ethidium bromide (EtBr) staining, excised, and ligated into appropriately digested pUC19 for sequencing by the ', dideoxy chain termination method of Sanger et al. (1977) Proc. Natl. Acad. Sci.
USA 74: 5463-5476) using a cornmercially available sequencing kit (Sequenase kit, i, .
U.S. Biochemicals, Cleveland, OH). All resultant clones were sequenced, and nonewere found to contain Cry j II sequence. An alternate 2 PCR reaction was performed with AP and the nested oligonucleotide CP-21. CP-21 has the sequence (SEQ ID NO: 18) 5'-CCTGCAGTACTTCTCIACGTTGAAGAT-3' wherein C at position 10 can be T, C at position 13 can be T, I at position 16 is inosine to reduce degeneracy as above, G at position 19 can be A, G at position 22 can be A, and G at position 25 can be A or T. The sequence (SEQ ID NO: 16) 5'-CCTGCAG-3' (bases 1 through 7 of CP-21) represent a Pst I site added for cloning purposes; the WO 94/1 1512 PfCrtUS93/1 1000 ~ i;~`
~l~lg71~ 24 `
remaining degencrate oligonucleotide sequence is the non-coding strand sequence corresponding to coding strand sequence substantially encoding amino acids IlePheAsnValGluLysTyr (SEQ ID NO: 17) (amino acids 58 to 64 of Fig. 4).
A primary PCR was also performed on double-stranded~ cered cDNA
s using CP-23D and AP, as above, to attempt to amplify the 3' end of the Cry j II
cDNA. A secondary PCR was performed using 5 % of ~e priinary reaction, using CP-24D and AP. CP-23D (sequence (SEQ ID NO: 19) 5'-GCIATTAATATTTTTAA-3', wherein the T at position 6 can be C or A, T at position 9 can be C, T at position 12 can be C or A, and T at position 15 can be C ) is the coding strand sequence substantially encoding amino acids AlaIleAsnIlePheAsn (SEQ ID NO: 20) (amino acids 55 to 60 of Fig. 4); CP-24D (SEQ ID NO: 21) ~sequence 5'-GGAATTCCGCIATTAATATTTTTAATGT-3', wnerein the T at position 14 can be C or A, T at position 17 can be C, T at position 20 can be C or A, T at position 23 can be C, and T a~ position 26 can be C ) contains the sequence 5'-GGAATTCC-3' (SEQ ID NO: 22) (bases 1 through 8 of CP-24), which represents an Eco Rl site added for cloning purposes. The remaining degenerate oligonucleotide sequence of CP-24D substantially encodes amino acids AlaIleAsnIlePheAsnVal (SEQ ID NO: 23) (amino acids 55 to 61 of Fig. 4). Again, multiple clones were sequenced, none of which could be identified as Cly j II, and this approach was not pursued further.
Upon the characterization of novel C~y j II protein sequence data described in Example 2, new degenerate oligonucleotides for cloning C~y j II were designed and ¦ synthesized. All oligonucleotides mentioned hereafter were synthesized on an ABI
394 DNA/RNA Synthesizer (Applied Biosystems, Foster City, CA), and purified on 2s NAP-10 colurnns (Pharrnacia, Uppsala, Sweden) as per the manufacturers' instructions. Degenerate oligonucleotide CP-35 was used with AP on the double-stranded linkered cDNA in a primary PCR reaction carried out as described herein.
CP-35 has the sequence (SEQ ID NO: 24) 5'-GCTTCGGTACAATCATGm-3', wherein T at position 3 can also be C; G at position 6 can also be A, T or C; A at position 9 can also be G; A at position 12 can also be G; A at position 15 can be G;
and T at position 18 can also be C; this degenerate oligonucleotide sequence is the non-coding strand sequence corresponding to coding strand sequence substantiallyencoding amino acids LysHisAspCysThrGluAla of Cry j II (SEQ Il:~ NO: 25) (amino acids 71 to 77 of Fig. 4). Five percent (5 ,ul) of this initial amplification, designated JC136, was then used in a secondary amplification with 100 pmoles each of AP anddegenerate Cly j II primer CP-36, an internally nested Cry j II oligonucleotide primer with the sequence (SEQ ID NO: 26) 5'-Wos4/llsl2 ~1 18713 pcr/lJs93/llooo GGCTGCAGGTACAATCATGTTTGCCATC-3' wherein A at position 11 can also be G; A at position 14 can also be G; A at position 17 can also be G; T at position 20 can also be C; G at position 23 can also be A, T, or C; and A at position 26 can~also be G. The nucleotides 5'-GGCTGCAG-3' (SEQ ID NO: 27) (bases 1 through 8 of s CP-36) represent a Pst I restriction site added for cloning purposes. The remaining }
degenerate oligonucleotide sequence of CP-36 is the noll-coding strand sequence corresponding to coding strand sequence substantially encoding amino acids AspGlyLysHisAspCysThr of Cry j II (SEQ ID NO: 28) (amino acids 69 to 75 of Fig.
4). The dominant amplified product, designated JC137, was a DNA band of o approximately 265 base pairs, as visual~zed on an EtBr-stained 2% GTG agarose gel.
Amplified DNA was recovered by sequential chloroform, phenol, and chloroform extractions, followed by precipitation at -20C with 0.5 volumes of 7~5 ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washingwith 70% ethanol, the DNA was simultaneously digested with X~a I and Pst I in a 15 ~l reaction and electrophoresed through a preparative 2% GTG SeaPlaque low ~; ~ melt gel (FMC, Rockport, ME). The appropriate sized DNA band was visualized by EtBr staining, excised, and ligated into appropriately digested pUC19 for sequencing by the dideoxy chain termination method (Sanger et al. (1977) Proc. Natl Acad Sci. lJSA 74: 5463-5476) using a commercially available sequencing kit (Sequenase kit, U.S. Biochemicals, Cleveland, OH).
The clones designated pUC19JC137a, pUC19JC137b, and pUC19JC137e were found to contain sequences encodin~ the amino terminus of Cty j II. All three clones had identical sequence in their regions of overlap, although all three clones had different lengths in the S' untranslated region. Clone pUC19JC137b was the longest clone. The translated sequence of these clones had complete identity to the disclosed 10 arnino acid sequence of C~y j II (Sakaguchi et al.,supra.), as well as to the Cry j II amino acid sequence described in Example 2. , Amino acid numbering is based on the sequence of the full length prote~n; amino acid 1 corresponds to the initiating methionine (Met) of Cry j II. The position of the initiating Met was supported by the presence of an upstrèam in-frame-stop codon and by 78% homology of the surrounding nucleotide sequence with the plant consensus sequence that encompasses the initiating Met, as reported by Lutcke et al. (1987) EMBO J. 6:43~8.
The cDNA encoding the remainder of Cry j II gene was cloned from the linkered cDNA by using oligonucleotides CP-37 (SEQ ID NO: 29) (which has the sequence 5'-ATGTTGGACAGTGTTGTCGAA-3') and AP in a primary PCR, `-designated JC138ii. Oligonucleotide CP-37 corresponds to nucleotides 129 to 149 of W094/11512 21 l~713 PCI`/VS93/11000 Fig. 4, and is based on the nucleotide sequence deteImined for the partial Cry j II
clone pUC19JC137b.
A secondary PCR reaction was performed on 5 % of the initial amplification mixture, with 100 pmoles each of AP and CP-38 (SEQ ID NO: 30) (which has the sequence 5'-GGGAATTCAGAAAAGTTGAGCATTCTCGT-3'), the nested primer.
The nucleotide sequence (SEQ I~) NO: 31) 5'-GG~AATTC-3' (bases 1 ~hrough 8 of CP-38) represents an Eco RI restriction site added for cloning purposes. The remaining oligonucleotide sequence corresponds to nucleotides 177 to 197 of Fig. 4, and is based on the nucleotide sequence determined for the partial Cry j II clone ; lo pUC19JC137b. The amplified DNA product, designated JC140iii, was purified and precipitated as above, followed by digestion with Eco RI and Asp 718 and electrophoresis through a preparative 1 % low melt gel. The dominant DNA band, which was approximately 1.55 kb in length, was excised and ligated into pUC19 for sequencing. DNA was sequenced by the dideoxy chain termination method (Sanger et al. supra) using a commercially available kit (sequenase kit (U.S. Biochemicals, Cleveland, OH). Both strands were completely sequenced using M13 forward and reverse primers (N.E. Biolabs, Beverly, MA) and internal sequencing primers CP-35,CP-38,CP40,CP-41,CP-42,CP-43,CP-44,CP-45,CP-46,CP-47,CP-48, CP-49,CP-50, and CP-51. CP-40 (SEQ ID NO: 32? has the sequence 5'-GTTCTTCAATGGGCCATGT-3' and corresponds to nucleotides 359 to 377 of Fig.
4. CP-41 (SEQ ID NO: 33) has the sequence 5'- GTGTTAGGACT-GTCTCTCGG-3', which is the non-coding strand sequence that corresponds to nucleotides 720 to 739 of Fig. 4. CP-42 (SEQ ID NO: 35) has the sequence 5'-TGTCCAGGCCAT-GGAATAAG-3', which corresponds to nucleotides 864 to 2s 883 of Fig. 4 except that the first nucleotide was synthesized as a T rather than the correct G. CP43 has the sequence (SEQ ID NO: 35)5'-GCCTTACATGGACTGCAACC-3', which is the non-coding strand sequence that corresponds to nucleotides 1476 to 1495of Fig. 4. CP44 has the sequence (SEQ
ID NO:36)5'-TCCACGGGTCTGATAATCCA-3', which corresponds to nucleotides 612 to 631ofPig. 4. CP-45has the sequence (SEQ ID NO:37) S'-AGGCAGGAAGCAATTTT-CCC-3', which is the non-coding strand sequence that corresponds to nucleotides 1254to1273ofFig. 4. CP-46 has the sequence ~ "
(SEQ ID NO:38)5'-TACTGCACTTCAGCT-TCTGC-3', which corresponds to nucleotides 1077 to 1096 ofFig. 4. CP-47 has the sequence (SEQ ID N(:): 39) 3S 5'-GGGGGTCTCCGAATTTATCA-3', which is the non-coding strand sequence thatsubstantially corresponds to nucleotides 1039to1058ofFig. 4, except that the fifth nucleotide of CP-47 was synthesized as a G rather than the correct nucleotide, T.
= t~ 21 4 ~ 7 1 3 Pcr/us93/l lO00 1~ ~
CP-48 (SEQ ID NO: 40), which has the sequence 5'-GGATATTTCAGTGGACACGT-3', corresponds to nucleotides 1290 to 1309 of Fig. 4. CP-49 (SEQ ID NO: 41) has the sequence 5'-TATTAGAAGACC-CTGTGCCT-3', which is the non-coding strand sequence that corresponds to nucleotides 821 to 840 of Fig. 4. CP-50 (SEQ ID NO: 42) has the sequence 5'-CCATGTAAGGCCAAGTTAGT-3', which corresponds to nucleotides 1485 to 1504 of Fig. 4. CP-51 (SEQ ID NO: 43) has the sequence 5'-ACACCTTTACCCATTAGAGT-3', which is the non-coding strand sequence that ~ ~ corresponds to nucleotides 486 to 505 of Fig. 4.
; ~ ~l o Three clones, designated pUC19JC140iiia, pUC19JC140iiid and pUC19JC140iiie, were subsequently found to contain partial Cry j II sequence. The sequence of clone pUC19JC140iiid was chosen as the consensus sequence since it had the longest 3' untranslated region. The sequences of pUC19JC140iiid and pUC19JC137b were used to construct the composite Cryj II sequence shown in Fig.
4. In this composite, nucleotide 230 is reported as the A found in pUC19JC137b (also, pUC19JC137a, pUC19JC140iiia and pUC19JC140iiie) not as the G found in pUC19JC140iiid; however both A and G at nucleotide 230 encode Lys at amino acid 63. The sequence of clone pUC19JC140iiia was identical to that of pUC19JC140iiid- ~ ~ except for the following: pUC19JC140iiia has a T at nucleotide 357 in place of a C
(no predicted change in amino acid 106), has C at nucleotide 754 instead of T
(changes amino acid 238 from Ile to Thr), C at nucleotide 1246 instead of T
(changes amino acid 402 from Leu to Pro), and T at nucleotide 1672 instead of C
(untranslated region). The sequence of clone pUC19JC140iiie was identical to that of pUC19JC140iiid except for G at nucleotide 794 instead of A (changes amino acid 25 ~ 251 from Ile to Met), and T at nucleotide 357 in place of C (no predicted change in amino acid 106).
An ear!ier attempt at cloning the JC140iii PCR product using an Eco Rl/Xba I digest (oligonucleotide AP has both Xba I and Asp 718 restriction enzyme sites) yielded cDNA that was cut in half due to an internal Xba I restriction site in the Cly `
j II cDNA, giving rise to 800 and 750 bp bands; the 750 bp band was succesfully cloned into Eco Rl/X~a I digested pUC19 and sequenced. Two 750 bp clones were ~"
- sequenced and found to be the 5' half of the C~y j II molecule: clones pUC19JC140- .
2a and pUC19JC140-2b. Clone pUC19JC140-2a has C for nucloeotide 297 instead of T (changes amino acid 86 from Cys to Arg) and clone pUC19JC140-2b has G for nucleotide 753 instead of A (changes amino acid 238 from Ile to Val). Both clonepUC19JC140-2a and clone pUC19JC140-2b have a T at nucleotide 357 in place of C
(no predicted change in amino acid 106).
~' ~.. , .. .. ~ .. . ...
. . - .. . .
WO94/11512 2148~i3 Pcr/US93/
Two different PCR amplifications were also sequenced directly to verify the clonal c,y j II sequence using the Amplitaq Cycle Seq~lencing kit (Perkin Elmer Cecus, Norwalk, CT). This procedure involves the ~32P}-end-labelling of ~ !
oligonucleotide sequencing primers which are then annealled (1.6 pmoles in l ~1) to i`
s template DNA and elongated with dideoxy NTPs (methodology of Sanger et al.
(1977) Proc. Natl. Acad. Sci. USA 74:5463-5476) in a PCR reaction also containing 4 ,ul 10X Cycling Mix (contains 0.5 U/~l Amplitaq DNA Polymerase), 5 ,ul template DNA (lO-100 fmoles) and dH20 to 20 ,ul . The dGTP in the termination mixes in ~: this kit have been replaced by 7-deaza-dGTP, which provides increased resolution of o sequences containing high G+C regions of DNA. The template DNA was a PCR
product that was recovered by sequential chloroform, phenol, and chloroform extractions, precipitated at -20C with 0.5 volumes of 7.5 ammonium acetate and 1.5 volumes of isopropanol, then electrophoresed through a preparative 1 or 2%
SeaPlaque low melt gel~ (FMC). Appropriate sized DNA bands were visualized by EtBr staining, excised, and treated with Gelase (Epicentre Technologies, Madison, WI) to remove the agarose. The DNA was again precipitated, and resuspended in 50 ~I TE (10 mM Tris, pH 7.4, 1 mM EDTA, pH 8.0) containing 20 ~4glml RNAse (Boehringer Mannheim, Indianapolis, IN). Two secondary amplifications which had been used to clone Cry j II were repeated, and used as template DNA for PCR cycle sequencing: JC137ii, the 5 ' end PCR, (amplified from the 1 PCR JCl36 above) was rearnplified with oligonucleotides AP and CP-36; and JC140ii, the 3' end PCR, (amplified from the l c PCR JCl38ii above) was reamplified with oligonucleotidesAP and CP-38. Both of the l ~ amplifications used were precipitated, electrophoresed through a preparative l or 2 % SeaPlaque low melt gel (FMC), and2S the appropriate sized bands were visualized by EtBr staining and excised. Two ,ul of each l ~ amplification was then used in the corresponding 2 PCR reaction. The 2 PCR product was then prepared as DNA template for PCR cycle sequencing as described above. The oligonucleotides used as primers in PCR cycle sequencing, many of which were used to sequence the clones, are as follows: for JC137ii,CP-36 and CP-39(SEQIDNO:44), which has the sequence 5'- ~
CTGTCCAACATAATTTGGGC-3' and is the non-coding strand sequence .
corresponding to nucleotides 120 to 139 ofFig.4. The oligonucleotide primers used .
for sequencing JC140ii were CP-38, CP-40,CP41,CP-42,CP-43,CP-44,CP-45, CP-46, CP47, CP49, CP-S0, CP-54(SEQIDNO: 45), which has the sequence 5'-3s CATGGCAGGGTGGTTCAGGC-3', corresponds to nucleotides 985 to 1004 of Fig.
4,CP-55(SEQIDNO: 46), which has ~e sequence 5'-TAGCCCCATTTACGTGCACG-3' and is the non-coding strand sequence that WO94/11512 214~ 1 13 pcr/us93t1looo ~.
: !:
~l 29 .
corresponds to nucleotides 929 to 948 of Fig. 4. and CP-56 (SEQ ID NO: 47), which has the sequence 5'-TTGGGGT~GAGGCCTCCGAA-3' and corresponds tO
nucleotides 1437 to 1456 of Fig. 4. The sequence of this full-length PCR cycle ~? sequencing had only 2 nucleotide changes from the composite pUC19JC137b/pUC19JC140iiid Cly j Il sequence shown in Figure 4, neither of which lead tO an amino acid change. There was a T instead of ~ at nucleotide 357(no predicted change in amino acid 106), and a C instead of A at nucleotide 635 (no ,:., amino acid change).
The nucleotide and predicted amino acid sequences of Cry j II are shown in lo Figs. 4 and 5. This is a composite nucleotide sequence from the two overlapping clones pUC19JC137b and pUC19JC140iiid. Sequencing of multiple independent clones and cycle sequencing of PCR product confirmed the nucleotide sequence of Figure 4. There were several nucleotide changes resulting in predicted amino acid changes, as cited above. However, all nucleotide polymorphisms, with the exception of the T for C substitition at nucleotide 357, were only observed in single clones or sequencing reactions. Although T was seen at nucleotide 357 in all clones except pUCi9JC140iiid, both C and T encode Leu at amino acid 106.
The complete cDNA sequence for C~y j II is composed of 1726 nucleotides, including 41 nucleotides of 5' untranslated sequence, an open reading frame of 1542 nucleotides starting with the codon for an inidating Met (nucleotides 42-44 of Fig.
4), and a 143 bp 3' untranslated region. There is a consensus polyadenylation signal sequence in the 3' untranslated region 64 nucleotides 5' to the poly A tail (nucleotides 1654-1659 of Fig. 4). The position of the initiating Met is confirmed by the presence of an in-frame upstream stop codon and by 78% homology with the plant consensus sequence that encompasses the initiating Met (TAAAAUGGC (bases 38 through 46 ~f Fig. 4 (SEQ ID NO: 48)) found in Cry j II compared with the AACAAUGGC (SEQ ID NO: 49) consensus sequence for plants, Lutcke et al.
(1987) EMBO J. 6: 4348). The open reading frame encodes a deduced protein of 514 amino acids that has complete sequence identity with the published partial -protein sequence for Cry j II (Sakaguchi et al. ~3apE~), which corresponds to amino acids 55 through 64 of Fig. 4. The predicted Cly j II protein has 20 Cys, contains four potential N-linked glycosylation sites corresponding to the consensus sequence ~`
N-X-S/T, has a predicted molecular weight of 56.6 kDa and a predicted pI of 9.08.
Detection of three separate NH2 termini sequences for Cry j II (the long form and the short form as determined in Example 2 and the NH2 terrninus determined by Sakaguchi et al., supra, as shown in Fig. 6) may suggest that the amino terminus of the mature C y j II protein is blocked and that the sequences obtained by sequence ~,~, .=, .,~, . . . .
.~, - . , .
wos4/~s~2 2Iq8713 Pcr/uss3/
':
. ~ analysis of purified protein represent proteolytic cleavage products. As shown in Fig. 6, the amino acid sequence of the long form of C~y j II begins at amino acid 46 '`~ an,d the amino acid sequence of the short forrn of Cry j II begins at arnino acid 51,~ j-` ~ and~the NH2-terminal sequence determed by Sakaguchi et al. begins at amino acid -~ ~ s ~ : 54. ~ It is ~also possible that amino acids 1 to 45 represent the leader/pre-pro position of ~y j~ll` that is enzymatically cleaved to give a functiorlal~y active protein -beginning ~at arnino acid 46 of Fig . 4. The sequences beginning at amino acids 51 and~54 represent~breakdo~vn products of the protein beginning at arnino acid 46.There~ is ~a predicted~cleavage site between amino acids 22 and 23 of Fig. 4 using the '-, lo ~ ~ method o~von~Heijne~(Nucleic Acids Res. (1986) 14:4683-4690). If the mature C~y D, proteih started' at an~ino acid' 23 in Fig. 4, the protein would be 492 amino acids `with~`a~predtct~ed~molecular weight of 54.2 kDa and a predicted pE of 9Ø
Searchmg the Swiss-Prot data base with the C~y j II sequence qemonstrated that ~C~y j II is 43.3 % homologous (33.3 % identical to polygalacturonase of tomato 15 ~ (Lycopets~ n esculentum) and~ 48.4% homologous (32.670 identical) to polygalacturonase of corn, Zea mays. All nucleotide and amino acid sequence analyses were performed using PCGENE (Intelligenetics, Mountain View, CA.).
: ~
.~ ~:
~ .
'~ . : ''"
'~
:~
?`
, ,~
`~
_ ` ' WO94/11512 214S713 PCr/US93/llOOO
31 :
!
Example 4 Extraction of R~A from Japanese Cedar Pollen Collected in Japan and Expression of Recombinant Cry j II - ~
Fresh pollen collected from a pool of Cryptomeria japonica (Japanese cedar) c tre~s in Japan was frozen imrnediately on dry ice. RNA was prepared from 500 mg of the pollen, essentially as described by Frankis and Mascarenhas Ann. Bot. 45 :595-599. The samples were ground by mortar and pestle on dry ice and suspended in 5 ml of 50 mM Tris pH 9.0 with 0.2 M NaCI, l mM EDTA, 1% SDS that had been treated overnight with O. l % DEPC. After five extractions with phenol/chloroforrn ,,:,~ ~, / isoamyl alcohol (mixed at 25:24:1), the RNA was precipitated from the aqueous phase ~with- 0.1 volume 3 M sodium acetate and 2 volumes ethanol. The pellets were recovered by centrifugation, resuspended in 2 ml dH20 and heated to 65C for 5 minutes. Two ml of 4 M lithium chloride were added to the RNA preparations and ;~ 15 ~ they ~were incubated overnight at 0C. The RNA pellets were recovered by cennifugation, resuspended in l ml dH20, and again precipitated with 3 M sodium acetate and ethanol overnight. The final pellets were resuspended in 100 ~41 dH20 and ~stored at -80C.
Double stranded cDNA was synthesized from 8 ~g pollen RNA using the ~ ~ c DNA~Synthesis Systems kit (BRL) with oligo dT priming according to the method `~ of ~Gubler and Hoffman (1983) Gene 25:263-269. PCRs were carried out using the ~ GeneAmp DNA Amplification kit (Perkin Elmer Cetus) whereby 10 ~l 10x buffer <~ containing dNTPs was mixed with lO0 pmol each of a sense oligonucleotide and an anti-sense oligonucleotide, cDNA (lO ~1 of a 400 ~l double stranded cDNA reaction ~-25 ~ mix), 0.5 ~ll Amplitaq DNA polymerase, and distilled water to 100 ,ul.
~- ~ The samples were amplified with a programmable thermal controller from MJ Research, Inc. (Cambridge, MA). The first S rounds of amplification consistedof denaturation at 94C for 1 min, annealing of primers to the template at 45C for 1 min, and chain elongation at 72C for 1 min. I~e final 20 rounds of amplification consisted of denaturation as above, annealing at 55C for l min, and elongation as above.
A new set of primer pairs was synthesized for amplification of a Cry j II ~:
cDNA from the initiating Met to the stop codon. CP-52 (SEQ ID NO: 50) has the ~ sequence 5'- GCCGAATTCATGGCCATGAAATTAATT-3' where the nucleotide 3 5 sequence 5'-GCCGAATTC-3' (SEQ ID NO: 51) (bases l through 9 of CP-52represents an Eco RI restriction site added for cloning purposes, and the remaining sequence corresponds to nucleotides 42 to 59 of Fig. 4. CP-53 (SEQ ID NO: 52) . .
WO94/11512 ~148713 pcr/uss3/l1ooo ~ ' has the sequence 5'-CGGGGATCCTCATTATGGATG-GTAGAT-3' where the nucleotide sequence 5'-CGGGGATCC-3'(SEQID NO:53) (bases 1 through 9 of CP-53 represents a Bam HI restriction site added for cloning purposes, and the remaining oligonucleotide sequence of CP-53 is complementary to coding strand 1~ s sequence corresponding to nucleotides 1572 to 1589 of Fig. 4. The PCR reaction with CP-52 and CP-53 on the double stranded Japanese Cedar pollen cDNA yiclded a band of approximately 1.55 kb on an EtBr-stained agarose minigel, and was called JC145. Amplified DNA was recovered by sequential chloroform, phenol, and chloroforrn extractions, followed by precipitation at -20C with 0.5 volumes of 7.5 amrnonium acetate and 1.5 volumes of isopropanol. After precipitation and washing with 70% ethanol, the DNA was simultaneously digested with Eco Rl and Bam HI in a 15 ,ul reaction, and electrophoresed through a preparative 1 % SeaPlaque low melt gel (FMC). Appropriate sized DNA bands were visualized by EtBr staining, excised, and ligated into appropriately digested pUC19 for sequencing by the dideoxy chain termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA
74:5463-5476) using a cornmercially available sequencing Icit (Sequenase kit, U.S.
Biochemicals, Cleveland, OH).
Clones pUC19JC145a and pUC19JC145b were completely sequenced using M13 forward and reverse primers (N.E. Biolabs, Beverly, MA) and internal sequencing primers CP-41, CP-42, CP44, CP-46, and CP-51. The nucleotide and deduced amino acid sequences of clones pUC19JC145a and pUC19JC145b were i dentical to the Cry j II sequence of Fig. 4, with the following exceptions. Clone pUC19JC145a was found to contain a single nucleotide difference from the previously Icnown C~y j II sequence: it has a C at nucleotide position 1234 of Fig~ 4 rather than the previously described T. This nucleotide change results in a predicted amino acid change from Ile to Thr at amino acid 398 of the C~y j II protein. Clone pUC19JC145b has a G at nucleotide position 1088 of Fig. 4 rather than the previously described A, and an A for a G at nucleotide 1339. The nucleotide change at 1088 is si!ent and does not result in a predicted amino acid change. The nucleotide change at position 1339 results in a predicted amino acid change from Ser i;
to Asn at amino acid 433 of the C~y j II protein~ None of these polymorphisms have yet been confirmed by independently-derived PCR clones or by direct amino acid sequencing and may be due to the inherent error rate of Taq polymerase t (appro~cimately 2 x 10~, Saiki et al. (1988) Science 239:487-491). However, suchpolymorphisms in primary nucleotide and amino acid sequences are expected.
¦ Expression of Cry j II was performed as follows. Ten ~g of pUC19JC145b was digested simultaneously with Eco Rl and Bam HI. The nucleotide insert .. ..
~h W094/11~12 2 1 4 8 7 i 3 PCI'/US93/11000 encoding Cry j II (extending ~rom nucleotide 42 through 1589 of Fig. 4) was isolated by electrophoresis of this digest through a 1% SeaPlaque low melt agarose :
gel. The insert was then ligated into the appropriately digested expression vector pET-l ld (Novagen, Madison, WI; Jameel et al. (1990) J. Virol. 64:3963-3966) -~ S ~ modified to contain a sequence encoding 6 histidines (His 6) immediately 3 ' of the }
ATG ir~itiàtion codon followed by a unique Eco RI endonuclease restriction site. A
second Eco RI endonuclease restriction site in the vector, along with neighboring Cla I and~ Hind III endonuclease restriction sites, had previously been removed by digosdon with Eco RI and Hind III, blunting and religation. The histidine (His6)lo ~ sequence was~added for affinity purification of the recombinant protein (Cryj I) on a Ni2~+~chelating column (Hochuli et al. (1987) J. Ckromatog. 411:177-184; Hochuliet~al.~(1988) Bio/Tech. 6:1321-1325.). A recombinant clone was used to transform`Escherichia coli strain BL21-DE3, which harbors a plasmid that has an isopropyl-13-D-thiogalactopyranoside (IPTG)-inducible promoter preceding the gene encoding T7~15~ polymerase. Induction with IPTG leads to high levels of T7 polymerase expression, is~necessary for expression of the recombinant protein in pET-lld. Clone s6JCI45b.a was confinned to be a Cry j II clone in the correct reading ~frame for expression by dideoxy se~uencing (Sanger et al. supra) with CP-39.
- ~2 o Expression of the recombinant protein was examined in an initial small c ulture. An overnight culture of clone pET-lld~HRhis6JC145b.a was used to inn~culate 50 ml of media (Brain Heart Inf~sion Mediat Difco) containing ampicillin (200 ~g/ml), grown to an A600 = 1.0 and then induced with IPTG (1 mMt final concentration) for 2 hrs. One ml aliquots of the bacteria were collected before and after inductiont pelleted by centrifugation, and crude cell Iysates prepared by boiling the pellets for 5 minutes in 50 mM Tris HCI, pH 6.8, 2 mM EDTA, 1% SDSt 1%
; B-mercaptoethanolt 10% glycerol, 0.25% bromophenol blue (Studier et al.t (1990) `~
Methods in Enz~mology 185:6~89). Recombinant protein expression was examined on a 12% Coomassie blue-stained SDS-PAGE gelt according to the method in Sambrook et al., supra, on which 25 ~1 of the crude Iysates were loaded. A negative control consisted of crude Iysate from unLnduced bacteria containing the plasmid ~,:
with Cry j II. There was no notable increase in production of any recombinant E. }
` ~ coli protein in the range of 58 Kd, the size predicted for the recombinant Cry j II
with the His6 leader.
- 3 5 The pET-lld~HRhis6JC145b.a clone was then grown on a larger scale to examine if there was any recombinant protein being expressed. A 2 ml culmre of : ~ bacteria containing the recombinant plasmid was grown for 8 hr, then 3 ~I was "~
, wo 94/l }512 2 1 4 8 7 1 3 PC-r/Uss3/l lO00 spread onto each of ~ (100 x 1~ mm) petri plates with 1.5% agarose in LB medium ,-(Gibco-BRL, Gaithersburg, MD) containing 200 ~g/ml ampicillin, grown to ¦-confluence overnight, then scraped into 6 L of liquid media (Brain Heart InfusiQn media, Difco) containing ampicillin (200 ~g/ml). The culture was grown until theabsorbance at A600 was 1.0, IPTG added (1 mM final concentration), and the culture grown for an additional 2 hours.
Bacteria were recovered by centrifugation (7,930 xg, 10 min) and lysed in 50 ml of 6M Guanidine-HCI, 0.1M Na2HPO4~ pH 8.0, for 1 hour with vigorous shaking. Insoluble material was removed by centrifugation (11,000 xg, 10 min, 4o C). The pH of the Iysate was adjusted to pH 8.0, and the Iysate applied tO a 50 ml Nickel NTA agarose column (Qiagen) that had been equilibrated with 6 M
Guanidine HCl, 100 mM Na2Hpo4~ pH 8Ø The column was sequentially washed with 6 M Guanidine HCI, 100 rnM Na2HP04, 10 mM Tris-HCl, pH 8.0, then 8 M
urea, 100 mM Na2HPO4, pH 8.0, and finally 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCI, pH 6.3. The column was washed with each buffer until the flow through had an A280~ 0-05 The recombinant Cry j II protein was eluted with 8 M urea, 100 mM sodium acetate, 10 rnM Tris-HCl, pH 4.S, and collected in 10 ml aliquots. The protein concentration of each fraction was determined by A280 and the peak fractions pooled. An ali~uot of the collected recombinant protein was analyzed on SDS-PAGE according to the method in Sarnbrook et al. supra.
This 6L prep, JCIIpET-1, yielded 1.5 mg of recombinant Cry j II, which was resolved into 2 major bands on SDS-PAGE at 58 kDa and 24 kDa. The 58 kDa band, which represents recombinant Cry j II, was approximately 9-10% of the total protein as determined by densitometry measurement (Shimadzu Flying Spot Scanner,Shimadzu Scientific Instruments, Inc., Braintree, MA). The 24 kDa band accounts for about 90% of the total protein and may represent a degradation product of the recombinant Cry j II or an E. coli contaminant. , Another C~y j II expression construct was made by the ligation of the pUC19JC140iiid Cryj II insert into appropriately digested pETlld~HR (with the 6 histidine leader). The vector was derived from another pETlld~HR construct whose insert supplied an EcoR I site (at the 5' pET1 ld~HR-insert junction) and an Asp 718 site (at the 3' end of the insert); the construct was digested with these two `~
enzymes, run on a low melt minigel as above, and the vector recovered as a band in low melt agarose. The pUC19JC140iiid construct was digested with Eco R I and Asp 718 to release the Cly j II insert, which was isolated on a low melt minigel and ligated into the Eco R I/Asp 718 digested pETlld~HR vector prepared above. Five 21~8713 WO94/11~12 pcr/us93/11 clones were found to contain the correct nuc!eotide sequence at the insert/vector 5' junction, when sequenced by dideoxy sequencing (as above) with CP-39. This new construct, when expressed, would begin at amino acid 46 of C~y j II as shown in~Figs. 4 and 5. This recombinant protein is designated rCry j II ~46. A 50 ml small '.
scale expression test (as performed above) showed that the expression level of rCry j 1l ~46 from this construct, designated pET11d~HRJC140iiid2, would be much greater than the initial expression level from pET1 ldAHRJC 145b2 . A 9L prep, JCIIpET-3, was processed as above, and yielded 200 mg of rCry j Il ~46 at 80%
purity as determined by densitometry of a Coomasie blue stained 12% SDS-PAGE
o gel.
Example S
Northern blot on RNA from Japanese Cedar Pollen Sources A northern blot analysis was perforrned on the R~A isolated from Japanese Cedar pollen from both the Arnold Arboretum tree and the pooled trees from Japan.
Using essentially the method of Sambrook, supra, ten ~g of RNA isolated from Japanese cedar pollen collected from the Arnold Arboretum (Boston, MA) and 15 ,ug pooled RNA from Japanese cedar pollen collected from trees in Japan were run on a 1.2% agarose gel containing 38% formaldehyde and lX MOPS (20X = 0.4M
MOPS, 0.02M EDTA, 0.1M NaOAc, pH 7.0) solution. The RNA samples (first precipitated with 1/10 volume sodium acetate, 2 volumes ethanol to reduce volumeand resuspended in 5.5 ~l dH20) were run with 10 ~l formaldehyde/forrnamide buffer containing loading dyes with 15.5% formaldehyde, 42% formamide, and 1.3X MOPS solution, final concentration. The samples were transferred to Genescreen Plus (NEN Research Products, Boston, MA) by capillary transfer in 10XSSC (20X = 3M NaCl, 0.3M Sodium Citrate), after which the membrane was baked 2 hrs at 80C and W irradiated for 3 minutes. Prehybridization of the membrane was at 60C for 1 hour in 4 ml 0.5M NaPo4 (pH 7.2), lrnM EDTA, 1%
BSA, and 7 % SDS. The antisense probe was synthesized by asymrnetric PCR on the t ' JC145 amplification in low melt agarose (above), where 2 ,ul DNA is amplified with 2 ,ul dNTP mix (0.167mM dATP, 0.167mM dTTP, 0.167mM dGTP, and 0.033mM
dCTP), 2 ,ul 10X PCR buffer, 10 ,ul 32P-dCTP (100 ~Ci; Amersham, Arlington }~
Heights, Il), 1 ~1(100 pmoles) antisense primer CP-53, 0.5 ~l Taq polymerase, and dH20 to 20 ~l; the 10X PCR buffer, dNTPs and Taq polymerase were from Perkin Elmer Cetus (Norwalk, CT). Amplification consisted of 30 rounds of denaturation at 94C for 45 sec, annealing of primer to the template at 60C for 45 sec, and chain `
elongation at 72C for 1 min. The reaction was stopped by addition of 100 ~l TE, ;~ .. , . . ~: .
WO 94/11512 2 1 4 8 7 1 3 pcr/us93/11000 - and the probe recovered over a 3cc G-50 spin column (2 ml G-50 Sephadex [Pharmacia, Uppsala, Sweden] in a 3cc syringe plugged with glass wool, equilibrated with TE) and counted on a 1500 TriCarb Liquid Scintillation Counter(Packard, Downers Grove, IL). The probe was added to the prehybridizing buffer at 106 cpm/ml and hybridization was carried out at 60C for 16 hrs. Tbe blot was s washed in high stringency conditions: 3x15 min at 65C with 0.2%SSC/1% SDS, followed by wrapping in plastic wrap and exposure to film at -80C. A seven hourexposure of this Northern blot analysis revealed a single thick band at approximately 1.7 kb for both RNA collected from the Arboretum tree and the RNA collected fromo~ the pooled trees from Japan. This message is the expected size for Cry j II as predicted by PCR analysis of the cDNA.
Example 6 Direct bindin~ assav of I~E to Crv i I. Cnl i II and recombinant Crv j II.
Corning assay plates (~25882-96) were coated with Cty j I or C~y j II at 2 g/mL or recombinant Cryj II preparation at 10 ~g/mL (approximately 20% pure) in a ~volume of 50 ~LL overnight at 4C. The coating antigens were removed and the wells were blocked with 0.5% gelatin, PVP (polyvinyl pyrolidine) 1 mg/ rnL in PBS, 200 ~L/well for 2 hours at room temperature. The anti-C~ j I monoclonal ~20 antibody, 4Bl 1, was serially diluted in PBS-Tween 20 starting at a 1:1000 dilution.
The human plasma were serially diluted in PBS-Tween at a starting dilution of 1:2.
For this set 23 plasma samples from patients symptomatic for Japanese cedar pollen allergy chosen for IgE binding analysis. The first antibody incubation proceededovernight at 4C~ Following three washes with PBS-Tween the second antibodies 2 5 were added (goat anti-mouse Ig or goat anti-human IgE both at 1:2000) andincubated for two hours at room temperature at 100 ~L/well. This solution was removed and streptavidin-HRPO diluted to 1:10,000, was added at 100~/well. The color was allowed to develop for 2-5 minutes. The reaction was stopped by the addition of lOO~L/well of lM phosphoric acid. Plates were read on a Microplate IL310 Autoreader (Biotek Instruments, Winooski, VT) with a 450nm filter. The absorbance levels of duplicate wells were averaged. The graphed results (log of the dilution vs. absorbance) of the ELISA assays are shown in Figs. 7 to 15. The I .
summary of the results are given in Fig~ 16. A positive binding result, indicated by a plus sign is determined to be a reading of two-fold or greater above background - 35 (no first antibody) at the second dilution of plasma (1:6).
In Fig. 7 the binding response of the monoclonal antibody, 4B11, and seven patieMs' (Batch 1) plasma IgE is shown to purified C1y j 1 as the coating antigen.
~ WO 94/1 15 12 2 1 4 ~ 7 1 3 PCI /US93/1 1000 37 ~`
i The monoclonal antibody, raised against purified Cry j I shows a saturatin~ level of binding for the whole dilution series. The individual patient samples show a variable - ¦
response of IgE binding to the Cry j I preparation. One patient, #1034, has no detectable binding to this protein preparation. All the patient samples were obtained s from individuals claiming to be symptomatic for Japanese cedar pollen allergy and : ~ the results of their MAST scores are shown in Fig. 16. Fig. 8 is a graph representing the binding of the same antibody set as in Fig. 7 to purified native C~y j II. The anti-Cry j I monoclonal antibody, 4B11, is negative on this preparation demonstrating lack of cross-reactivity between the two allergen antigens. In general, o there is a lower overall response to this allergenic component of cedar pollen with more patient samples showing decreased binding. However, patient #1034, that wasnegative on Cry j I shows very strong reactivity to Cry j II. In the last antigen set, Fig. 9, using recombinant C~y j II (rC~y j II), monoclonal antibody 4B11 reactivity ; is negative and there is further reduc~ion in binding of the human IgE samples compared to biochemically purified Cry j II. Two of the patients, #1143 and #1146, are clearly positive for IgE binding to the recombinant form of C~y j II although the pat~ient that reacted the strongest to biochemically purified form is negative here, 1034. Figs. 10^15 represent the application of the same antigen sets for the direct binding analysis of the next sixteen patients designated patient Batch 2 and patient Batch 3 in Figs. 10-15.
The table shown in Fig. 16 sumrnarizes both the MAST scores, performed in - ~ Japan on the plasma samples before shipment using a commercially available kit, and the direct ELISA results outlined above. Two patients were negative by the MAST
assay, however, one of these patients, #1143, was positive on all the ELISA
antigens. The number of positive responses for each antigen is shown and this represents a measure relative allergenicity of the different allergen preparations.
These results demonstrate that C y j II is an allergen as defined by human allergic patient IgE reactivity and that there are some patients who are not reactive to Cry j I
but are reactive to Gy j II. The frequency of response in this population of patients is less to Cry j II than to C1y j I.
Example 7 -~ .
Japanese Cedar Pollen Allergic Patient T Cell Studies with CrY i II and Crv j II3S Peptides.
Synthesis of C~y j II Peptides WO 94/11512 Pcr/uss3/llooo 2148713 38 " ` ~
Japanese cedar pollen C,~y j II peptides designated Cry j IIA Cry j IIB were synthesized using standard Fmoc/tBoc synthetic chemistry and puri~led by ReversePhase HPLC. The amino acid sequence of peptide Cry J IIA is FTFKVDGIIAAYQ
(SEQ ID NO: 54) which corresponds tO amino acids 116-128 as shown if Figs 4 and s 5. The amino acid sequence of peptide Cry j IIB is NGYFSGHVIPACKN ~SEQ ID
NO: 55) which corresponds to amino acids 416-429 dS shown in Figs 4 and 5. The peptide names are consistent throughout.
T Cell Responses to Japanese Cedar Pollen Antigen Peptides Peripheral blood mononuclear cells (PBMC) were purified by lymphocyte separation medium (LSM) centrifugation of 60 ml of heparinized blood from one Japanese cedar pollen-allergic patient who exhibited clinical symptoms of seasonal rhinitis and was MAST and/or skin test positive for Japanese cedar pollen. Long term T cell lines were established by stirnulation of 2 X 106 PBL/ml in bulk cultures of complete medium (RPMI-1640, 2 mM L-glutamine, 100 U/ml ~- penicillinlstreptomycin, sx10-5M 2-mercaptoethanol, and 10 mM HEPES
supplemented with 5 % heat inactivated human AB serum) with 10 ~g/ml of partially purified native C)y j II for 7 days at 37C in a humidified 5 % C02 incubator to~;~ select for C~y j II reactive T cells. This amount of priming antigen was determined to be optimal for the activation of T cells from most Japanese cedar pollen allergic patients. Viable cells were purified by LSM centrifu~ation and cultured in complete medium supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to three weeks until the cells no longer responded to lymphokines and were considered "rested". The ability of the T cells to 2s proliferate to peptides Cry j IIA and Cry j IIB, recombinant Cry j II (rCry j II), purified native C~y j II, or purified native C1y j I was then assessed. For assay, 2 X
104 rested cells were restimulated in the presence of 2 X 104 autologous Epstein-Barr virus (EBV)-transformed B cells (prepared as described below) (gamma-irradiated with 25,000 RADS) with 2-50 ~lg/ml of rCry j II, purified native C~y j II, peptides Cry j IIA and Cry j IIB, of purified native Cry j I, in a volume of 200 ~l complete medium in duplicate or triplicate wells in 96-well round bottom plates for 2-4 days. The optimal incubation was found to be 3 days. Each well then received .
1 ~lCi tritiated thymidine for 16-20 hours. The counts incorporated were collected onto glass ~lber filter mats and processed for liquid scintillation counting. The 3s maximum response in a titration of each peptide is expressed as the stimulation index (S.I.). The S.I. is the counts per minute (CPM) incorporated by cells in response to peptide, divided by the CPM incorporated by cells in medium only. An S.I. value ~. ~ ~",. . . .. . .. .
`WO 94/1 1512 2 1 4 8 ~ 1 3 Pcr/US93/ 1 loOO ~
39 i:
equal to or greater than 2 times the background level is considered "positive" and indicates that the peptide contains a T cell epitope. The results of this assay indicated that peptides Cr j II, and Cry j IIB did noit appear to contain a T cell ;epitope for this particular allergenic patient. However, additional Japanese cedar S ~ pollen allergic patients will be tested in this assay system and one or both of these peptides may contain T cell epilopes for other allergic individuals ; ~
~.":.:
~, ;:
r > ~
.~, ~',, ~;;
., W094/11512 21~871:~ pCI/US93/11000 ~
Preparation of (EBV)-transformed B Cells for Use as Antigen Presenting Cells Autologous EBV-transformed cell lines were y-irradiated with2S,000 Rad ¦
and used as antigen presenting cells in secondary proliferation assays and secondary ' bulk stimu!ations. These cell lines were also used as a control in the immuno-s fluorescence flow cytometry analysis. These EBV-transformed cell lines were made by incubating S X 106 PBL with 1 ml of B-59/8 Marmoset cell line (ATCC
CRL1612, American Type Culture Collection, Rockville, MD) conditioned medium ;in the presence of 1 llg/ml phorbol 12-myristate 13-acetate (PMA) at 37C for 60 minutes in 12 X 75 mm polypropylene round-bottom Falcon snap cap tubes (Becton o ; Dickinson Labware, Lincoln Park, NJ) . These cells were then diluted to 1 .2S X 106 cellsiml in RPMI~ 0 as described above except supplemented with 10% heat-irlactivated fetal bovine serum and cultured in 200 !11 aliquots in flat bottom culture plates until visible colonies were detected~ They were then transferred to larger wells until the cell !ines were established.
15~ Although the invention has been described with reference to its preferred embodiments, othèr embodiments, can achieve the same results. Variations and modifications to the present invention will be obvious to those skilled in the art and it is inended to cover in the appended claims all such modification and equivalents and fo!low in the true spirit and scope of this invention.
,~, .
.. ~ ~ . .
t i,, `
`~:
, , ,, . . - ` . ~ ` : : . :.
214~7~3 l~
/ c ,,.. ; ;`
SEQUENCE LISTING
i ( (1) GENERAL INFORMATION:
S
(i) APPLICANT:
(A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION
(B) STREET: 610 Lincoln Street (C) CITY: Waltham ~D) STATE: MA
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 02154 (G) TELEPHONE: (617) 466-6000 (H) TELEFAX: (617)466-6040 (ii) TITLE OF INVENTION: Allergenic Proteins and Peptides From Japanese Cedar Pollen (iii) NUMBER OF SEQUENCES: 55 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (TEXT) `: :
:~ (v) CURRENT APPLICATION DATA:
(A) APPLIC~TION NUMBER:
: (B) FILING DATE:
~vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT. INFORMATION:
(A)- NAME: Vanstone, Darlene (B) REGISTRATION NUMBER: 35,729 (C) REFERENCE/DOCKET NUMBER: IPC-033PC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 466-6000 (B) TELEFAX: (617) 466-6040 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1726 base pairs i`
(B) TYPE: nucleic acid (C) STRANDEDNESS: single ~;
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA `-(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 42..1586 WO94/11512 PCI/US93/11000 ~ ~ ~14~713 42 (xi) SEQ~NCE DESCRIPTION: SEQ ID NO:l:
TGAGTTCGAG ACAAGTATAG AAAGAATTTT CTTTTATTAA A ATG GCC ATG AAA
Met Ala Met Lys ) `
TTA ATT GCT CCA ATG GCC TTT CTG GCC ATG CAA TTG ATT ATA ATG GCG
Leu Ile Ala Pro Met Ala Phe Leu Ala Met Gln Leu Ile Ile Met Ala GCA GCA GAA GAT CAA TCT GCC CAA ATT ATG TTG GAC AGT GTT GTC GAA
~: Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp Ser Val Val Glu : 25 30 35 .
AAA TAT CTT AGA TCG AAT CGG AGT TTA AGA AAA GTT GAG CAT TCT CGT
: 197 :: Lys Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val Glu His Ser Arg CAT GAT GCT ATC AAC ATC TTC AAT GTG GAA AAG TAT GGC GCA GTA GGC
His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly : ~ 55 60 65 GAT GGA AAG CAT GAT TGC ACT GAG GCA TTT TCA ACA GCA TGG CAA GCT
: 293 Asp Gly Lys ~is Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala ~ .
: 35 GCA TGC AAA AAC CCA TCA GCA ATG TTG CTT GTG CCA GGC AGC AAG AAA
Ala Cys Lys Asn Pro Ser Ala Met Leu Leu Val Pro Gly Ser Lys Lys : TTT GTT GTA AAC AAT CTG TTC TTC AAT GGG CCA TGT CAA CCT CAC TTT
Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys Gln Pro His Phe ACT TTT AAG GTA GAT GGG ATA ATA GCT GCG TAC CAA AAT CCA GCG AGC
: Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser TGG AAG AAT AAT AGA ATA TGG TTG CAG TTT GCT AAA CTT ACA GGT TTT i ;.
:~ 485 Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys Leu Thr Gly Phe , 135 140 145 `~
ACT CTA ATG GGT AAA GGT GTA ATT GAT GGG CAA GGA AAA CAA TGG TGG ', 533 . t:~
Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly Lys Gln Trp Trp ~-150 155 160 . j.
:: 60 ~;
: GCT GGC CAA TGT AAA TGG GTC AAT GGA CGA GAA ATT TGC AAC GAT CGT
Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg 165 170 175 180 .
~-: 65 GAT AGA CCA ACA GCC ATT AAA TTC GAT TTT TCC ACG GGT CTG ATA ATC
, .
':
;
-:
. ,~' WO 94/1 1512 2 1 ~ 8 7 1 3 PCI`/US93/1 1000 r~
~. -43 ~ :
Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr Gly I.eu Ile Ile 18S 190 1~5 CAA GGA CTG AAA CTA ATG AAC AGT CCC GAA TTT CAT TTA GTT TTT GGG
Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe Hls Leu Val Phe Gly AAT TGT GAG GGA GTA AAA ATC ATC GGC ATT AGT ATT ACG GCA CCG AGA
Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile Thr Ala Pro Arg GAC AGT CCT AAC ACT GAT GGA ATT GAT ATC TTT GCA TCT AAA AAC TTT
Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala Ser Lys Asn Phe CAC TTA CAA AAG AAC ACG ATA GGA ACA GGG GAT GAC TGC GTC GCT ATA
His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp Cys Val Ala Ile GGC ACA GGG TCT TCT AAT ATT GTG ATT GAG GAT CTG ATT TGC GGT CCA
Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu Ile Cys Gly Pro GGC CAT GGA ATA AGT ATA GGA AGT CTT GGG AGG GAA AAC TCT AGA GCA
Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu Asn Ser Arg Ala GAG GTT TCA TAC GTG CAC GTA AAT GGG GCT AAA TTC ATA GAC ACA CAA
Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe Ile Asp Thr Gln AAT GGA TTA AGA ATC AAA ACA TGG CAG GGT GGT TCA GGC ATG GCA AGC
Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser Gly Met Ala Ser CAT ATA ATT TAT GAG AAT GTT GAA ATG ATA AAT TCG GAG AAC CCC ATA
His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser Glu Asn Pro Ile TTA ATA AAT CAA TTC TAC TGC ACT TCA GCT TCT GCT TGC CAA AAC CAG
Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala Cys Gln Asn Gln AGG TCT GCG GTT CAA ATC CAA GAT GTG ACA TAC AAG AAC ATA CGT GGG
Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys Asn Ile Arg Gly ~:
360 365 370 ~-ACA TCA GCA ACA GCA GCA GCA ATT CAA CTT AAG TGC AGT GAC AGT ATG
Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys Ser Asp Ser Met CCC TGC AAA GAT ATA AAG CTA AGT GAT ATA TCT TTG AAG CTT ACC TCA
WO 94/ 1 1 5 1 2 ,~ 8 ~1 3 PCl / US93/ 11 000 . :-Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu Lys Leu Thr Ser GGG AAA ATT GCT TCC TGC CTT AAT GAT AAT GCA AAT GGA TAT TTC AGT
Gly Lys Ile Ala Ser Cys Leu Asn Asp Asn Ala Asn Gly Tyr Phe Ser 495 ~10 415 4~0 GGA CAC GTC ATC CCT GCA TGC AAG AAT TTA AGT CCA AGT GCT AAG CGA ¦.
Giy His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro Ser Ala Lys Arg AAA GAA TCT AAA TCC CAT AAA CAC CCA AAA ACT GTA ATG GTT GAA AAT
Lys Glu Ser Lys Ser His Lys His Pro Lys Thr Val Met Val Glu Asn ATG CGA GCA TAT GAC AAG GGT AAC AGA ACA CGC ATA TTG TTG GGG TCG
Met Arg Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile Leu Leu Gly Ser AGG CCT CCG AAT TGT ACA AAC AAA TGT CAT GGT TGC AGT CCA TGT AAG
Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys Ser Pro Cys Lys GCC AAG TTA GTT ATT GTT CAT CGT ATT ATG CCG CAG GAG TAT TAT CCT
: Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln Glu Tyr Tyr Pro 485 490 495 500 ~:
CAG AGG TGG ATA TGC AGC TGT CAT GGC AAA ATC TAC CAT CCA TAATGAGATA
Gln Arg Trp Ile Cys Ser Cys His Gly Lys Ile Tyr Hls Pro CATTGAAACT GTATGTGCTA GTGAATATTC TTGTGGTACA ATATTAGAAC TGATATTGAA
AATAAATCAT CAATGTTTCT AAGGCATTTA TAATAGATTA TATTAATGGT TCAGCCTGGT
GCAAAAAAAA AAA
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 514 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Ala Met Lys Leu Ile Ala Pro Met Ala Phe Leu Ala Met Gln Leu Ile Ile Met Ala Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp ~` W094/11512 214S713 PCI/US93/11000 4 5 s Ser Val Val Glu Lys Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr ¦
Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala Ala Cys Lys Asn Pro Ser Ala Met Leu Leu Val Pro Gly Ser Lys Lys Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys Gln Pro His Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys . ~ Leu Thr Gly Phe Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly 145 150 155 1~0 Lys Gln Trp Trp Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr ~:~ Gly Leu Ile Ile Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe His : 195 200 205 ' ~";
.~
Leu Val Phe Gly Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile :: Thr Ala Pro Arg Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala Ser Lys Asn Phe His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp Cys Val Ala Ile Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu Ile Cys Gly Pro Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu Asn Ser Arg Ala Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe 2~0 295 300 Ile Asp Thr Gln Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser 305 310 315 320 ~.
Gly Met Ala Ser His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser 325 330 335 P:~
Glu Asn Pro Ile Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala Cys Gln Asn Gln Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys Asn Ile Arg Gly Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys WO94/11512 2 1 ~87 13 PCT/US93/11000 ~
46 ~:
Ser Asp Ser Met Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu Lys Leu Thr Ser Gly Lys Ile AIa Ser Cys Leu Asn Asp Asn Ala Asn 405 410 415 ~ I
Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro 4 , , Ser Ala Lys Arg Lys Glu Ser Lys Ser His ky- His Pro Lys Thr Val 435 440 44s Met Val Glu Asn Met Arg Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile ~ .
450 455 460 :~.
: Leu Leu Gly Ser Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys 20:
: ~ Ser Pro Cys Lys Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln Glu Tyr Tyr Pro Gln Arg Trp Ile Cys Ser Cys His Gly Lys Ile Tyr s00 505 S10 :
His Pro , (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide :::
40~ (v) FRAGMENT TYPE: internal : ' ' ~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala Ala Cys Lys Asn Pro Ser 35 : 40 45 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE OEARACTERISTICS: ;.
(A) LENGTH: 41 amino acids (B) TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide : ~v) FRAGMENT TYPE: internal :
'` W094/llSi2 2148713 PCI/U593/11000 4 7 ~i .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val .
Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Lys Asn Pro ~2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE C~ARACTERISTICS:
~A) LENGTH: 36 amino acids (B~ TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp 20 ~ 25 30 Gln Lys Asn Pro (2) INFORMATION FOR SEQ ID NO:6:
(i) 5EQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr 1 5 10 ~-(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1410 base pairs '.-(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
WO94/1151~ 713 PCI/US93/11000 '~ ~;
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: '~
AGAAAAGTTG AGCATTCTCG TCATGATGCT ATCAACATCT TCAATGTGGA AAAGTATGGC , .
GCAGTAGGCG ATGGAAAGCA TGATTGCACT GAGGCATTTT CAACAGCATG GCAAGCTGCA~
TGCAAAAACC CATCAGCAAT GTTGCTTGTG CCAGGCAGCA AGAAATTTGT TGTAAACAAT
CTGTTCTTCA ATGGGCCATG TCAACCTCAC TTTACTTTTA AGGTAGATGG GATAATAGCT
GCGTACCAAA ATCCAGCGAG CTGGAAGAAT AATAGAATAT GGTTGCAGTT TGCTAAACTT
ACAGGTTTTA CTCTAATGGG TAAAGGTGTA ATTGATGGGC AAGGAAAACA ATGGTGGGCT
GGCCAATGTA AATGGGTCAA TGGACGAGAA ATTTGCAACG ATCGTGATAG ACCAACAGCC
ATTAAATTCG ATTTTTCCAC GGGTCTGATA ATCCAAGGAC TGAAACTAAT GAACAGTCCC
GAATTTCATT TAGTTTTTGG GAATTGTGAG GGAGTAAAAA TCATCGGCAT TAGTATTACG
GCACCGAGAG ACAGTCCTAA CACTGATGGA ATTGATATCT TTGCATCTAA AAACTTTCAC
TTACAAAAGA ACACGATAGG AACAGGGGAT GACTGCGTCG CTATAGGCAC AGGGTCTTCT
AATATTGTGA TTGAGGATCT GATTTGCGGT CCAGGCCATG GAATAAGTAT AGGAAGTCTT
GGGAGGGAAA ACTCTAGAGC AGAGGTTTCA TACGTGCACG TAAATGGGGC TAAATTCATA
GACACACAAA ATGGATTAAG AATCAAAACA TGGCAGGGTG GTTCAGGCAT GGCAAGCCAT
ATAATTTATG AGA~TGTTGA AATGATAAAT TCGGAGAACC CCATATTAAT AAATCAATTC
TACTGCACTT CAGCTTCTGC TTGCCAAAAC CAGAGGTCTG CGGTTCAAAT CCAAGATGTG
ACATACAAGA ACATACGTGG GACATCAGCA ACAGCAGCAG CAATTCAACT TAAGTGCAGT
GACAGTATGC CCTGCAAAGA TATAAAGCTA AGTGATATAT CTTTGAAGCT TACCTCAGGG
AAAATTGCTT CCTGCCTTAA TGATAATGCA AATGGATATT TCAGTGGACA CGTCATCCCT ;`
GCATGCAAGA ATTTAAGTCC AAGTGCTAAG CGAAAAGAAT CTAAATCCCA TAAACACCCA
AAAACTGTAA TGGTTGAAAA TATGCGAGCA TATGACAAGG GTAACAGAAC ACGCATATTG
TTGGGGTCGA GGCCTCCGAA TTGTACAAAC AAATGTCATG GTTGCAGTCC ATGTAAGGCC
¦ r ~
~;`` W O 94/llS12 214S7 1 ~ PCT/US93tll000 AAGTTAGTTA TTGTTCATCG TATTATGCCG CAGGAGTATT ATCCTCAGAG GTGGATATGC
AGCTGTCATG GCAAAATCTA CCATCCATAA ~ 3 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 1395 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
~5 TCTCGTCATG ATGCTATCAA CATCTTCAAT GTGGAAAAGT ATGGCGCAGT AGGCGATGGA
AAGCATGATT GCACTGAGGC ATTTTCAACA GCATGGCAAG CTGCATGCAA AAACCCATCA
GCAATGTTGC TTGTGCCAGG CAGCAAGAAA TTTGTTGTAA ACAATCTGTT CTTCAATGGG
CCATGTCAAC CTCACTTTAC TTTTAAGGTA GATGGGATAA TAGCTGCGTA CCAAAATCCA
GCGAGCTGGA AGAATAATAG AATATGGTTG CAGTTTGCTA AACTTACAGG TTTTACTCTA
ATGGGTAAAG GTGTAATTGA TGGGCAAGGA AAACAATGGT GGGCTGGCCA ATGTAAATGG
GTCAATGGAC GAGAAATTTG CAACGATCGT GATAGACCAA CAGCCATTAA ATTCGATTTT
TCCACGGGTC TGATAATCCA AGGACTGAAA CTAATGAACA GTCCCGAATT TCATTTAGTT :
TTTGGGAATT GTGAGGGAGT AAAAATCATC GGCATTAGTA TTACGGCACC GAGAGACAGT
CCTAACACTG ATGGAATTGA TATCTTTGCA TCTAAAAACT TTCACTTACA AAAGAACACG ;~
ATAGGAACAG GGGATGACTG CGTCGCTATA GGCACAGGGT CTTCTAATAT TGTGATTGAG
GATCTGATTT GCGGTCCAGG CCATGGAATA AGTATAGGAA GTCTTGGGAG GGAAAACTCT
AGAGCAGAGG TTTCATACGT GCACGTAAAT GGGGCTAAAT TCATAGACAC ACAAAATGGA
TTAAGAATCA AAACATGGCA GGGTGGTTCA GGCATGGCAA GCCATATAAT TTATGAGAAT
W0 94/11512 i~ 1 ~ 8 ~1 3 PCr/US93/11000 ~ :
GTTGAAATGA TAAATTCGGA GAACCCCATA TTAATAAATC AATTCTACTG CACTTCAGCT
TCTGCTTGCC AAAACCAGAG GTCTGCGGTT CAAATCCAAG ATGTGACATA CAAGAACATA ~ :~
CGTGGGACAT CAGCAACAGC AGCAGCAATT CAACTTAAGT GCAGTGACAG TATGCCCTGC
AAAGATATAA AGCTAAGTGA TATATCTTTG AAGCTTACCT CAGGGAAAAT TGCTTCCTGC
CTTAATGATA ATGCAAATGG ATATTTCAGT GGACACGTCA TCCCTGCATG CAAGAATTTA
AGTCCAAGTG CTAAGCGAAA AGAATCTAAA TCCCATAAAC ACCCAAAAAC TGTAATGGTT
GAAAATATGC GAGCATATGA CAAGGGTAAC AGAACACGCA TATTGTTGGG GTCGAGGCCT
CCGAATTGTA CAAACAAATG TCATGGTTGC AGTCCATGTA AGGCCAAGTT AGTTATTGTT
ATCTACCATC CATAA
.
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1479 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPO~OGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: :;
GAAGATCAAT CTGCCCAAAT TATGTTGGAC AGTGTTGTCG AAAAATATCT TAGATCGAAT
CGGAGTTTAA GAAAAGTTGA GCATTCTCGT CATGATGCTA TCAACATCTT CAATGTGGAA
AAGTATGGCG CAGTAGGCGA TGGAAAGCAT GATTGCACTG AGGCATTTTC AACAGCATGG `~
CAAGCTGCAT GCAAAAACCC ATCAGCAATG TTGCTTGTGC CAGGCAGCAA GAAATTTGTT
.GTAAACAATC TGTTCTTCAA TGGGCCATGT CAACCTCACT TTACTTTTAA GGTAGATGGG
ATAATAGCTG CGTACCAAAA TCCAGCGAGC TGGAAGAATA ATAGAATATG GTTGCAGTTT
GCTAAACTTA CAGGTTTTAC TCTAATGGGT AAAGGTGTAA TTGATGGGCA AGGAAAACAA : :
.... WO94/11512 214~71 3 PCT/US93/11000 TGGTGGGCTG GCCAATGTAA ATGGGTCAAT GGACGAGAAA TTTGCAACGA TCGTGATAGA
CCAACAGCCA TTAAATTCGA TTTTTCCACG GGTCTGATAA TCCAAGGACT GAAACTAATG
AACAGTCCCG AATTTCATTT AGTTTTTGGG AATTGTGAGG GAGTAAA~AT CATCGGCATT ' `
AGTATTACGG CACCGAGAGA CAGTCCTAAC ACTGATGGAA TTGATATCTT TGCATCTAAA
AACTTTCACT TACAAAAGAA CACGATAGGA ACAGGGGATG ACTGCGTCGC TATAGGCACA
GGGTCTTCTA ATATTGTGAT TGAGGATCTG ATTTGCGGTC CAGGCCATGG AATAAGTATA
GGAAGTCTTG GGAGGGAAAA CTCTAGAGCA GAGGTTTCAT ACGTGCACGT AAATGGGGCT
~0. 840 ` AAATTCATAG ACACACAAAA TGGATTAAGA ATCAAAACAT GGCAGGGTGG TTCAGGCATG
GCAAGCCATA TAATTTATGA GAATGTTGAA ATGATAAATT CGGAGAACCC CATATTAATA ~.
AATCAATTCT ACTGCACTTC AGCTTCTGCT TGCCAAAACC AGAGGTCTGC GGTTCAAATC
3o CAAGATGTGA CATACAAGAA CATACGTGGG ACATCAGCAA CAGCAGCAGC AATTCAACTT
AAGTGCAGTG ACAGTATGCC CTGCAAAGAT ATAAAGCTAA GTGATATATC TTTGAAGCTT ~.
~35 1140 .
ACCTCAGGGA AAATTGCTTC CTGCCTTAAT GATAATGCAA ATGGATATTT CAGTGGACAC ~
1200 .
GTCATCCCTG CATGCAAGAA TTTAAGTCCA AGTGCTAAGC GAAAAGAATC TAAATCCCAT
AAACACCCAA AAACTGTAAT GGTTGAAAAT ATGCGAGCAT~ATGACAAGGG TAACAGAACA
1320 ` ::
::
CGCATATTGT TGGGGTCGAG GCCTCCGAAT TGTACAAACA AATGTCATGG TTGCAGTCCA
TGTAAGGCCA AGTTAGTTAT TGTTCATCGT ATTATGCCGC AGGAGTATTA TCCTCAGAGG
TGGATATGCA GCTGTCATGG CAAAATCTAC CATCCATAA
~ `
~2) INFORMATION FOR SEQ ID NO:10:
~i) SEQUENCE CHARACTERISTICS: .
~A) LENGTH: 35 base pairs ~B) TYPE: nucleic acid ~-~C) STRANDEDNESS: single `~ .
~D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
`
W094/11512 2,~48rl 13 ~ PCr/US93/11000 ~- ~
~xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGGTCTAGAG GTACCGTCCG TCCGATCGAT CCATT
S
(2~ INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) ST ~NDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
AATGATCGAT GCT
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
RTAYTTYTCN ACRTTRAA
~2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
5~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
GGGTCTAGAG GTA
~ `
(2) INFORMATION FOR SEQ ID NO:14:
:
: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ~ W 0 94/11512 ~14~713 PCT/US93/llOOO
53 ~;
(v) FRAGMENT TYPE: internal ~xi) SEQUENCE DESCRIPTION: SEQ ID NO :14:
Phe Asn Val Glu Lys Tyr - ~10 (2) INFORMATION FOR SEQ ID NO:15:
~ i) SEQUENCE CHARACTERISTICS:
s-~ (A) LENGTH; 27 base pairs ~15 ~ TYPE: nucleic acid ~ (C) STRANDEDNESS: single `~: (D) TOPOLOGY: linear ii) MOLECULE TYPE: cDNA
~20 : ~
~xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
CCTGCAGTAY TTYTCNACRT TRAANAT
(2) ~INFORMATION FOR SEQ ID NO:16:
,30~ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
. ~
~40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
CCTGCAG
:~`45 ~ ~:
:: (2) INFORMATION FOR SEQ ID NO:17:
~ ~i) SEQUENCE CHARAcTERIsTIcs :~SO (A) LENGTH: 7 amino acids .
. (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ` (v) FRAGMENT TYPE: internal :~-:- ; ~ :.
~60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Ile Phe Asn Val Glu Lys Tyr 5 ~ ` ~
(2) INFORMATION FOR SEQ ID NO:18:
~`, ~ ' ;
.~ , .
W 0 94/1l512 pCT/US93/11000 .~
214~7~3 54 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH. 27 base pairs I -(B) TYPE: nucleic acid l:~
(C) STRANDEDNESS: single `:
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
CCTGCAGTAY TTYTCNACRT TRAADAT
(2) INFORMATION FOR SEQ ID NO:l9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MO~ECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
GCNATHAAYA THTTYAA
: 17 (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amlno acid (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Ala Ile Asn Ile Phe Asn ~2) INFORMATION FOR SEQ ID NO:21:
(i) SEQOE NCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
WO 94/11512 2 1~ ~ 71 3 PCr/US93/11000 i`i GGAATTCCGC NATHAAYATH TTYAAYGT
~2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs ?
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GGAATTCC
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid ¦l ~ (D) TOPOLOGY: linear 3 (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Ala Ile Asn Ile Phe Asn Val (2) INFORMATION FOR SEQ ID NO:24:
~ (i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid . (C) STRANDEDNESS: single (D) TOPOLOGY linear ~ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
GCYTCNGTRC ARTCRTGYTT
3 20 ~i `3. ( 2) INFORMATION FOR SEQ ID NO:25: --1 60 (i) SEQUENCE CHARACTERISTICS: ~
' (A) LENGTH: 7 amino acids ~.
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide , ., Wo94/11512 21 ~713 PCr/US9~/11000 1`
(v) FRAGMENT TYPE: internal S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Lys His Asp Cys Thr Glu Ala l 5 (2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: llnear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
~5 GGCTGCAGGT RCARTCRTGY TTNCCRTC
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs (B) TYPE: nucleic acid ~ (C) STRANDEDNESS: single ¦ 35 (D) TOPOLOGY: linear ¦ (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
GGCTGCAG
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide `
(v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Asp Gly Lys ~is Asp Cys Thr .
(2) INFORMATION FOR SEQ ID NO:29:
~W094/11512 2la~ 3 PCI/U593/1100 I
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid .
S (C) STRANDEDNESS: single (D~ TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
1:0 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
ATGTTGGACA GTGTTGTCGA A
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
,: :
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
~30: ~ :
GGGAATTCAG AA~AGTTGAG CATTCTCGT
~ (2) INFORMATION FOR SEQ ID NO:31:
j 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~:40 (D) TOPOLOGY: linear ~- (ii) MOLECULE TYPE: cDNA
~'-;
(xi) SEQOE NCE DESCRIPTION: SEQ ID NO:31:
GGGAATTC
.
, (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs .
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~: (ii) MOLECULE TYPE: cDNA
' . 65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
W 0 94/11512 PC'r/US93/11000 ~
~ GTTCTTCAAT GGGCCATGT .
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS: ;~
(A) LENGTH: 20 base pairs - (B) TYPE: nucleic acid (C) STRANDEDNESS: single : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xl) SEQUENCE DESCRIPTION: SEQ ID NO:33:
GTGTTAGGAC TGTCTCTCGG
~2) INFORMATION FOR SEQ ID NO:34:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single :: (D) TOPOLOGY: linear ~: 30 (ii) MOLECULE TYPE: cDNA
~ .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
TGTCCAGGCC ATGGAATAAG
:
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 20 base pairs , (B) TYPE: nucleic acid . (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~ 50 (ii) MOLECULE TYPE: cDNA
.~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
S5 i.
GCCTTACATG GACTGCAACC
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
-~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~ 65 (D) TOPOLOGY: linear J.~
~' ~ ~ WOg4/11512 21~S~l~ Pcr/us93/llooo ~
(ii) MOLECULE TYPE cDNA
:' 5~ (xi) SEQUENCE DESCRIPTION SEQ ID NO 36 _ TCCACGGGTC TGATAATCCA
2~INFORMATION FOR SEQ ID NO 37 SEQUENCE CHARACTERISTICS
(A) LENGTH 20 base pairs (B)~TYPE nucleic acid 15~ (C) STRANDEDNESS single (D~TOPOLOGY linear ~ ( i i ? MOLECULE TYPE cDNA
(x~)~SEQOE NC~ DECCRIPTIO~ SEQ ID NO 37 ; AGGCAGGAAG CAATTTTCCC
~25~ 20 ~
21~NF M~TIGN FOR 53Q~ID NO~38 `(i3 SEQUENCE CHARACTERISTICS
(A) LENGTH `20 base pairs (B) TYPE ~nucleic acid (C) STRANDE NESS single ~5 ~ (D) TOPOLOGY~ linear ii) MOLECULE TYPE cDNA
(xi) SEQ OENCE DESCRIPTION SEQ ID NO 38 TACTGCACTT CAGCTTCTGC
f -''" , ~ ~ 20 ,-~45 2~INFORMATION FOR SEQ ID NO 39 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 20 base pairs ~50 (B) TYPE nuclelc acid }
(C) STRANDEDNESS single s ~ (D) TOPOLOGY linear ;~ (ii) MOLECULE TYPE cDNA
~55 ~ ;`
(xi) SEQUENCE DESCRIPTION SEQ ID NO 39 ~`-60 GGGGGTCTCC GAATTTATCA
(2) ~INFORMATION FOR SEQ ID NO 40 ~6S~ (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 20 base pairs 1` ~'-`
2 1 4 .3 7 1 3 WO 94/ 1 1 5 1 2 PCr/ ~IS93/ 1 1 000 1 . .
i~`
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA . -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
GGATATTTCA GTGGACACGT
(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2G base pairs ~B) TYPE: nucleic acid : (C) STRANDEDNESS: single (D) TOPOLOGY~ linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
. ~
¦ ~ 30 TATTAGAAGA CCCTGCGCCT
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid ¦ (C) STRANDEDNESS: single I (D) TOPOLOGY: linear ¦ (ii) MOLECULE TYPE: cDNA
1` .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
CCATGTAAGG CCAAGTTAGT
(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single .
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
1, (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
: - ACACCTTTAC CCATTAGAGT
:
`~
;~ 214~713 1~
WO 94/1 1512 PCr/US93/1 1000 ~' 61 r ~: i (2) INFORM~TION FOR SEQ ID NO:44:
~ 5 (i) SEQUENCE CHARACTERISTICS:
`:~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ` ~; (D) TOPOLOGY: linear `'` ~`'10 ~
ii) MOLECULE TYPE: cDNA
, ~
~:.15~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
CTGTCCAACA TAATTTGGGC
.: ~ 20 ~20 ~ :
(2) INFORMATION FOR SEQ ID NO:45:
~ (i) SEQUENCE CHARACTERISTICS:
;~ (A) LENGTH: 20 base pairs ~25 ~B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
CATGGCAGGG TGGTTCAGGC
~ ~ .
(2) INFORMATION FOR SEQ ID NO:46:
~ (i) SEQUENCE CHARACTERISTICS:
G~ : ~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid :: (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~45 (ii) MOLECULE TYPE: cDNA
-50 ~xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
TAGCCCCATT TACGTGCACG
55~
~2) INFORMATION FOR SEQ ID NO:47: ` ~.
SEQUENCE CHARACTERISTICS:
:~60 ~A) LENGTH: 20 base pairs ~ B) TYPE: nucleic acid ~
: ~C) STRANDEDNESS: single (D) TOPOLOGY: linear , ~:65 (ii) MOLECULE TYPE: cDNA
:
~:
:
~ .
~;~: ....... .
W O 94J11512 PCTtUS93/11000 `~
4 8 7 1 3 62 11``
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
~: 5 TTGGGGTCGA GGCCTCCGAA
~ (2) INFORMATION FOR SEQ ID NO:48:
;~ 10 (i) SEQUENCE CXARACTERISTICS:
(A) LENGTH: 9 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single : (D) TOPOLOGY: linear 1:5 (ii) MOLECULE TYPE: cDNA
t~ -~
.~ 20:~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
TAAAAUGGC
(2) INFORMATION FOR SEQ ID NO:49:
~: (i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
;~35 ~ .
~:~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
:
AACAAUGGC
: 40 9 (2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear . (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DE5CRIPTION: SEQ ID NO:50 GCCGAATTCA TGGCCATGAA ATTAATT
(2) INFORMATION FOR SEQ ID NO:51:
; (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 base pairs (B) TYPE: nucleic acid - (C) STRANDEDNESS: single ,~
2 .
WC~ 94/11512 214 8 713 PCI/US93/11000 Ir ~ `
(D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
S ~ ~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5l:
GCCGAATTC t (2) INFORMATION FOR SEQ ID NO:52:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
CGGGGATCCT CATTATGGAT GGTAGAT
, ~2) INFORMATION FOR SEQ ID NO:53:
3 (i) SEQUENCE CHARACTERISTICS:
'35 ~A) LENGTH: 9 base pairs J (B) TYPE: nucleic acid ~C) STRANDEDNESS: single (D) TOPOLOGY: linear ~40 (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
~45 CGGGGATCC
~50 ( 2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid ~D) TOPOLOGY: linear ~.
(ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln ~1 t ~
WO 94111~12 21~ ~ 71 3 PCr/US93/11000 ~ ~
64 1.
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acld ~`
10(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGM$NT TYPE: internal 1~
(xi) SEQUENGE DESCRIPTION: SEQ ID NO:55:
Asn Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn
FROM JAPANESE CEDAR POLLEN
.
Back~round of the Invention Genetically predisposed individuals, who make up about 10% of the population, become hypersensitized (allergic) to antigens from a variety of ~` environmental sources to which they are exposed. Those antigens that can induce immediate and/or delayed types of hypersensitivity are known as allergens. ~King, - T.P., Adv. Immunol. 23: 77-105, (1976)). Anaphylaxis or atopy, which includes the - symptoms of hay fever, asthma, and hives, is one form of immediate allergy. It can be caused by a variety of atopic allergens, such as products of grasses, trees. weeds, animal dander, insects, food, drugs, and chemicals.
The antibodies involved in atopic allergy belong primarily to the IgE class of immunoglobulins. IgE binds to mast cells and basophils. Upon combination of a - ~ ~; specific allergen with IgE bound to mast cells or basophils, the IgE may be cross-link~ed on the cell surface, resulting in the physiological effects of IgE-antigen interaction. These physiological effects include the release of, among other substances, histamine, serotonin, heparin, a chemotactic factor for eosinophilicleukocytes and/or the leukotrienes, C4, D4, and E4, which cause prolonged constriction of bronchial smooth muscle cells (Hood, L.E. et al. Immunology (2nded.), The Benjamin/Cumming Publishing Co., Inc. (1984)). These released substances are the mediators which result in allergic symptoms caused by a combination of IgE with a specific allergen. Through them. the effects of an allergen are manifested. Such effects may be systemic or local in nature, depending on the route by which the antigen entered the body and the pattern of deposition of IgE on mast cells or basophils. Local manifestations generally occur on epithelial surfaces at the location at which the allergen entered the body. Systemic effects can ~, include anaphylaxis (anaphylac~ic shock), which is the result of an IgE-basophilresponse to circulating (intravascular) antigen.
Japanese cedar (Sugi; C yptomeria japonica) pollinosis is one of the most r important allergic diseases in Japan. The number of patients suffering from thisdisease is on the increase and in some areas, more than 10% of the population are affected. Treatment of Japanese cedar pollinosis by administration of Japanese cedar pollen extract to effect hyposensitization to the allergen has been attempted.
Hyposensitization using Japanese cedar pollen extract, however, has drawbacks in WO 94/l1~12 ~ 1 1 8 71 c~ PCI/US93/11000 ~t that it can elicit anaphylaxis if high doses are used, whereas when low doses are used to avoid anaphylaxis, treatment must be continued for several years to build up a tolerance for the extract.
The major allergen from Japanese cedar pollen has been purified and s designated as Sugi basic protein (SBP) or Cry j I. This protein is reported to be a basic protein with a molecular weight of 41-S0 kDa and a pI of 8.8. There appear tO
be multiple isoforms of the allergen, apparently due in part to differential glycosylation (Yasueda et al. (1983) J. Allergy Clin. Immunol. 71: 77-86; and Taniai et al . (1988) FEBS Letters 239: 329-332 . The sequence of the first twenty amino lo acids at the N-terrninal end of Cry j I and a sixteen amino acid internal sequence have been determined (Taniai supra).
A second allergen has recently been isolated from the pollen of Cryptomeria japonica (Japanese cedar) (Sakaguchi et al. (1990) Allergy 45:309-312). This allergen, designated Cry j II, has been reported to have a molecular weight of s approximately 37 kl~a and 45 kDa when assayed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing and reducing conditions, respectively (Sukaguchi et al., supra). Cry j II was found to have no immunological cross-reactivity with Cly j I (Sakaguchi (1990) supra; Kawashima et ~`:
al. (1992) Int. Arch. Allergy Immunol. 98:110-117). Most patients with Japanese ;~ 20 cedar pollinosis were found to have IgE antibodies to both C~y j I and C~y j II.
- however, 29% of allergic patients had IgE that only reacted with Cry; I and 14% of ~ allergic patients had IgE that only reacted with C~y j II (Sakaguchi (1990) supra).
J Isoelectric focusing of Cry j II indicated that this protein has a pI above 9.5. as ~, compared to pI 8.6-8.8 for C)y; I (Sakaguchi (1990) supra). Further, the reported 2s NH2-terminal sequence for Cry j II, NH2-AlaIleAsnIlePheAsnValGluLysTyr-COOH, did not match that reported for C~y j I (Sakaguchi (1990) ~E~) Despite the attention Japanese cedar pollinosis allergens have received, definition or characteri~ation of the allergens responsible for its adverse effects on people is far from complete. Current desensitization therapy involves treatment with pollen extract with its attendant risks of anaphylaxis if high doses of pollen exlract are administered, or long desensitization times when low doses of pollen extract are ~-administered~ ,~
J
Sun~nar~ of the Invention The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j II and fragments thereof. The present invention also provides purified Cly j II and at least one fragment thereof /094/11512 21'1~713 Pcr/uss3/llooo produced in a host cell transformed with a nucleic acid sequence coding for C~y j II i or at least one fragment thereof and fra~ments of C y j II prepared synthetically.
~; ~ As used herein, a fragment of the nucleic acid sequence coding for the entire amin~o acid sequence of C~y j II refers to a nucleotide sequence having fewer bases than the 1-nucleotide sequence coding for the entire amino acid sequence of Cry j II and/ormature CrY J; II. Cry j II and fragments thereof are useful for diagnosing, treating~
and preventing Japanese cedar pollinosis. This invention is more particularly described in the appended claims and is described in its preferred embodiments in the following description.
Description of the Drawin~s Fig. la shows an SDS-PAGE (12%) analysis of C~yj II under non-reducing conditions.
Fig. lb shows an SDS-PAGE (12%) analysis of Cry j II under reducing conditions.
- Fig~ 2 shows the results of mono S column chromatography of Cry j II eluted with a step gradient of NaCI in 10mM sodium acetate buffer, pH 5Ø
Fig. 3 shows an SDS-PAGE (12%) of purified subfractions of C~yj II
analyzed under reducing conditions.
20 ~ ~ ~ Fig. 4 shows the nucleic acid sequence (SEQ ID N0: 1) and the deduced amino acid (SEQ ID N0: 2) coding for C~y j II.
Fig. S shows the deduced amino acid sequence of C~y j II (SEQ ID N0: 2).
Fig. 6 shows the long form (SEQ ID N0: 4) and short forrn (SEQ ID N0: 5) NH2-terrninii amino acid sequences of C~y j II deterrnined by protein sequence ;25 analysis as discussed in Example 2 aligned with the ten amino acid sequence of C~y j II (SEQ ID N0: 3) defined by Sakaguchi et al., supra (SEQ ID N0: 6).
Fig. 7 is a graphic representation of the results of a direct ELISA assay showing the binding response of the monoclonal antibody 4Bl l and seven patients' (Batch l) plasma IgE to purified Cry j I as the coating antigen.
Fig. 8 is a graphic representation of a direct ELISA assay showing the - ~ binding response of the monoclonal antibody 4Bl l, and seven patients' (Batch 1) plasma IgE to purified native Cry j II as the coating antigen. ~-Fig. 9 is a graphic representation of a direct ELISA assay showing the ~ binding response of the monoclonal antibody, 4Bll, and seven patients' (Batch 1) - ~ 3S plasma IgE to recombinant Cry j II (rCry j II) as the coating antigen.
Fig. lO is a graphic representation of a direct ELISA assay showing the binding response of eight patients' (Batch 2) plasma IgE to purified native C~y j E
~:
. : .
'~
~,~ ..... ". . . . .- . .. .. ~.. . . . .
WO 94/l 1512 ~ 1 4 ~ ~ 1 3 4 Pcr/us93/
Fig. 11 is a graphic representation of a direct ELISA assay showing the ' binding response of eight patients' (Batch 2) plasma IgE to purified native Cry j II.
Fig. 12 is a graphic representation of a direct ELISA assay showing the binding response of eight patients' (Batch 2) plasma IgE to recombinant Cry j II.
s Fig. 13 is a graphic representation of a direct ELISA assay showing the ~, binding response of eight patients' (Batch 3) plasma IgE to purified natilve Cr),~ j I.
Fig. 14 is a graphic representation of a direct ELISA assay showing the ` binding response of eight patients' (Batch 3) plasma IgE to purified na~ive Crv j II.
Fig. 15 is a graphic representation of a direct ELISA assay showing the 0 binding response of eight patients' (Batch 3) plasma IgE to recombinant Cry j II.
Fig. 16 is a table which summarizes both the MAST scores performed on patient's plasma samples (Batch 1-3) and the direct ~LISA results shown in Figs. 7-15; a positive response is indicated by a (+) sign and the number of positive responses for each antigen is shown at the bottom of each column.
Detailed Description of the Invention The present invention provides nucleic acid sequences coding for C~ j II, an allergen found in Japanese cedar pollen. The nucleic acid sequence coding for Cry j II shown in Fig. 4 (SEQ ID NO: 1) encodes a protein of 514 amino acids. The deduced C7y j II amino acid sequence is shown in Figs. 4 and 5 (SEQ ID NO: 2) .
Direct protein sequence analysis of native purified Cry j II resulted in two separate overlapping NH2-termini sequences, designated Long and Short, corresponding respectively to amino acids 46 through 89 (SEQ ID NO: 4) and 51 through 89 (SEQ
l ID NO: 5) of Figs. 4, 5 and 6. The ten amino acid sequence NH2-AlaIleAsnIlePhe-2s AsnValGluLysTry-COOH (SEQ ID NO: 6) previously defined by Sakaguchi et al, su~ra for c~y j II corresponds to amino acids 55 through 64 of Figs. 4 and 6. The full-length cry j II sequence contains 20 cysteine residues and three potential N-linked glycosylation sites with the consensus sequence of Asn-Xxx-Ser/Thr.
According to the program contained in PC Gene, Intelligenetics (Mountain View, CA) the proteins with the NH2-termini defined by the Long and Short forms of C~y j II would contain 469 and 464 amino acids, respectively, and have predicted molecular weights of 51.5 kDa (long) and 50.9 kDa (short). The amino acid sequence representing the long form of C~y j II is encoded by the nucleotide sequence extending from bases 177-1586 (SEQ ID NO: 7) as shown in Fig. 4, and the arnino acid sequence representing the short form of Cry j II is encoded by the nucleotide sequence extending from 192-1586 (SEQ ID NO: 8) as shown in Fig. 4.
A host cell transformed with a vector containing the cDNA insert coding for full-"~
: . . . .
~;-r~t ~ 1 4 ~ 7 1 3 2 ~ ~Cr/uss3/1 1000 1 --i --length C~y j II has been deposited with the American Type Culture Collection, ATCC No. 69105 .
Fragments of the nucleic acid sequence coding for fragments of Cry j II are~
also within the scope of the invention. Fragments within the scope of the invention mclude those coding for parts of Cry j II which induce an immune respanse in 1.
!- mammals, preferably humans, such as stimulation of minimal amounts of IgE;
;~ bindlng of IgE; eliciting the production of IgG and IgM antibodies; or the eliciting ~t: of a T cell response such as proliferation and/or Iymphokine secretion and/or the 1 ~ induction of T cell anergy. The foregoing fragments of Cry j II are referred to herein i ~lo as antigenic fragments. Fragments within the scope of the invention also include those capable of hybridizing with nucleic acid from other plant species for use in screening protocols to detect allergens that are cross-reactive with Cry j II. As used herein, a fragment of the nucleic acid sequence coding for Cry j II refers to a nucleotide sequence having fewer bases than the nucleotide sequence coding ~or the entire amino acid sequence of C~y j II and/or mature Cry j II. Generally, the nucleic acid sequence coding for the fragment or fragments of Cry j II will be selected from the bases coding for the mature protein, however, in some instances it may be desirable to select all or a part of a fragment or fragments from the leader sequence ; ponion of the nucleic acid sequence of the invention. The nucleic acid sequence of t he invention may also contain linker sequences, modified restriction endonuclease sites and other sequences useful for cloning, expression or purification of C~y j II or fragments thereof.
A nucleic acid sequence coding for Cry j II may be obtained from Cryptomeria japonica plants. Applicants have found that fresh pollen and staminate 2s cones are a good source of Cry j II mRNA. It may also be possible tO obtain the nucleic acid sequence coding for Cry j II from genomic DNA. C~yptomeria japonica is a well-known species of cedar, and plant material may be obtained from wild, cultivated, or ornamental plants. The nucleic acid sequence coding for Cry j II
~ may be obtained using the method disclosed herein or any other suitable techniques for isolation and cloning of genes. The nucleic acid sequence of the invention may be DNA or RNA.
The present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention. Nucleic acid coding for Cry j II, or at least one fragment thereof may be expressed in bacterial cells such as E.
3s coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. Molecular Cloning: A
. .
~1~8713 wo s4t l l 512 PCr/ US93/ 11000 Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art.
Expression in mammalian, yeast or insect cells leads to partial or complete glycosylation of the recombinant material and formation of any inter- or intra-chain disulfide bonds. ~Suitable vectors for expression in yeast include ~epSecl (Baldari et al. (1987) Embo J. 6: 229-234); pMFa (Kurjan and Herskowitz (1982~ Cell 30: 933-943); JRY88 (Schultz et al. (1987) Gene 54: 113-123) and pYES2 (lnvitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and0 mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego, CA) for expression in insect cells while the pMSG vector is commerically available (Pharmacia, ~, Piscataway, NJ) for expression in mammalian cells.
For expression in E. coli. suitable expression vectors include, among others, pTRC (Amann et al. (1988) Gene 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRlT5 (Pharmacia, Piscataway, NJ); pET-lld (Novagen, Madison, WI) Jameel et al., (1990) J. Virol. 64:3963-3966; and pSEM (Knapp et al. (1990) BioTechniques 8: 280-281). The use of pTRC, and pET-l ld, for example, will lead to the expression of unfused protein.The use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of allergen fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated B-galactosidase (PSEM), or glutathione S-transferase (pGEX). When Cry j II, fragment, or fragments thereof is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and Cly j II or fragment thereof. C~y j II or fragment thereof may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from for example Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann et al., (1988) supra; pET-lld, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, 3s NJ) . It may also be appropriate to express recombinant C~y j II in different E. coli hosts that have an aleered capacity to degrade recombinantly expressed proleins (e.g.
U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic WO 94/11512 2 1 4 8 7 1 3 PC~`~US93/t 1000 ~;
acid sequence to use codons preferentially utilized by E. coli, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.
Host cells can be transformed to express the nucleic- acid sequences of the invention using conventional techniques such as calcium phosphate or calcium ~5 chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation.
Suitable methods for transforrning the host cells may be found in Sambrook et al.
supra, and other laboratory textbooks. The nucleic acid sequences of the invention may also be synthesized using standard techniques.
The present invention also provides a method of producing purified Japanese 0~ ~ cedar pollen allergen C~y j II or at least one fragment thereof comprising the steps of culturing a host cell transformed with a DNA sequence encoding Japanese cedar pollen allergen C)y j II or at least one fragment thereof in an appropriate medium to produce a mixture of cells and medium containing said Japanese cedar pollen allergen Cry j II or at least one fragment thereof; and purifying the mixture toi5 ~ produce substantially pure Japanese cedar pollen allergen Cry j II or at least one fragment thereof. Host cells transformed with an expression vector containing DNA
coding ~for Cly j II or at least one fragment thereof are cultured in a suitable medium for the host cell. Cry j II protein and peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for Cly j II or fragments thereof. The terms isolated and purified are used interchangeably herein and refer to peptides, protein, protein fragments, and nucleic acid sequences substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors~
Cr~ j II protein may also be isolated from lapanese cedar pollen as described in Exarnple l . C~y j II isolated directly from Japanese cedar pollen is referred to herein as "purif~ed native" C~y j II. It is preferable that purified native C~y j II of ~
the invention be at least 80% pure, and more preferably at least 90% pure and even ' more preferably be purified to homogeneity (at least 99% pure).
Another aspect of the invention provides preparations comprising lapanese cedar pollen allergen Cry j II or at least one fragment thereof synthesized in a host cell transformed with a DNA sequence encoding all or a portion of Japanese cedarpollen allergen Cry j II, or chemically synthesued, and purified Japanese cedar pollen allergen Cry j II protein, or at least one aMigenic fragment thereof produced ~`
in a host cell transformed with a nucleic acid sequence of the invention, or chemically synthesized. In preferred embodiments of the invention the Cr~ j II
~__, WO 94/11512 2 1 1 g 7 1 3 PCr/US93/1 1000 ~;
8 . -protein is produced in a host cell transformed with the nucleic acid sequence coding for at least the mature C~y j II protein. t Fragments of an allergen from Cry j II, eliciting a desired antigenic response ', (referred to herein as antigenic fragments) are defined herein as any protein fragment ' s or peptide which can be derived from the Cry j II proteins, but does not include the ,.
ten amino acid fragments which extends from amino acid residues 55-64~ as shown in Figs. 4, 5 and 6, but may include any portion of that ten amino acid fragment in conjunction with another fragment derived from C)y j Il. Antigenic fragments of ~ ; C~y j Il may be obtained, for example, by screening peptides recombinantly ! ~ o produced from the corresponding fragment of the nucleic acid sequence of the invention coding for such peptides, or by screening peptides which have been synthesized chemically using techniques known in the art, or by screening peptides ;~ produced by chemical cleavage of the allergen. The allergen may be arbitrarily divided into fragments of a desired length with no overlap of the peptides, or preferably divided into fragments of a desired length with no overlap of the peptides, or preferably divided into overlapping fragments of a desired length.~ The fragments . are tested to determine their antigenicity (e.g. the ability of the fragment tO induce an immune response such as T cell proliferation as discussed in Example 7).
Antigenic fragments may also be predicted using an algorithm such as that discussed in a paper by Hill et al, ~ournal of Immunology, 147:184-197 (199l).
Algorithms for predicting peptides which elicit T cell activity such as the algorithm discussed by Hill et al. are based on the protein's sequence wherein certain patterns within the sequence are likely to bind MHC and therefore may contain T cell epitopes. The peptides predicted by the algorithm such as Cry j IIA and Cry j IIB
discussed in Example 7 may be produced recombinantly or synthetically and testedfor T cell activity as discussed in Example 7.
If fragments of Japanese cedar pollen allergen, e.g. C)y j Il are to be used fortherapeutic purposes, then the fragments of Japanese cedar pollen allergen which are capable of eliciting a T cell response such as stimulation (i.e., proliferation or '.
lymphokine secretion) and/or are capable of inducing T cell anergy are particularly desirable and fragments of Japanese cedar pollen which have min~mal IgE
stimulating activity are also desirable. Additionally, for therapeutic purposes, ~ -purified Japanese cedar pollen allergens, e.g. Cly j Il, and fragments thereof preferably do not bind IgE specific for Japanese cedar pollen or bind such IgE to a substantially lesser extent than the purified native Japanese cedar pollen allergen binds such IgE. If the purified Japanese cedar pollen allergen or fragment or fragments thereof bind IgE, it is preferable that such binding does not result in the ;~ W094/11~12 2 1 4 8 ~ 1 3 PCr/US93/11000 9 1:~
release of mediators (e.g. histamines) from mast cells or basophils. Minimal IgEstimulating activity refers to IgE stimulating activity that is less than the amount of IgE production stimulated by the native Cry j II protein.
"r~ Isolated antigenic fragments or peptides of the present invention which have s ~ T~ cell stimulating activity, and thus comprise at least one T cell epitope are particularb desirable. T cell epitopes are believed to be involved in initiation and "`'t~ perpetuation of the imrnune response to a protein allergen which is responsible for the ~linicàl~symptoms of allergy. These T cell epitopes are thought to trigger early ` ~ events ~at the level of the T helper cell by binding to an appropriate HLA molecule ~l0 ~ ~ on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulatlon. These events lead to T cell proliferation, Iymphokine secretion, local inflammatory reactions, recruitrnent of additional immune cells to the site, andactivation of the B cell cascade leading to production of antibodies. One isotype of - ~ ~ these~ antibodies, IgE, is fundamentally important to the development of allergic ~15~ symptoms and its production is influenced early in the cascade of events, at the level of ~the T:helper cell, by the nature of the Iymphokines secreted. An epitope is the ; ~ basic~elem~nt or smallest unit of recognition by a receptor, particularly immunoglobulins, histocompatibility antigens and T cell receptors, where the epitope comprises ~amino acids essential to receptor recognition. Amino acid sequences 20 ~ which mimic those of the epitopes particularly T cell epitopes and which modify the allergic response to protein allergens including those capable of down regulating allergic response to Cry j II, are within the scope of this invention.
As discussed in Example 7, human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to Japanese cedar pollenS ~ allergen, (i.e., an individual who has an IgE mediated immune response to Japanese cedar~ pollen allergen) with a peptide derived from the allergen and determining. ~ whether proliferation of T cells occurs in response to the peptide as measured, e.g., it by cellular uptake of tritiated thymidine. Stimulation indices for responses by T t cells to peptides can be c?lculated as the maximum CPM in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background level is considered "positive" . Positive results are used to L `
calculate the mean stimulation index for each peptide tested. Preferred peptides of ~ `
this invention comprise at least one T cell epitope and have a mean T cell stimulation index of greater than or equal to 2Ø A peptide having a mean T cell stimulation 3S ~ index of greater than or equal to 2.0 is considered useful as a therapeutic agent. As shown in Fig. 17 Cr~ j Il peptides Cry j IIA and Cry j IIB have mean stirnulation - ~ indexes of at least two and therefore comprise at least one T cell epitope as 8~ WO 94/1 1512 1 ~ 7 1 3 Pcr/us93/l lO00 3 lo predicted.
Purified protein allergens from Japanese cedar pollen or preferred antigenic ;
fragments thereof, when administered to a Japanese cedar pollen-sensitive individual, or an individual allergic to an allergen cross-reactive with Japanese cedar pollen ' l -5 ~ ` allergen, are capable of modifying the allergic response of the individual to Japanese cedar poilen or such cross-reactive allergen of the individual, and preferably are capable ~of modifying the B-cell response, T-cell response or both the B-cell and the T-cell response of the individual to the allergen. As used herein, modification of the~allergic response of an individual sensitive to a Japanese cedar pollen allergen o ~ can be defined as wn-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See e.g. Varney et al, British Medical Jou~nal, 302:265-269 (1990)) including dirninution in Japanese cedarpollen induced asthmatic symptoms. As referred to herein, a diminution in symptoms includes any reduction in allergic response of an individual to the allergen after the 15 ~ individual has completed a treatment regimen with a peptide or protein of the invention. This diminution may be subjective (i.e. the patient feels more comforta'ole in the presence of the allergen). Diminution in symptoms can be deterrnined clinically as well, using standard skin tests as is known in the art.
The purified C~y j II protein or fragments thereof are preferably tested in 20 mammalian models of Japanese cedar pollinosis such as the mouse model disclosed i n Tamura et al. (1986) Microbiol. Immunol. 30: 883-896, or U.S. patent 4,939,239; or the primate model disclosed in Chiba et al. (1990) Int. Arch. Allergy mmunol. 93: 83-88. Initial screening for IgE binding to the protein or fragmentsthereof may be perforrned by scratch tests or intradermal skin tests on laboratory 2S ~ animals or human vo!unteers, or in in vitro systems such as RAST
(radioallergosorbent test), RAST inhibition, ELISA assay, radioimmunoassay (RIA), or histamine release.
Exposure of allergic individuals to purified protein allergens of the present invention or to the antigenic fragments of the present invention which comprise at 30 least one T cell epitope and are derived from protein allergens may tolerize or anergize appropriate T cell subpopulations such that they become unresponsive to the protein allergen and do not participate in stimulating an immune response upon such exposure. In addition, administration of the protein allergen of the invention or an antigenic fragment of the preseM invention which comprises at least one T cell 35~ epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring protein allergen or portion thereof (e.g. result in a decrease of IL4 and/or an increase in IL-2). Furthermore, exposure to such antigenic :: .
~ :
_ . . . . . . . . . . . . . . .
~ 214~713 ; WO 94/11~12 ~ Pcr/uS93/llOOO
11 f-.
- ~ fragment or protein allergen may influence T cell subpopulations which norrnally participate in the response to the allergen such that these T cells are drawn away ¦ ~ from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and~ !
lung) towards the site(s) of therapeutic administration of the fragment or protein 5; ~ ~ allergen. This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate thc usual irmIlune response at the site of normal exposure to the allergen, resulting in a dirnunution in allergic symptoms.
The isolated Cry j II protein, and fragments or portions derived therefrom can 10 ~ ~ be used in methods of diagnosing, treating and preventing allergic reactions to Japanese cedar pollen allergen or a cross reactive protein allergen. Thus the present invention provides therapeutic compositions comprising purified Japanese cedar `~ ~ pollen allergen Cly j II or at least one fragment thereof produced in a host cell transformed to express C~y j II or at least one fragment thereof, and a ~15 ~ ~ pharmaceutically acceptable carrier or diluent. The therapeutic compositions of the mvention may also comprise synthetically prepared Cry j II or at least one fragment thereof and a pha~naceutically acceptable carrier or diluent. Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. C~ j II protein or at least one fragment thereof may be administered to an individual in combination with, for example, an appropriate diluent, a carrier and/or an adjuvant. Pharmaceutically acceptable - ~ diluents include saline and aqueous buffer solutions. Pharrnaceutically acceptable carriers include polyethylene glycol (Wie et al. (1981) Int. Arch. Allergy Appl.Immunol. 64~ 99) and liposomes (Strejan et al. (1984) J. Neuroimmunol 7: 27).
2 5 For purposes of inducing T cell anergy, the therapeutic composition is preferably administered in nonimmunogenic form, e.g. it does not contain adjuvant. Such compositions will generally be administered by injection (subcutaneous, intravenous, ~ . ~
etc.), oral administration, inhalation, transdermal application or rectal administration. The therapeutic compositions of the invention are administered to 3 0 Japanese cedar pollen-sensitive individuals at dosages and for lengths of time effective to reduce sensitivity (i.e, reduce the allergic response~ of the individual to Japanese cedar pollen. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to Japanese ; - cedar pollen, the age, sex, and weight of the individual, and the ability of the Cty j t.
II protein or fragment thereof to elicit an antigenic response in the individual.
The Cty j II cDNA (or the mRNA from which it was transcribed) or a portion thereof can be used to identify similar sequences in any variety or type of ,~
WO 94/1 1512 2 1 ~ 8 7 1 3 ~ PCr/US93/1 1000 plant and thus, to identify or "pull out" sequences which have sufficient homology to hybridize to the Cry j II cDNA or mRNA or portion thereof, for exarnple, DNA
~ ;~ from allergens of Cupressus sempervirens, Juniperus sabinoides etc., under ~ ~
conditions of low stringency. Those sequences which have sufficient homology ~ .
5~ (generally greater than 40%) can be selected for further assessment using the method described herein Alternatively, high stringency conditiolls can be used. In thismarmer, DNA of the present invention can be used to identify, in other types of - ~ plants, preferably related families, genera, or species such as Juniperus, or Cupressus, sequences encoding polypeptides having amino acid sequences similar to lo~ that of ~Japanese cedar pollen allergen Cry j II, and thus to identify allergens in other species. Thus, the present invention includes not only Cry j II, but also other allergens~ encoded~ by DNA which hybridizes to DNA of the present invention. Theinvention further includes previously unidentified isolated allergenic proteins or fragments thereof that are irnmunologically related to Crv j II or fragments thereof, 15 ~ such~as by antibody cross-reactivity wherein the isolated allergenic proteins or f~ments~ therèof are capable of binding to antibodies specific for the protein and peptides of ~the invention, or by T cell cross-reactivity wherein the isolated al!ergenic proteins or fragments thereof are capable of stimulating T cells specific for the protein and peptides of this invention.
20 ~ ~`Proteins or peptides~ encoded by the cDNA of the present invention can be used,~ for example as "purified" allergens. Such purified allergens aro useful in the standardization of allergen extracts which are key reagents for the diagnosis and treatment of Jàpanese cedar pollinosis~ Furthermore, by using peptides based on the nucleic acid sequences of Cry j II, antl-peptide antisera or monoclonal antibodies can 2s ~ be ~made using standard methods. These sera or monoclonal antibodies can be used to standardize~allergen extracts.
Through use of the peptides and protein of the present invention, preparations of consistent, well-de~med composition and biological activity can be made and administered for therapeutic purposes (e.g. to modify the allergic response of a- ~ 30 Japanese cedar sensitive individual to pollen of such trees). Administration of such peptides or protein may, for example, modify B-cell response to Cry j II allergen, modify T-cell response to C~y j II allergen or modify both B-cell and T-cell 1 -~
responses. Purified peptides can also be used to study the mechanism of immunotherapy of C~yptomeria japonica allergy and to design modified derivatives, ~ ~ t 35 ~ ~ or analogues useful in immunotherapy.
Work by others has shown that high doses of allergens generally produce the best results (i.e., best symptom relief). However, many people are unable to s'~
-~?~ :
WO 94/1 ISI 2 ~ 1 4 ~ 7 ~ 3 pcrtus93J1 1000 tolerate large doses of allergens because of allergic reactions to the allergens.
Modification of naturally-occurring allergens can be designed in such a manner that modified peptides or modified allergens which have the same or enhanced therapeutic properties as the corresponding naturally-occurring allergen but have ~: s ~ reduced side effects (especially anaphylactic reactions) can be produced. These can be, for example, a protein or peptide of the present invention (e.g., one having all or a portion of the amino acid sequence of Cry j II), or a modified protein or peptide, or protein or peptide analogue.
It is possible to modify the structure of a protein or peptide of the invention lo ~ ~ for such purposes as increasing solubility, enhancing therapeutic or preventive efficacy, or stability (e.g., shelf life ex vivo, and resistance to proteolytic degradadon in vivo). ~ A modified protein or peptide can be produced in which the ~; amino acid sequence has been altered, such as by amino acid substitution. deletion, or addition, to modify imrnuno~enicity and/or reduce allergenicity, or to which a component has been added for the same purpose. For example, the arnino acid residues essential to T cell epitope function can be determined using known techniques ~e.g., substitution of each residue and determination of the presence or absence of T cell re?ctivity).
For example, a peptide can be modified so that it maintains the ability to induce T cell anergy and bind MHC proteins without the ability to induce a strong proliferative response or possibly any proliferative response when administered in unmunogenic forrn. In this instance, critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue anddetermination of the presence or absence of T cell reactivity). Those residues shown 2s to be essential to interact with the T cell receptor can be modified by replacing the essential amino acid with another, preferably similar amino acid residue (a . ~.
conservative substitution) whose presence is shown to enhance, diminish but not eliminate binding to relevant MHC.
Additionally, peptides of the invention can be modified by replacing an amino acid shown to be essential to interact with the MHC protein complex with another, preferably sirnilar amino acid residue (conservative substitution) whose ` ~ ~ ~ presence is shown to enhance, diminish but not elirninate or not effect T cell ~r .
activity. In addition, amino acid residues which are not essential for interaction with the MHC protein complex but which still bind the MHC protein complex can be 3 5 modified by being replaced by another amino acid whose incorporation may enhance, not effect, or diminish but not eliminate T cell reactivity. Preferred amino - acid substitutions for non-essential amino acids include, but are not limited to ,;
., `' wos4/ll5l2 21~8713 Pcr/US93/llOOO ~ ``
substiNtions with alanine, glutamic acid, or a methyl amino acid.
Another example of a modification of protein or peptides is substitution of cysteine residues preferably with alanine, serine, threonine, leucine or glutamic acid to mini nize dimerization via disulfide linkages. Another example of modification of s the peptides of the invention is by chemical modification of amino acid side chains or cyclization of the peptide.
In order to enhance stability and/or reactivity, the protein or peptides of the invention Gan also be modified to incorporate one or more polymorphisms in the àrnino acid sequence of the protein allergen resulting from natural allelic variation.
o~; Addltionally, D-amino acids, non-natural amino acids or non-amino acid analogues can~be substituted or added to produce a modified protein or peptide within the scope of lhis lnvention. Furthermore, proteins or peptides of the present invention can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers ~; (Wie et al. supra) to produce a protein or peptide conjugated with PEG. In addition, 5 ~ PEG~ can be added during chemical synthesis of a protein or peptide of the invention.
M~ifications~ of proteins or peptides or portions thereof can also include reduction/
abklation (Tarr in: Methods of Protein Microcharacterization, J.E. Silver ed.
Hurnana Press, ~Clifton, NJ, pp 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an appropriate`carrier (Mishell and Shiigi, eds, Selected Methods inCellular Immunology, WH Freeman, San Francisco, CA (1980); U.S. Patent 4,939,239; or mild formalin treatment (Marsh International Archives of Allergy and Applied :lmmunology, 41:199-215 (1971)).
` To facilitate purification and potentially increase solubility of proteins or peptldes of the invention, it is possible to add reporter group(s) to the peptide 25~ backbone. For example, poly-histidine can be added to a peptide to purify the peptide on~immobilized metal ion affinity chromatography (Hochuli, E. et al., io/lechnology, 6:1321^1325 (1988)). In addition, specific endoprotease cleavage sitès can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences.
In order to successfully desensitize an individual to a protein antigen, it may be necessary to increase the solubility of a protein or peptide by adding functional :~
~ ~ ~ groups to the peptide or by not including hydrophobic T cell epitopes or regions containing hydrophobic epitopes in the peptides or hydrophobic regions of the protein or peptide.
3S~ To potentially aid proper antigen processing of T cell epitopes within a peptide, canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope. For ,~
,,., .','.~-~ ' .
~ !' W094/11512 2I~713 PCI`/US93/11000 1:
example, charged amino acid pairs, SUC~I as KK or RR, can be introduced between regions within a peptide during recombinant construction of the peptide. The resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell s epitopes. In addition, such charged arnino acid residues can result in an increase in ;- ~ solubility of a peptide.
Site-directed mutagenesis of DNA encoding a peptide or protein of the invention (e.g. Cry j II or a fragment thereof) can be used to modify the structure of the peptide or protein by methods known in the art. Such methods may, among o~ others, include PCR withdegenerate oliganucleotides (Ho et al., Gene, 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z. et al., Biochem. Biophvs, Res. Comm., 161:1056-1063 (1989)). Toenhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to chan~e ~- the eucaryotic codons in I;)NA constructs encoding protein or peptides of the l5 ~ invention to ones preferentially used in E. coli, yeast, marnmalian cells, or other `` ~ eukaryotic cells.
Using the structural information now available, it is possible to design Cr~
II peptides which, when administered to a Japanese cedar pollen sensitive individual in s~ufficient quantities, will modify the individual's allergic response to Japanese ~20~ cedar~pollen. This can be done, for example, by examining the structure of C~yj II, producing~peptides (via an expression system, synthetically or otherwise) to be ex`amined for their ability to influence B-cell and/or T-cell responses in Japanese cedar pollen sensitive individuals and selecting appropriate peptides which contain ~ epitopes recogr~ized by the cells. It is now also possible to design an agent or a drug ;~ 25 ~ ~ ~ capable of blocking or inhibiting the ability of Japanese cedar pollen allergen to induce an allergic reaction in Japanese cedar pollen sensitive individuals. Suchagents could be designed, for example, in such a maMer that they would bind to relevant anti-Cry j II IgEs, thus preventing IgE-allergen binding and subsequent mast cell degranulation. Alternatively, such agents could bind to cellular components of the imrnune system, resulting in suppression or desensitization of the allergic response to Cryptomeria japonica pollen allergens. A non-restrictive exarnple of~;~ ~is is the use of appropriate B- and T-cell epitope peptides, or modifications ~ `
thereof, based on the cDNA/protein structures of the present invention to suppress the allergic response to Japanese cedar pollen. This can be carried out by defining 35 ~ the strucmres of B- and T-cell epitope peptides which affect B- and T-cell function in - in vitro studies with blood components from Japanese cedar pollen sensitive individuals .
:
:
' ~ ! .
WO 94/11512 2 1 4 8 71 3 pcr/us93/11000 16 ~`
Protein, peptides or antibodies of the present invention can also be used for detecting and diagnosing Japanese cedar pollinosis. For example, this could be done by combining blood or blood products obtained from an individual to be assessed^ for sensitivity to Japanese cedar pollen with an isolated antigenic peptide or peptides of Cly j II, or isolated Cry j II protein, under conditions appropriate for binding of t components in the blood (e.g., antibodies, T-cells, B-cells) with the peptide(s) or i! protein and determining the extent to which such binding occurs. Other diagnostic ~- methods for allergic diseases which the protein, peptides or antibodies of the present invention can be used include radio-allergosorbent test (RAST), paper j 10 radioimmunosorbent test (PRIST), enzyme linked immunosorbent assay (ELISA), 1 radioimrnunoassays (RIA), immuno-radiometric assays (IRMA), luminescence ¦ immunoassays (LIA), histamine release assays and IgE imrnunoblots.
In another diagnostic test, the presence in individuals of IgE specific for Cry j II at least one protein allergen and the abilitv of T cells of the individuals to respond to T cell epitope(s) of C~y j Il protein allergen can be determined by adminis~ering to the individuals an Irnmediate Type Hypersensitivity test and a Delayed Type Hypersensitivity test. The individuals are administered an Immediate Type Hypersensitivity test (see e.g. Immunology (1985) Roitt, I.M., Brostoff, J., Male, D.K. (eds), C.V. Mosby Co., Gower Medical Publishing, London, NY, pp.
~ 20 19.2-19.18; pp. 22.1-22.10) utilizing the Cry i II protein allergen or a portion `-~ ~ thereof, or a modified form of the Cry j Il protein allergen or a portion thereof, each of which binds IgE specific for the allergen. The same individuals are administered a Delayed Type Hypersensitivity test prior to, simultaneously with, or subsequent to administraiton of the Imrnediate Type Hypersensitivity test. Of course, if the Irnmediate Type Hypersensitivity test is administered prior to the Delayed Type Hypersensitivity test, the Delayed Type Hypersensitivity test would be given to those individuals exhibiting a specific Immediate Type Hypersensitivityreaction. The Delayed Type Hypersensitivity test utilizes a modified form of theprotein allergen or a portion thereof, the protein allergen produced recombinantly, or a recombitope peptide derived from the protein allergen, each of which has human T
cell stimulating activity and each of which does not bind IgE specific for the allergen in a substantial percentage of the population of individuals sensitive to the allergen 7 "
(e.g., at least about 75 %). Based on the results of the above diagnostic tests, those individuals found to have both a specific lmmediate Type Hypersensitivity reaction 3s and a specific Delayed Type Hypersensitivity reaction are suitable candidates for administration of a therapeutically effective amount of a therapeutic composition The thFrapeutic composition comprises the modified forrn of the protein or portion WO94tllS12 21 4 ~, ~1 3 pcr/uss3/1looo thereof, the recombinantly produced protein allergen, or the recombitope peptide~
each as used in the Delayed Type Hypersensitivity test, and a pharmaceutically acceptable carrier or diluent. ~ 3 The present invention also provides a method of producing C~y j II or fragment thereof comprising culturing a host cell containing an expression vector which contains DNA encoding all or at least one fiagnient of C~yJ II under conditions appropriate for expression of C~y j II or at least one fragment. The expressed product is then récovered, using known techniques. Alternatively, Cry j II
or fragment thereof can be synthesized using known mechanical or chemical techniques.
;~ The DNA used in any embodiment of this invention can be cDNA obtained as described herein, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or ls ~ enzymatically, using known techniques. A functional equivalent of an oligonucleotide sequence is one which is 1) a sequence capable of hybridizing to a complemeMary oligonucleotide to which the sequence (or corresponding sequence ~portions) of Cry j II or fragments thereof hybridizes, or 2) the sequence (or corresponding sequence portion) complementary to C~y j II? and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or correspondin~ sequence portion) of C~y j II. Whether a functional equivalent must meet one or both criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first or second criteria and if it is to be used to produce a Cty j II allergen, ~25 it need only meet the third criterion).
The invention is further illustrated by the following non-limiting examples.
Example 1 Purification of Native Japanese Cedar Pollen Aller~en (CrY i II) :
The following purification of native C~y j II from Japanese cedar pollen was ~, modified from previously published reports (Yasueda et al, J. Allergy Ctin.
Immunol. 71:77 (1983); Sukaguchi et al., Allergy, 45:309 (l990)).
100g of Japanese cedar pollen obtained from Japan (Hollister-Stier, Spokane, WA) was defatted in lL diethyl ether three times, the pollen was collected afterfiltration and the ether was dried off in a vacuum.
The defatted pollen was extracted at 4C overnight in 2L extraction buffer :
.
~,.. .~ .. , - . . . ~ -,. .:
WO 94/11512 Pcr/uss3/1looo ~ '~!~ ~,','' 2148713 1~ :
containing 50 mM tris-HCl, pH 7.~, 0.2 M NaCl and protease inhibitors in final .~; concentrations: soybean trypsin inhibitor (2 !lg/mL), leupeptin (1 ,ug/mL), pepstatin A (1 ~Lg/mL) and phenyl methyl sulfonyl fluoride (0.17 mg/mL). The insoluble~
material was re-extrated with 1.2L extraction buffer at 4C overnight and both ~,1 s extracts were combined together and depigmented by batch absorption with 'J
Whatman DE-52 (200g dry weight) equilibrated wilh the extraction buffer.
,~ The depigmented material was then fractionated by ammonium sulfate precipitation at 80% saturation (4C), which removed much of the lower molecularweight material. The resulting pellet was resuspended in 0.4 L of 50 mM Na-3 lo acetate, pH 5.0 containing protease inhibitors and was dialyzed extensively against the same buffer.
The sample was further subjected to purification by either one of the two methods described below.
Method A
The sample was applied to a 100 rnL DEAE cellulose column (Whatman DE-52) equilibrated at 4C with 50 mM Na-acetate, pH 5.0 with protease inhibitors.
The unbound material (basic proteins) from the DEAE cellulose column was then applied to a 50 ml cation exchange column (Whatman CM-52) which was equilibrated with 10 rnM Na-acetate, pH 5.0 at 4C with protease inhibitors. A
linear gradient of 0-0.3 M NaCI was used to elute the proteins. The early fractions were enriched in C~y j I whereas the later fractions were enriched in Cly j II.
Fractions containing Cr,v j II were pooled and next applied to an 1 mL Mono S HR5/5 column (Pharmacia, Piscataway, NJ) in 10 mM Na-acetate, pH 5.0, and proteinswere eluted with a linear gradient of NaCI at room temperature. Residual Cry j Iwas eluted at -0.2 M NaCI and Cry j II was eluted between 0.3 to 0.4 M NaCI.
The C~ j II peak was pooled and concentrated to twofold by Iyophilization and subjected to gel filtration chromatography.
The sample was applied to FPLC Superdex 75 16/60 column (Pharmacia, Piscataway, NJ) in 10 mM acetate buffer, pH 5.0 and 0.15 M NaCI at a flow rate of 30 ml/min. at room temperature. Purified Cr,v j II was recovered in the 35-30 kDregion. Cr,v j II migrated as ~wo broad bands lower than Cry j I under non-reducing j conditions (Fig. la) but both bands shifted upward and migrated as C~y j I under '1 reducing condition (Fig. lb) when analyzed by silver-stained SDS-PAGE. This 3s highly puri~led C~y j II still contained a small amount (~5 %) of Cry j I as detected by Western blot using MAb CBF2, which has been shown to bind to C~y j I and by N-terminal protein sequencing. This C~y j II preparation was used to generate primary ;~, . ~ ... . . .;
WO94/11512 21'1~ 713 pcr/us93/llooo 19 !`
protein sequence of Cry J II as described below.
Method B ~ j The dialyzed sample from the amrnonium sulfate precipitation was applied at ~-1 ml/min to an 5.0 ml Q-Sepharose Econapac anion exchange cartridge (BioRad, Richmond, CA) equilibrated with 50 mM Na-acetate, pH 5.0 with protease inhibitors at 4C. Elution was performed with the above buffer containing 0.5 M
NaCI. The basic unbound material was then applied to a 5.0 ml CM-Sepharose Econopac cation exchange cartridge (BioRad, Richmond, CA) equilibrated in 50 rnM~10 `~ ~ sodium~acetate pH 5.0 with protease inhibitors. Basic proteins were eluted with a linear gradient up to 0.1 M sodium phosphate pH 7.0, 0.3 M NaCI at 1 ml/min at 4C. A CtyJ II -enriched peak was collected late in the gradient and further purified by gel filtration chromatography.
FPLC gel filtration was performed using a 320 mL Superdex 75 26/60 15~ (Pharmacia, Piscataway, NJ) column at 0.5 ml/min in 20 mM sodium acetate, pH
5.0, in~the presence of 0.15 M NaCI. The major peak containing mostly Cry j II
eluted between 160 and 190 ml. Contaminating Cry j I was next removed by FPLC
using a 1.0 ml Mono S 515 (Pharmacia, Piscataway, NJ) cation exchaIlge column ; equilibrated with 10 mM sodium acetate pH 5Ø A stepwise gradient of 0^1 M
~o ~ NaCl was~utilized by~holding isocratically at 0.2 M, 0.3 M, 0.4 M and 1 M salt concenttation.
Multiple peaks (up to nine peaks) were obtained (Fig. 2) and analyzed by silver stained SDS-PAGE under reducing conditions (Fig 3). Cry j I with a ~ reported pI of 8.6-8.9 (Yasueda et al, J. Allergy Clin. Immunol., vol. 17 (1983)), 25 ~ ~eluted in the earlier peaks and displayed a molecular weight of about 40 kD. Cry j II
was purified to homogeneity as two bands (Fig. 3) and eluted in the later multiple peaks, suggesting the existence of isofor ns. ELlSA analysis using the mouse monoclonal 8Bl I IgG antibody which was raised against biochemically purified Cry ~ j I confirmed the absence of Cry j I in these purified Cry j II preparation. This ¦ 30 purified C~ j Il was used in the human IgE reactivity studies (Example 6).
Phvsical properties of Cns j II ~`~
The physiochemical properties of Cr~ j II were studied and sumrnarized as ¦ ~ ~ below. Under non-reducing SDS-PAGE conditions Cr~ j II consists of two bands with molecular weights ranged 34000-32000. The molecular weights of both bands ~- are shifted higher to about 38-36 kD under reducing conditions (Fig. lb). This shift in SDS-polyacrylamide gel has also been observed by others (Sakaguchi et al, Wo 94/l 1512 2 1 4 ~ 7 1 3 Pcr/uss3/l 1000 `!` ~
Aller~45:309-312 (1990)). These results suggest that intra-disulfide bonds are probably present in the protein, and it is supported by the present findings that cloned Cry j II contains 20 cysteines deduced from the nucleotide sequence (Example ~ 3). The pI of Cry j II estimated from IEF gel is about 10. The purifled Cry j II
- ~ ~ s binds human IgE of some allergic patients.
The two moleeular weight bands of Cr~ j II wele ~eparated on a 12~ SDS-polyacrylamide gel and was then electroblotted onto PVDF membrane (Applied Biosystems, Foster City, CA). The blot was stained with coomassie brilliant blueand was cut and subjected to N-terrninal amino acid sequencing. (Example 2). Theo results showed that the upper and lower molecular weight bands had identical N-terminal sequences except the lower molecular weight band missed the first five arnino acids. The estimated molecular weight of the upper band based on the cDNAsequence is about 52,000, which is significantly higher than the molecular weight estimated from SDS-polyacrylamide gel either in the presence or absence of reducing ls ~ ~ reagent. It is also higher than that obtained from gel filtration and preliminary mass spectroscopy analysis. These are several possibilities to account for this difference.
One possibility is that C~y j II protein is processed. It is probable that the N-terminal and C-terminal of the protein are cleaved. It is not clear at the present time whether this processing occurs in the cell or due to proteolysis during purification even though four different protease inhibitors were added in most of the purification steps. Nevertheless, the two N-terminal sequences obtained from the purified Cry j II (Example 2) also contained the N-terminal sequence (10 amino acid) published by Sakaguchi et al (Allergy, 45:309-312(1990)) suggesting that the N-terminal of C~II is probably hydrolyzed. Since Sakaguchi et al. (supra), did not use any protease inhibitors in their purification, a higher degree of hydrolysis might have occurred.
This could explain why the N-terminal amino acid sequence that Sakaguchi et al.
obtained was downstream of the N-terminal sequences as discussed in Example 2.
Another approach which may be used to purify native C~ j II or recombinant Cry j II is in~nunoaf~mity chromatography. This technique provides a very selective protein purification due to the speci~lcity of the interaction between monoclonal antibodies and antigen. Murine polyclonal and monoclonal antibodies are generated against purified C~y j II. These antibodies are used for purification, characterization, analysis and diagnosis of the allergen C~y j II. `
: :
Example 2 Protein Sequencing of Purified CJY j II
C.Yi II protein was isolated as in Exarnple l . The doublet band shown on ~: ' ~ WO 94/11512 2 1 4 ~ 7 1 3 PCr/USs3/1 1000 SDS-PAGE (Fig. la) was electroblotted onto ProBlott (Applied Biosystems, Foster City, CA). Sequencing was performed with the Beckman/Porton Microsequencer (model LF3000, Beckman Instruments, Carlsbad, CA), a Programmable Solvent Module (Beckman System Gold Model 126, Beckman Instuments, Carlsbad, CA) and a Diode Array Detector Module for PTH-amino acid detection (Beckman System Gold Model 168, Beckman Inslruments, Carlsbad, CA) foliowing manufacturers specifications.
A~single N-terrninal sequence analysis of the upper doublet band and multiple N-tèrminal sequence analyses of the lower doublet band showed that both bands o ~ contained two N-termini, designated "long" and "short". The lower doublet band contained~approximately 3.3 picomoles of the long form and 8.3 picomoles of the shon~form. This difference in yields was sufficient to make sequence assignmentsaccording to the quantitation at each sequencer cycle. The upper doublet band contained approximatelyl8.3 picomoles of both sequences. The revealed long ,~ s- ~ sequence~wasNH2-RKVEHSRHDAINIFNVEKYGAVGDGKH-DCTEAFSTAW(Q) ) ( ) KNP ( ) -COOH, (SEQ ID NO: 4) where (Q) indicates a tentative i dent~ication of glutarnine at position 38 and () indicated unknown residues atpositions 39~1 and 45. The revealed "short" sequence was NH2-; SRHDA:tNIFNVE~YGAVGDGKHDCTEAFSTAWS-COOH (SEQ ID NO: 5).
Thus ~the ~ long Cry j II sequence had five additional amino terminal residues than the short~for n~and the sequence of the short form exactly matched that of the long form.
In addition,~both the long and short forms of Cry j II contained the ten amino acids, NH2-AINIFNVEKY-COOH (SEQ ID NO 6), previously described for Crv j II
(Sakaguchi et al. 1990t ~). The previously published ten amino acids ~: 25 ~ (Sal~aguchi et al. 1990, suora) correspond to amino acids ten through 19 of the long form described above.
` Example3 ; , ~ Extraction of RNA From Japanese Cedar Pollen and Staminate Cones and '.
Clonin~ of Crv iII
Fresh pollen and staminate cone samples, collected from a single ~yptomena japonica (Japanese Cedar) tree at the Arnold Arboretum (Boston, MA), were frozen ~mmediately on dry ice. RNA was prepared from 500 mg of each ; sample, essentially as described by Frankis and Mascarhenas (1980) Ann. Bot~ 45:
595-599. The samples were ground by mortar and pestle on dry ice and suspended in 5 ml of 50 mM Tris pH 9.0 with 0.2 M NaCI, 1 mM EDTA, 0.1~ SDS that had been treated overnight with 0.1~ diethyl pyrocarbonate (DEPC). After five . ~ .
':
WO 94/~ 1512 2 1 4 ~ 7 1 3 Pcr/uS93/~ lOoo extractions with phenol/chloroform/isoamyl alcohol (mixed 25:24:1), the RNA was precipitated from the aqueous phase with 0.1 volume 3M sodium acetate and 2 volumes ethanol. The pellets were recovered by centrifugation, resuspended in 2~ml dH2O and heated to 65C for 5 minutes. Two ml 4M lithium chloride was added to s the preparation and the RNA was precipitated overnight at 0C. The RNA pellets .`
were rècovered by centrifugation, resuspended in 1 ml dH2O~ and again preeipitated with 3M sodium acetate and ethanol on dry ice for one hour. The final pellet waswashed with 70% ethanol, air dried and resuspended in 100 ~I DEPC-treated dH2O
;~ ~ and stored at -80C.
lo ~ Double stranded cDNA was synthesized from 4 ~g pollen RNA or 8 ,ug flowerhead RNA using a commercially available kit (cDNA Synthesis System kit, BRL, Gaithersburg, MD). The double-stranded cDNA was phenol extracted, ethanol precipitated, blunted with T4 DNA polymerase (Promega, Madison, WI), and then ligated to ethanol precipitated, self annealed, AT and AL oligonucleotides for use in a modified Anchored PCR reaction, according to the method of Rafnar et al. (1990) J. Biol. Chem. 266: 1229-1236; Frohman et al. (1990) Proc. Natl.
Acad~. Sci. USA 85: 8998-9002; and Roux et al. (1990) BioTech. 8: 48-57.
~; Oligonucleotide AT has the sequence (SEQ ID NO: 10) 5'-GGGTCTAGAGGTACCG-TCCGTCCGATCGATCATT-3' (Rafnar et al.
- 20 su~ra). Oligonucleotide AL has the sequence (SEQ ID NO: 11) 5'-AATGATCGATGCT (Rafnar et al. supra).
d ~ -~ The first attempts at amplifying the amino terminus of Cry j II from the linkered cDNA (2 ~l of a 20 ~l reaction) was made using the degenerate.
oligonucleotide CP-11 and oligonucleotide AP. CP-11 has the sequence (SEQ ID
- ~ 25 NO: 12) 5'-ATACTTCTCIACGI~GAA-3', wherein A at positon 1 can be G, C at position 4 can be T, C at position 7 can be T, I at position 10 is inosine to reduce degeneracy (Knoth et al. (1988) Nucleic Acids Res. I6: 10932), G at position 13 can be A, and G at position 16 can be A). AP, which has the sequence (SEQ ID NO:
13) 5'-GGGTCTAGAGGTA-CCGTCCG-3', corresponds to nucleotides 1 through 20 of the oligonucleotide AT. CP-11 is the degenerate oligonucleotide sequence that is complementary to the coding strand sequence substantially encoding amino acids PheAsnValGluLysTyr (SEQ ID NO: 14) (amino acids 59 to 64 of Fig. 4), which ~:
correspond to the carboxy terminus of the previously published Cry j II sequence(Sakaguchi et al., supra) shown in Fig. 4. All oligonucleotides were synthesized by Research Genetics Inc., Huntsville, AL.
Polymerase chain reactions (PCR) were carried out using a commercially available kit (GeneAmp DNA Arnplification kit, Perkin Elmer Cetus, Norwalk, CT) :; .
:
`` W 0 94/11512 21~1~713 PCr/US93/11000 ~ 23 t~
,~ J
whereby 10 ,ul 10x buffer contair~ing dNTPs was mixed with 100 pmoles of each oligonucleotide, cDNA (3-5 ,ul of a 20 ~l first strand cDNA reaction mix), 0.5 ,ul Amplitaq DNA polymerase, and distilled water to 100 ~
The samples were amplified with a programmable thermal controller (MJ
s Research, Inc., Cambridge, MA). The first ~ rounds of amplification consisted of denaturation at 94C for 1 min, annealing of primers to tlle t~mplate at 45C for 1 min, and chain elongation at 72C for 1 min. The final 20 rounds of amplification consisted of denaturation as above, annealing at 55C for 1 min~ and elongation as above. The-primary PCR reaction was carried out with 100 pmol each of the 0 oligonucleotides AP and CP-11. Five percent (S ,ul) of this initial amplification was then used in a secondary amplification with 100 pmoles each of AP and CP-12. CP-12 has the sequence (SEQ ID NO: 15) 5'-CCTGCAGTACTTCT-CIACGTTGAAIAT-3', wherein C at position 10 can be T, C at position 13 can be T, I at positions 16 and 25 are inosines to reduce degeneracy as above, G at position 19 can 've A, and G at position 22 can be A. The sequence (SEQ ID NO: 16) 5'-CCTGCAG-3' (bases 1 through 7 of CP-12) represents a Pst I site added for cloning pulposes; the remaining degenerate oligonucleotide sequence is complementary to the coding strand sequence that substantially encodes the amino -acids IlePheAsnValGluLysTyr (SEQ ID NO: 17) (amino acids 58-64 of Fig. 4).
Ampli~led DNA was recovered by sequential chloroforrn, phenol, and chlorofo~n extractions, followed by precipitation on dry ice with 0.5 volumes of 7.5M
ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washing `
with 70% ethanol, the DNA was simultaneously digested with Xba I and Pst I in a 50 ~l reaction, precipitated to reduce the volume to 10 ~1, and electrophoresed through a preparative 2% GTG NuSeive low melt gel (EMC, Rockport, ME). The appropriate sized DNA area was visualized by ethidium bromide (EtBr) staining, excised, and ligated into appropriately digested pUC19 for sequencing by the ', dideoxy chain termination method of Sanger et al. (1977) Proc. Natl. Acad. Sci.
USA 74: 5463-5476) using a cornmercially available sequencing kit (Sequenase kit, i, .
U.S. Biochemicals, Cleveland, OH). All resultant clones were sequenced, and nonewere found to contain Cry j II sequence. An alternate 2 PCR reaction was performed with AP and the nested oligonucleotide CP-21. CP-21 has the sequence (SEQ ID NO: 18) 5'-CCTGCAGTACTTCTCIACGTTGAAGAT-3' wherein C at position 10 can be T, C at position 13 can be T, I at position 16 is inosine to reduce degeneracy as above, G at position 19 can be A, G at position 22 can be A, and G at position 25 can be A or T. The sequence (SEQ ID NO: 16) 5'-CCTGCAG-3' (bases 1 through 7 of CP-21) represent a Pst I site added for cloning purposes; the WO 94/1 1512 PfCrtUS93/1 1000 ~ i;~`
~l~lg71~ 24 `
remaining degencrate oligonucleotide sequence is the non-coding strand sequence corresponding to coding strand sequence substantially encoding amino acids IlePheAsnValGluLysTyr (SEQ ID NO: 17) (amino acids 58 to 64 of Fig. 4).
A primary PCR was also performed on double-stranded~ cered cDNA
s using CP-23D and AP, as above, to attempt to amplify the 3' end of the Cry j II
cDNA. A secondary PCR was performed using 5 % of ~e priinary reaction, using CP-24D and AP. CP-23D (sequence (SEQ ID NO: 19) 5'-GCIATTAATATTTTTAA-3', wherein the T at position 6 can be C or A, T at position 9 can be C, T at position 12 can be C or A, and T at position 15 can be C ) is the coding strand sequence substantially encoding amino acids AlaIleAsnIlePheAsn (SEQ ID NO: 20) (amino acids 55 to 60 of Fig. 4); CP-24D (SEQ ID NO: 21) ~sequence 5'-GGAATTCCGCIATTAATATTTTTAATGT-3', wnerein the T at position 14 can be C or A, T at position 17 can be C, T at position 20 can be C or A, T at position 23 can be C, and T a~ position 26 can be C ) contains the sequence 5'-GGAATTCC-3' (SEQ ID NO: 22) (bases 1 through 8 of CP-24), which represents an Eco Rl site added for cloning purposes. The remaining degenerate oligonucleotide sequence of CP-24D substantially encodes amino acids AlaIleAsnIlePheAsnVal (SEQ ID NO: 23) (amino acids 55 to 61 of Fig. 4). Again, multiple clones were sequenced, none of which could be identified as Cly j II, and this approach was not pursued further.
Upon the characterization of novel C~y j II protein sequence data described in Example 2, new degenerate oligonucleotides for cloning C~y j II were designed and ¦ synthesized. All oligonucleotides mentioned hereafter were synthesized on an ABI
394 DNA/RNA Synthesizer (Applied Biosystems, Foster City, CA), and purified on 2s NAP-10 colurnns (Pharrnacia, Uppsala, Sweden) as per the manufacturers' instructions. Degenerate oligonucleotide CP-35 was used with AP on the double-stranded linkered cDNA in a primary PCR reaction carried out as described herein.
CP-35 has the sequence (SEQ ID NO: 24) 5'-GCTTCGGTACAATCATGm-3', wherein T at position 3 can also be C; G at position 6 can also be A, T or C; A at position 9 can also be G; A at position 12 can also be G; A at position 15 can be G;
and T at position 18 can also be C; this degenerate oligonucleotide sequence is the non-coding strand sequence corresponding to coding strand sequence substantiallyencoding amino acids LysHisAspCysThrGluAla of Cry j II (SEQ Il:~ NO: 25) (amino acids 71 to 77 of Fig. 4). Five percent (5 ,ul) of this initial amplification, designated JC136, was then used in a secondary amplification with 100 pmoles each of AP anddegenerate Cly j II primer CP-36, an internally nested Cry j II oligonucleotide primer with the sequence (SEQ ID NO: 26) 5'-Wos4/llsl2 ~1 18713 pcr/lJs93/llooo GGCTGCAGGTACAATCATGTTTGCCATC-3' wherein A at position 11 can also be G; A at position 14 can also be G; A at position 17 can also be G; T at position 20 can also be C; G at position 23 can also be A, T, or C; and A at position 26 can~also be G. The nucleotides 5'-GGCTGCAG-3' (SEQ ID NO: 27) (bases 1 through 8 of s CP-36) represent a Pst I restriction site added for cloning purposes. The remaining }
degenerate oligonucleotide sequence of CP-36 is the noll-coding strand sequence corresponding to coding strand sequence substantially encoding amino acids AspGlyLysHisAspCysThr of Cry j II (SEQ ID NO: 28) (amino acids 69 to 75 of Fig.
4). The dominant amplified product, designated JC137, was a DNA band of o approximately 265 base pairs, as visual~zed on an EtBr-stained 2% GTG agarose gel.
Amplified DNA was recovered by sequential chloroform, phenol, and chloroform extractions, followed by precipitation at -20C with 0.5 volumes of 7~5 ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washingwith 70% ethanol, the DNA was simultaneously digested with X~a I and Pst I in a 15 ~l reaction and electrophoresed through a preparative 2% GTG SeaPlaque low ~; ~ melt gel (FMC, Rockport, ME). The appropriate sized DNA band was visualized by EtBr staining, excised, and ligated into appropriately digested pUC19 for sequencing by the dideoxy chain termination method (Sanger et al. (1977) Proc. Natl Acad Sci. lJSA 74: 5463-5476) using a commercially available sequencing kit (Sequenase kit, U.S. Biochemicals, Cleveland, OH).
The clones designated pUC19JC137a, pUC19JC137b, and pUC19JC137e were found to contain sequences encodin~ the amino terminus of Cty j II. All three clones had identical sequence in their regions of overlap, although all three clones had different lengths in the S' untranslated region. Clone pUC19JC137b was the longest clone. The translated sequence of these clones had complete identity to the disclosed 10 arnino acid sequence of C~y j II (Sakaguchi et al.,supra.), as well as to the Cry j II amino acid sequence described in Example 2. , Amino acid numbering is based on the sequence of the full length prote~n; amino acid 1 corresponds to the initiating methionine (Met) of Cry j II. The position of the initiating Met was supported by the presence of an upstrèam in-frame-stop codon and by 78% homology of the surrounding nucleotide sequence with the plant consensus sequence that encompasses the initiating Met, as reported by Lutcke et al. (1987) EMBO J. 6:43~8.
The cDNA encoding the remainder of Cry j II gene was cloned from the linkered cDNA by using oligonucleotides CP-37 (SEQ ID NO: 29) (which has the sequence 5'-ATGTTGGACAGTGTTGTCGAA-3') and AP in a primary PCR, `-designated JC138ii. Oligonucleotide CP-37 corresponds to nucleotides 129 to 149 of W094/11512 21 l~713 PCI`/VS93/11000 Fig. 4, and is based on the nucleotide sequence deteImined for the partial Cry j II
clone pUC19JC137b.
A secondary PCR reaction was performed on 5 % of the initial amplification mixture, with 100 pmoles each of AP and CP-38 (SEQ ID NO: 30) (which has the sequence 5'-GGGAATTCAGAAAAGTTGAGCATTCTCGT-3'), the nested primer.
The nucleotide sequence (SEQ I~) NO: 31) 5'-GG~AATTC-3' (bases 1 ~hrough 8 of CP-38) represents an Eco RI restriction site added for cloning purposes. The remaining oligonucleotide sequence corresponds to nucleotides 177 to 197 of Fig. 4, and is based on the nucleotide sequence determined for the partial Cry j II clone ; lo pUC19JC137b. The amplified DNA product, designated JC140iii, was purified and precipitated as above, followed by digestion with Eco RI and Asp 718 and electrophoresis through a preparative 1 % low melt gel. The dominant DNA band, which was approximately 1.55 kb in length, was excised and ligated into pUC19 for sequencing. DNA was sequenced by the dideoxy chain termination method (Sanger et al. supra) using a commercially available kit (sequenase kit (U.S. Biochemicals, Cleveland, OH). Both strands were completely sequenced using M13 forward and reverse primers (N.E. Biolabs, Beverly, MA) and internal sequencing primers CP-35,CP-38,CP40,CP-41,CP-42,CP-43,CP-44,CP-45,CP-46,CP-47,CP-48, CP-49,CP-50, and CP-51. CP-40 (SEQ ID NO: 32? has the sequence 5'-GTTCTTCAATGGGCCATGT-3' and corresponds to nucleotides 359 to 377 of Fig.
4. CP-41 (SEQ ID NO: 33) has the sequence 5'- GTGTTAGGACT-GTCTCTCGG-3', which is the non-coding strand sequence that corresponds to nucleotides 720 to 739 of Fig. 4. CP-42 (SEQ ID NO: 35) has the sequence 5'-TGTCCAGGCCAT-GGAATAAG-3', which corresponds to nucleotides 864 to 2s 883 of Fig. 4 except that the first nucleotide was synthesized as a T rather than the correct G. CP43 has the sequence (SEQ ID NO: 35)5'-GCCTTACATGGACTGCAACC-3', which is the non-coding strand sequence that corresponds to nucleotides 1476 to 1495of Fig. 4. CP44 has the sequence (SEQ
ID NO:36)5'-TCCACGGGTCTGATAATCCA-3', which corresponds to nucleotides 612 to 631ofPig. 4. CP-45has the sequence (SEQ ID NO:37) S'-AGGCAGGAAGCAATTTT-CCC-3', which is the non-coding strand sequence that corresponds to nucleotides 1254to1273ofFig. 4. CP-46 has the sequence ~ "
(SEQ ID NO:38)5'-TACTGCACTTCAGCT-TCTGC-3', which corresponds to nucleotides 1077 to 1096 ofFig. 4. CP-47 has the sequence (SEQ ID N(:): 39) 3S 5'-GGGGGTCTCCGAATTTATCA-3', which is the non-coding strand sequence thatsubstantially corresponds to nucleotides 1039to1058ofFig. 4, except that the fifth nucleotide of CP-47 was synthesized as a G rather than the correct nucleotide, T.
= t~ 21 4 ~ 7 1 3 Pcr/us93/l lO00 1~ ~
CP-48 (SEQ ID NO: 40), which has the sequence 5'-GGATATTTCAGTGGACACGT-3', corresponds to nucleotides 1290 to 1309 of Fig. 4. CP-49 (SEQ ID NO: 41) has the sequence 5'-TATTAGAAGACC-CTGTGCCT-3', which is the non-coding strand sequence that corresponds to nucleotides 821 to 840 of Fig. 4. CP-50 (SEQ ID NO: 42) has the sequence 5'-CCATGTAAGGCCAAGTTAGT-3', which corresponds to nucleotides 1485 to 1504 of Fig. 4. CP-51 (SEQ ID NO: 43) has the sequence 5'-ACACCTTTACCCATTAGAGT-3', which is the non-coding strand sequence that ~ ~ corresponds to nucleotides 486 to 505 of Fig. 4.
; ~ ~l o Three clones, designated pUC19JC140iiia, pUC19JC140iiid and pUC19JC140iiie, were subsequently found to contain partial Cry j II sequence. The sequence of clone pUC19JC140iiid was chosen as the consensus sequence since it had the longest 3' untranslated region. The sequences of pUC19JC140iiid and pUC19JC137b were used to construct the composite Cryj II sequence shown in Fig.
4. In this composite, nucleotide 230 is reported as the A found in pUC19JC137b (also, pUC19JC137a, pUC19JC140iiia and pUC19JC140iiie) not as the G found in pUC19JC140iiid; however both A and G at nucleotide 230 encode Lys at amino acid 63. The sequence of clone pUC19JC140iiia was identical to that of pUC19JC140iiid- ~ ~ except for the following: pUC19JC140iiia has a T at nucleotide 357 in place of a C
(no predicted change in amino acid 106), has C at nucleotide 754 instead of T
(changes amino acid 238 from Ile to Thr), C at nucleotide 1246 instead of T
(changes amino acid 402 from Leu to Pro), and T at nucleotide 1672 instead of C
(untranslated region). The sequence of clone pUC19JC140iiie was identical to that of pUC19JC140iiid except for G at nucleotide 794 instead of A (changes amino acid 25 ~ 251 from Ile to Met), and T at nucleotide 357 in place of C (no predicted change in amino acid 106).
An ear!ier attempt at cloning the JC140iii PCR product using an Eco Rl/Xba I digest (oligonucleotide AP has both Xba I and Asp 718 restriction enzyme sites) yielded cDNA that was cut in half due to an internal Xba I restriction site in the Cly `
j II cDNA, giving rise to 800 and 750 bp bands; the 750 bp band was succesfully cloned into Eco Rl/X~a I digested pUC19 and sequenced. Two 750 bp clones were ~"
- sequenced and found to be the 5' half of the C~y j II molecule: clones pUC19JC140- .
2a and pUC19JC140-2b. Clone pUC19JC140-2a has C for nucloeotide 297 instead of T (changes amino acid 86 from Cys to Arg) and clone pUC19JC140-2b has G for nucleotide 753 instead of A (changes amino acid 238 from Ile to Val). Both clonepUC19JC140-2a and clone pUC19JC140-2b have a T at nucleotide 357 in place of C
(no predicted change in amino acid 106).
~' ~.. , .. .. ~ .. . ...
. . - .. . .
WO94/11512 2148~i3 Pcr/US93/
Two different PCR amplifications were also sequenced directly to verify the clonal c,y j II sequence using the Amplitaq Cycle Seq~lencing kit (Perkin Elmer Cecus, Norwalk, CT). This procedure involves the ~32P}-end-labelling of ~ !
oligonucleotide sequencing primers which are then annealled (1.6 pmoles in l ~1) to i`
s template DNA and elongated with dideoxy NTPs (methodology of Sanger et al.
(1977) Proc. Natl. Acad. Sci. USA 74:5463-5476) in a PCR reaction also containing 4 ,ul 10X Cycling Mix (contains 0.5 U/~l Amplitaq DNA Polymerase), 5 ,ul template DNA (lO-100 fmoles) and dH20 to 20 ,ul . The dGTP in the termination mixes in ~: this kit have been replaced by 7-deaza-dGTP, which provides increased resolution of o sequences containing high G+C regions of DNA. The template DNA was a PCR
product that was recovered by sequential chloroform, phenol, and chloroform extractions, precipitated at -20C with 0.5 volumes of 7.5 ammonium acetate and 1.5 volumes of isopropanol, then electrophoresed through a preparative 1 or 2%
SeaPlaque low melt gel~ (FMC). Appropriate sized DNA bands were visualized by EtBr staining, excised, and treated with Gelase (Epicentre Technologies, Madison, WI) to remove the agarose. The DNA was again precipitated, and resuspended in 50 ~I TE (10 mM Tris, pH 7.4, 1 mM EDTA, pH 8.0) containing 20 ~4glml RNAse (Boehringer Mannheim, Indianapolis, IN). Two secondary amplifications which had been used to clone Cry j II were repeated, and used as template DNA for PCR cycle sequencing: JC137ii, the 5 ' end PCR, (amplified from the 1 PCR JCl36 above) was rearnplified with oligonucleotides AP and CP-36; and JC140ii, the 3' end PCR, (amplified from the l c PCR JCl38ii above) was reamplified with oligonucleotidesAP and CP-38. Both of the l ~ amplifications used were precipitated, electrophoresed through a preparative l or 2 % SeaPlaque low melt gel (FMC), and2S the appropriate sized bands were visualized by EtBr staining and excised. Two ,ul of each l ~ amplification was then used in the corresponding 2 PCR reaction. The 2 PCR product was then prepared as DNA template for PCR cycle sequencing as described above. The oligonucleotides used as primers in PCR cycle sequencing, many of which were used to sequence the clones, are as follows: for JC137ii,CP-36 and CP-39(SEQIDNO:44), which has the sequence 5'- ~
CTGTCCAACATAATTTGGGC-3' and is the non-coding strand sequence .
corresponding to nucleotides 120 to 139 ofFig.4. The oligonucleotide primers used .
for sequencing JC140ii were CP-38, CP-40,CP41,CP-42,CP-43,CP-44,CP-45, CP-46, CP47, CP49, CP-S0, CP-54(SEQIDNO: 45), which has the sequence 5'-3s CATGGCAGGGTGGTTCAGGC-3', corresponds to nucleotides 985 to 1004 of Fig.
4,CP-55(SEQIDNO: 46), which has ~e sequence 5'-TAGCCCCATTTACGTGCACG-3' and is the non-coding strand sequence that WO94/11512 214~ 1 13 pcr/us93t1looo ~.
: !:
~l 29 .
corresponds to nucleotides 929 to 948 of Fig. 4. and CP-56 (SEQ ID NO: 47), which has the sequence 5'-TTGGGGT~GAGGCCTCCGAA-3' and corresponds tO
nucleotides 1437 to 1456 of Fig. 4. The sequence of this full-length PCR cycle ~? sequencing had only 2 nucleotide changes from the composite pUC19JC137b/pUC19JC140iiid Cly j Il sequence shown in Figure 4, neither of which lead tO an amino acid change. There was a T instead of ~ at nucleotide 357(no predicted change in amino acid 106), and a C instead of A at nucleotide 635 (no ,:., amino acid change).
The nucleotide and predicted amino acid sequences of Cry j II are shown in lo Figs. 4 and 5. This is a composite nucleotide sequence from the two overlapping clones pUC19JC137b and pUC19JC140iiid. Sequencing of multiple independent clones and cycle sequencing of PCR product confirmed the nucleotide sequence of Figure 4. There were several nucleotide changes resulting in predicted amino acid changes, as cited above. However, all nucleotide polymorphisms, with the exception of the T for C substitition at nucleotide 357, were only observed in single clones or sequencing reactions. Although T was seen at nucleotide 357 in all clones except pUCi9JC140iiid, both C and T encode Leu at amino acid 106.
The complete cDNA sequence for C~y j II is composed of 1726 nucleotides, including 41 nucleotides of 5' untranslated sequence, an open reading frame of 1542 nucleotides starting with the codon for an inidating Met (nucleotides 42-44 of Fig.
4), and a 143 bp 3' untranslated region. There is a consensus polyadenylation signal sequence in the 3' untranslated region 64 nucleotides 5' to the poly A tail (nucleotides 1654-1659 of Fig. 4). The position of the initiating Met is confirmed by the presence of an in-frame upstream stop codon and by 78% homology with the plant consensus sequence that encompasses the initiating Met (TAAAAUGGC (bases 38 through 46 ~f Fig. 4 (SEQ ID NO: 48)) found in Cry j II compared with the AACAAUGGC (SEQ ID NO: 49) consensus sequence for plants, Lutcke et al.
(1987) EMBO J. 6: 4348). The open reading frame encodes a deduced protein of 514 amino acids that has complete sequence identity with the published partial -protein sequence for Cry j II (Sakaguchi et al. ~3apE~), which corresponds to amino acids 55 through 64 of Fig. 4. The predicted Cly j II protein has 20 Cys, contains four potential N-linked glycosylation sites corresponding to the consensus sequence ~`
N-X-S/T, has a predicted molecular weight of 56.6 kDa and a predicted pI of 9.08.
Detection of three separate NH2 termini sequences for Cry j II (the long form and the short form as determined in Example 2 and the NH2 terrninus determined by Sakaguchi et al., supra, as shown in Fig. 6) may suggest that the amino terminus of the mature C y j II protein is blocked and that the sequences obtained by sequence ~,~, .=, .,~, . . . .
.~, - . , .
wos4/~s~2 2Iq8713 Pcr/uss3/
':
. ~ analysis of purified protein represent proteolytic cleavage products. As shown in Fig. 6, the amino acid sequence of the long form of C~y j II begins at amino acid 46 '`~ an,d the amino acid sequence of the short forrn of Cry j II begins at arnino acid 51,~ j-` ~ and~the NH2-terminal sequence determed by Sakaguchi et al. begins at amino acid -~ ~ s ~ : 54. ~ It is ~also possible that amino acids 1 to 45 represent the leader/pre-pro position of ~y j~ll` that is enzymatically cleaved to give a functiorlal~y active protein -beginning ~at arnino acid 46 of Fig . 4. The sequences beginning at amino acids 51 and~54 represent~breakdo~vn products of the protein beginning at arnino acid 46.There~ is ~a predicted~cleavage site between amino acids 22 and 23 of Fig. 4 using the '-, lo ~ ~ method o~von~Heijne~(Nucleic Acids Res. (1986) 14:4683-4690). If the mature C~y D, proteih started' at an~ino acid' 23 in Fig. 4, the protein would be 492 amino acids `with~`a~predtct~ed~molecular weight of 54.2 kDa and a predicted pE of 9Ø
Searchmg the Swiss-Prot data base with the C~y j II sequence qemonstrated that ~C~y j II is 43.3 % homologous (33.3 % identical to polygalacturonase of tomato 15 ~ (Lycopets~ n esculentum) and~ 48.4% homologous (32.670 identical) to polygalacturonase of corn, Zea mays. All nucleotide and amino acid sequence analyses were performed using PCGENE (Intelligenetics, Mountain View, CA.).
: ~
.~ ~:
~ .
'~ . : ''"
'~
:~
?`
, ,~
`~
_ ` ' WO94/11512 214S713 PCr/US93/llOOO
31 :
!
Example 4 Extraction of R~A from Japanese Cedar Pollen Collected in Japan and Expression of Recombinant Cry j II - ~
Fresh pollen collected from a pool of Cryptomeria japonica (Japanese cedar) c tre~s in Japan was frozen imrnediately on dry ice. RNA was prepared from 500 mg of the pollen, essentially as described by Frankis and Mascarenhas Ann. Bot. 45 :595-599. The samples were ground by mortar and pestle on dry ice and suspended in 5 ml of 50 mM Tris pH 9.0 with 0.2 M NaCI, l mM EDTA, 1% SDS that had been treated overnight with O. l % DEPC. After five extractions with phenol/chloroforrn ,,:,~ ~, / isoamyl alcohol (mixed at 25:24:1), the RNA was precipitated from the aqueous phase ~with- 0.1 volume 3 M sodium acetate and 2 volumes ethanol. The pellets were recovered by centrifugation, resuspended in 2 ml dH20 and heated to 65C for 5 minutes. Two ml of 4 M lithium chloride were added to the RNA preparations and ;~ 15 ~ they ~were incubated overnight at 0C. The RNA pellets were recovered by cennifugation, resuspended in l ml dH20, and again precipitated with 3 M sodium acetate and ethanol overnight. The final pellets were resuspended in 100 ~41 dH20 and ~stored at -80C.
Double stranded cDNA was synthesized from 8 ~g pollen RNA using the ~ ~ c DNA~Synthesis Systems kit (BRL) with oligo dT priming according to the method `~ of ~Gubler and Hoffman (1983) Gene 25:263-269. PCRs were carried out using the ~ GeneAmp DNA Amplification kit (Perkin Elmer Cetus) whereby 10 ~l 10x buffer <~ containing dNTPs was mixed with lO0 pmol each of a sense oligonucleotide and an anti-sense oligonucleotide, cDNA (lO ~1 of a 400 ~l double stranded cDNA reaction ~-25 ~ mix), 0.5 ~ll Amplitaq DNA polymerase, and distilled water to 100 ,ul.
~- ~ The samples were amplified with a programmable thermal controller from MJ Research, Inc. (Cambridge, MA). The first S rounds of amplification consistedof denaturation at 94C for 1 min, annealing of primers to the template at 45C for 1 min, and chain elongation at 72C for 1 min. I~e final 20 rounds of amplification consisted of denaturation as above, annealing at 55C for l min, and elongation as above.
A new set of primer pairs was synthesized for amplification of a Cry j II ~:
cDNA from the initiating Met to the stop codon. CP-52 (SEQ ID NO: 50) has the ~ sequence 5'- GCCGAATTCATGGCCATGAAATTAATT-3' where the nucleotide 3 5 sequence 5'-GCCGAATTC-3' (SEQ ID NO: 51) (bases l through 9 of CP-52represents an Eco RI restriction site added for cloning purposes, and the remaining sequence corresponds to nucleotides 42 to 59 of Fig. 4. CP-53 (SEQ ID NO: 52) . .
WO94/11512 ~148713 pcr/uss3/l1ooo ~ ' has the sequence 5'-CGGGGATCCTCATTATGGATG-GTAGAT-3' where the nucleotide sequence 5'-CGGGGATCC-3'(SEQID NO:53) (bases 1 through 9 of CP-53 represents a Bam HI restriction site added for cloning purposes, and the remaining oligonucleotide sequence of CP-53 is complementary to coding strand 1~ s sequence corresponding to nucleotides 1572 to 1589 of Fig. 4. The PCR reaction with CP-52 and CP-53 on the double stranded Japanese Cedar pollen cDNA yiclded a band of approximately 1.55 kb on an EtBr-stained agarose minigel, and was called JC145. Amplified DNA was recovered by sequential chloroform, phenol, and chloroforrn extractions, followed by precipitation at -20C with 0.5 volumes of 7.5 amrnonium acetate and 1.5 volumes of isopropanol. After precipitation and washing with 70% ethanol, the DNA was simultaneously digested with Eco Rl and Bam HI in a 15 ,ul reaction, and electrophoresed through a preparative 1 % SeaPlaque low melt gel (FMC). Appropriate sized DNA bands were visualized by EtBr staining, excised, and ligated into appropriately digested pUC19 for sequencing by the dideoxy chain termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA
74:5463-5476) using a cornmercially available sequencing Icit (Sequenase kit, U.S.
Biochemicals, Cleveland, OH).
Clones pUC19JC145a and pUC19JC145b were completely sequenced using M13 forward and reverse primers (N.E. Biolabs, Beverly, MA) and internal sequencing primers CP-41, CP-42, CP44, CP-46, and CP-51. The nucleotide and deduced amino acid sequences of clones pUC19JC145a and pUC19JC145b were i dentical to the Cry j II sequence of Fig. 4, with the following exceptions. Clone pUC19JC145a was found to contain a single nucleotide difference from the previously Icnown C~y j II sequence: it has a C at nucleotide position 1234 of Fig~ 4 rather than the previously described T. This nucleotide change results in a predicted amino acid change from Ile to Thr at amino acid 398 of the C~y j II protein. Clone pUC19JC145b has a G at nucleotide position 1088 of Fig. 4 rather than the previously described A, and an A for a G at nucleotide 1339. The nucleotide change at 1088 is si!ent and does not result in a predicted amino acid change. The nucleotide change at position 1339 results in a predicted amino acid change from Ser i;
to Asn at amino acid 433 of the C~y j II protein~ None of these polymorphisms have yet been confirmed by independently-derived PCR clones or by direct amino acid sequencing and may be due to the inherent error rate of Taq polymerase t (appro~cimately 2 x 10~, Saiki et al. (1988) Science 239:487-491). However, suchpolymorphisms in primary nucleotide and amino acid sequences are expected.
¦ Expression of Cry j II was performed as follows. Ten ~g of pUC19JC145b was digested simultaneously with Eco Rl and Bam HI. The nucleotide insert .. ..
~h W094/11~12 2 1 4 8 7 i 3 PCI'/US93/11000 encoding Cry j II (extending ~rom nucleotide 42 through 1589 of Fig. 4) was isolated by electrophoresis of this digest through a 1% SeaPlaque low melt agarose :
gel. The insert was then ligated into the appropriately digested expression vector pET-l ld (Novagen, Madison, WI; Jameel et al. (1990) J. Virol. 64:3963-3966) -~ S ~ modified to contain a sequence encoding 6 histidines (His 6) immediately 3 ' of the }
ATG ir~itiàtion codon followed by a unique Eco RI endonuclease restriction site. A
second Eco RI endonuclease restriction site in the vector, along with neighboring Cla I and~ Hind III endonuclease restriction sites, had previously been removed by digosdon with Eco RI and Hind III, blunting and religation. The histidine (His6)lo ~ sequence was~added for affinity purification of the recombinant protein (Cryj I) on a Ni2~+~chelating column (Hochuli et al. (1987) J. Ckromatog. 411:177-184; Hochuliet~al.~(1988) Bio/Tech. 6:1321-1325.). A recombinant clone was used to transform`Escherichia coli strain BL21-DE3, which harbors a plasmid that has an isopropyl-13-D-thiogalactopyranoside (IPTG)-inducible promoter preceding the gene encoding T7~15~ polymerase. Induction with IPTG leads to high levels of T7 polymerase expression, is~necessary for expression of the recombinant protein in pET-lld. Clone s6JCI45b.a was confinned to be a Cry j II clone in the correct reading ~frame for expression by dideoxy se~uencing (Sanger et al. supra) with CP-39.
- ~2 o Expression of the recombinant protein was examined in an initial small c ulture. An overnight culture of clone pET-lld~HRhis6JC145b.a was used to inn~culate 50 ml of media (Brain Heart Inf~sion Mediat Difco) containing ampicillin (200 ~g/ml), grown to an A600 = 1.0 and then induced with IPTG (1 mMt final concentration) for 2 hrs. One ml aliquots of the bacteria were collected before and after inductiont pelleted by centrifugation, and crude cell Iysates prepared by boiling the pellets for 5 minutes in 50 mM Tris HCI, pH 6.8, 2 mM EDTA, 1% SDSt 1%
; B-mercaptoethanolt 10% glycerol, 0.25% bromophenol blue (Studier et al.t (1990) `~
Methods in Enz~mology 185:6~89). Recombinant protein expression was examined on a 12% Coomassie blue-stained SDS-PAGE gelt according to the method in Sambrook et al., supra, on which 25 ~1 of the crude Iysates were loaded. A negative control consisted of crude Iysate from unLnduced bacteria containing the plasmid ~,:
with Cry j II. There was no notable increase in production of any recombinant E. }
` ~ coli protein in the range of 58 Kd, the size predicted for the recombinant Cry j II
with the His6 leader.
- 3 5 The pET-lld~HRhis6JC145b.a clone was then grown on a larger scale to examine if there was any recombinant protein being expressed. A 2 ml culmre of : ~ bacteria containing the recombinant plasmid was grown for 8 hr, then 3 ~I was "~
, wo 94/l }512 2 1 4 8 7 1 3 PC-r/Uss3/l lO00 spread onto each of ~ (100 x 1~ mm) petri plates with 1.5% agarose in LB medium ,-(Gibco-BRL, Gaithersburg, MD) containing 200 ~g/ml ampicillin, grown to ¦-confluence overnight, then scraped into 6 L of liquid media (Brain Heart InfusiQn media, Difco) containing ampicillin (200 ~g/ml). The culture was grown until theabsorbance at A600 was 1.0, IPTG added (1 mM final concentration), and the culture grown for an additional 2 hours.
Bacteria were recovered by centrifugation (7,930 xg, 10 min) and lysed in 50 ml of 6M Guanidine-HCI, 0.1M Na2HPO4~ pH 8.0, for 1 hour with vigorous shaking. Insoluble material was removed by centrifugation (11,000 xg, 10 min, 4o C). The pH of the Iysate was adjusted to pH 8.0, and the Iysate applied tO a 50 ml Nickel NTA agarose column (Qiagen) that had been equilibrated with 6 M
Guanidine HCl, 100 mM Na2Hpo4~ pH 8Ø The column was sequentially washed with 6 M Guanidine HCI, 100 rnM Na2HP04, 10 mM Tris-HCl, pH 8.0, then 8 M
urea, 100 mM Na2HPO4, pH 8.0, and finally 8 M urea, 100 mM sodium acetate, 10 mM Tris-HCI, pH 6.3. The column was washed with each buffer until the flow through had an A280~ 0-05 The recombinant Cry j II protein was eluted with 8 M urea, 100 mM sodium acetate, 10 rnM Tris-HCl, pH 4.S, and collected in 10 ml aliquots. The protein concentration of each fraction was determined by A280 and the peak fractions pooled. An ali~uot of the collected recombinant protein was analyzed on SDS-PAGE according to the method in Sarnbrook et al. supra.
This 6L prep, JCIIpET-1, yielded 1.5 mg of recombinant Cry j II, which was resolved into 2 major bands on SDS-PAGE at 58 kDa and 24 kDa. The 58 kDa band, which represents recombinant Cry j II, was approximately 9-10% of the total protein as determined by densitometry measurement (Shimadzu Flying Spot Scanner,Shimadzu Scientific Instruments, Inc., Braintree, MA). The 24 kDa band accounts for about 90% of the total protein and may represent a degradation product of the recombinant Cry j II or an E. coli contaminant. , Another C~y j II expression construct was made by the ligation of the pUC19JC140iiid Cryj II insert into appropriately digested pETlld~HR (with the 6 histidine leader). The vector was derived from another pETlld~HR construct whose insert supplied an EcoR I site (at the 5' pET1 ld~HR-insert junction) and an Asp 718 site (at the 3' end of the insert); the construct was digested with these two `~
enzymes, run on a low melt minigel as above, and the vector recovered as a band in low melt agarose. The pUC19JC140iiid construct was digested with Eco R I and Asp 718 to release the Cly j II insert, which was isolated on a low melt minigel and ligated into the Eco R I/Asp 718 digested pETlld~HR vector prepared above. Five 21~8713 WO94/11~12 pcr/us93/11 clones were found to contain the correct nuc!eotide sequence at the insert/vector 5' junction, when sequenced by dideoxy sequencing (as above) with CP-39. This new construct, when expressed, would begin at amino acid 46 of C~y j II as shown in~Figs. 4 and 5. This recombinant protein is designated rCry j II ~46. A 50 ml small '.
scale expression test (as performed above) showed that the expression level of rCry j 1l ~46 from this construct, designated pET11d~HRJC140iiid2, would be much greater than the initial expression level from pET1 ldAHRJC 145b2 . A 9L prep, JCIIpET-3, was processed as above, and yielded 200 mg of rCry j Il ~46 at 80%
purity as determined by densitometry of a Coomasie blue stained 12% SDS-PAGE
o gel.
Example S
Northern blot on RNA from Japanese Cedar Pollen Sources A northern blot analysis was perforrned on the R~A isolated from Japanese Cedar pollen from both the Arnold Arboretum tree and the pooled trees from Japan.
Using essentially the method of Sambrook, supra, ten ~g of RNA isolated from Japanese cedar pollen collected from the Arnold Arboretum (Boston, MA) and 15 ,ug pooled RNA from Japanese cedar pollen collected from trees in Japan were run on a 1.2% agarose gel containing 38% formaldehyde and lX MOPS (20X = 0.4M
MOPS, 0.02M EDTA, 0.1M NaOAc, pH 7.0) solution. The RNA samples (first precipitated with 1/10 volume sodium acetate, 2 volumes ethanol to reduce volumeand resuspended in 5.5 ~l dH20) were run with 10 ~l formaldehyde/forrnamide buffer containing loading dyes with 15.5% formaldehyde, 42% formamide, and 1.3X MOPS solution, final concentration. The samples were transferred to Genescreen Plus (NEN Research Products, Boston, MA) by capillary transfer in 10XSSC (20X = 3M NaCl, 0.3M Sodium Citrate), after which the membrane was baked 2 hrs at 80C and W irradiated for 3 minutes. Prehybridization of the membrane was at 60C for 1 hour in 4 ml 0.5M NaPo4 (pH 7.2), lrnM EDTA, 1%
BSA, and 7 % SDS. The antisense probe was synthesized by asymrnetric PCR on the t ' JC145 amplification in low melt agarose (above), where 2 ,ul DNA is amplified with 2 ,ul dNTP mix (0.167mM dATP, 0.167mM dTTP, 0.167mM dGTP, and 0.033mM
dCTP), 2 ,ul 10X PCR buffer, 10 ,ul 32P-dCTP (100 ~Ci; Amersham, Arlington }~
Heights, Il), 1 ~1(100 pmoles) antisense primer CP-53, 0.5 ~l Taq polymerase, and dH20 to 20 ~l; the 10X PCR buffer, dNTPs and Taq polymerase were from Perkin Elmer Cetus (Norwalk, CT). Amplification consisted of 30 rounds of denaturation at 94C for 45 sec, annealing of primer to the template at 60C for 45 sec, and chain `
elongation at 72C for 1 min. The reaction was stopped by addition of 100 ~l TE, ;~ .. , . . ~: .
WO 94/11512 2 1 4 8 7 1 3 pcr/us93/11000 - and the probe recovered over a 3cc G-50 spin column (2 ml G-50 Sephadex [Pharmacia, Uppsala, Sweden] in a 3cc syringe plugged with glass wool, equilibrated with TE) and counted on a 1500 TriCarb Liquid Scintillation Counter(Packard, Downers Grove, IL). The probe was added to the prehybridizing buffer at 106 cpm/ml and hybridization was carried out at 60C for 16 hrs. Tbe blot was s washed in high stringency conditions: 3x15 min at 65C with 0.2%SSC/1% SDS, followed by wrapping in plastic wrap and exposure to film at -80C. A seven hourexposure of this Northern blot analysis revealed a single thick band at approximately 1.7 kb for both RNA collected from the Arboretum tree and the RNA collected fromo~ the pooled trees from Japan. This message is the expected size for Cry j II as predicted by PCR analysis of the cDNA.
Example 6 Direct bindin~ assav of I~E to Crv i I. Cnl i II and recombinant Crv j II.
Corning assay plates (~25882-96) were coated with Cty j I or C~y j II at 2 g/mL or recombinant Cryj II preparation at 10 ~g/mL (approximately 20% pure) in a ~volume of 50 ~LL overnight at 4C. The coating antigens were removed and the wells were blocked with 0.5% gelatin, PVP (polyvinyl pyrolidine) 1 mg/ rnL in PBS, 200 ~L/well for 2 hours at room temperature. The anti-C~ j I monoclonal ~20 antibody, 4Bl 1, was serially diluted in PBS-Tween 20 starting at a 1:1000 dilution.
The human plasma were serially diluted in PBS-Tween at a starting dilution of 1:2.
For this set 23 plasma samples from patients symptomatic for Japanese cedar pollen allergy chosen for IgE binding analysis. The first antibody incubation proceededovernight at 4C~ Following three washes with PBS-Tween the second antibodies 2 5 were added (goat anti-mouse Ig or goat anti-human IgE both at 1:2000) andincubated for two hours at room temperature at 100 ~L/well. This solution was removed and streptavidin-HRPO diluted to 1:10,000, was added at 100~/well. The color was allowed to develop for 2-5 minutes. The reaction was stopped by the addition of lOO~L/well of lM phosphoric acid. Plates were read on a Microplate IL310 Autoreader (Biotek Instruments, Winooski, VT) with a 450nm filter. The absorbance levels of duplicate wells were averaged. The graphed results (log of the dilution vs. absorbance) of the ELISA assays are shown in Figs. 7 to 15. The I .
summary of the results are given in Fig~ 16. A positive binding result, indicated by a plus sign is determined to be a reading of two-fold or greater above background - 35 (no first antibody) at the second dilution of plasma (1:6).
In Fig. 7 the binding response of the monoclonal antibody, 4B11, and seven patieMs' (Batch 1) plasma IgE is shown to purified C1y j 1 as the coating antigen.
~ WO 94/1 15 12 2 1 4 ~ 7 1 3 PCI /US93/1 1000 37 ~`
i The monoclonal antibody, raised against purified Cry j I shows a saturatin~ level of binding for the whole dilution series. The individual patient samples show a variable - ¦
response of IgE binding to the Cry j I preparation. One patient, #1034, has no detectable binding to this protein preparation. All the patient samples were obtained s from individuals claiming to be symptomatic for Japanese cedar pollen allergy and : ~ the results of their MAST scores are shown in Fig. 16. Fig. 8 is a graph representing the binding of the same antibody set as in Fig. 7 to purified native C~y j II. The anti-Cry j I monoclonal antibody, 4B11, is negative on this preparation demonstrating lack of cross-reactivity between the two allergen antigens. In general, o there is a lower overall response to this allergenic component of cedar pollen with more patient samples showing decreased binding. However, patient #1034, that wasnegative on Cry j I shows very strong reactivity to Cry j II. In the last antigen set, Fig. 9, using recombinant C~y j II (rC~y j II), monoclonal antibody 4B11 reactivity ; is negative and there is further reduc~ion in binding of the human IgE samples compared to biochemically purified Cry j II. Two of the patients, #1143 and #1146, are clearly positive for IgE binding to the recombinant form of C~y j II although the pat~ient that reacted the strongest to biochemically purified form is negative here, 1034. Figs. 10^15 represent the application of the same antigen sets for the direct binding analysis of the next sixteen patients designated patient Batch 2 and patient Batch 3 in Figs. 10-15.
The table shown in Fig. 16 sumrnarizes both the MAST scores, performed in - ~ Japan on the plasma samples before shipment using a commercially available kit, and the direct ELISA results outlined above. Two patients were negative by the MAST
assay, however, one of these patients, #1143, was positive on all the ELISA
antigens. The number of positive responses for each antigen is shown and this represents a measure relative allergenicity of the different allergen preparations.
These results demonstrate that C y j II is an allergen as defined by human allergic patient IgE reactivity and that there are some patients who are not reactive to Cry j I
but are reactive to Gy j II. The frequency of response in this population of patients is less to Cry j II than to C1y j I.
Example 7 -~ .
Japanese Cedar Pollen Allergic Patient T Cell Studies with CrY i II and Crv j II3S Peptides.
Synthesis of C~y j II Peptides WO 94/11512 Pcr/uss3/llooo 2148713 38 " ` ~
Japanese cedar pollen C,~y j II peptides designated Cry j IIA Cry j IIB were synthesized using standard Fmoc/tBoc synthetic chemistry and puri~led by ReversePhase HPLC. The amino acid sequence of peptide Cry J IIA is FTFKVDGIIAAYQ
(SEQ ID NO: 54) which corresponds tO amino acids 116-128 as shown if Figs 4 and s 5. The amino acid sequence of peptide Cry j IIB is NGYFSGHVIPACKN ~SEQ ID
NO: 55) which corresponds to amino acids 416-429 dS shown in Figs 4 and 5. The peptide names are consistent throughout.
T Cell Responses to Japanese Cedar Pollen Antigen Peptides Peripheral blood mononuclear cells (PBMC) were purified by lymphocyte separation medium (LSM) centrifugation of 60 ml of heparinized blood from one Japanese cedar pollen-allergic patient who exhibited clinical symptoms of seasonal rhinitis and was MAST and/or skin test positive for Japanese cedar pollen. Long term T cell lines were established by stirnulation of 2 X 106 PBL/ml in bulk cultures of complete medium (RPMI-1640, 2 mM L-glutamine, 100 U/ml ~- penicillinlstreptomycin, sx10-5M 2-mercaptoethanol, and 10 mM HEPES
supplemented with 5 % heat inactivated human AB serum) with 10 ~g/ml of partially purified native C)y j II for 7 days at 37C in a humidified 5 % C02 incubator to~;~ select for C~y j II reactive T cells. This amount of priming antigen was determined to be optimal for the activation of T cells from most Japanese cedar pollen allergic patients. Viable cells were purified by LSM centrifu~ation and cultured in complete medium supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to three weeks until the cells no longer responded to lymphokines and were considered "rested". The ability of the T cells to 2s proliferate to peptides Cry j IIA and Cry j IIB, recombinant Cry j II (rCry j II), purified native C~y j II, or purified native C1y j I was then assessed. For assay, 2 X
104 rested cells were restimulated in the presence of 2 X 104 autologous Epstein-Barr virus (EBV)-transformed B cells (prepared as described below) (gamma-irradiated with 25,000 RADS) with 2-50 ~lg/ml of rCry j II, purified native C~y j II, peptides Cry j IIA and Cry j IIB, of purified native Cry j I, in a volume of 200 ~l complete medium in duplicate or triplicate wells in 96-well round bottom plates for 2-4 days. The optimal incubation was found to be 3 days. Each well then received .
1 ~lCi tritiated thymidine for 16-20 hours. The counts incorporated were collected onto glass ~lber filter mats and processed for liquid scintillation counting. The 3s maximum response in a titration of each peptide is expressed as the stimulation index (S.I.). The S.I. is the counts per minute (CPM) incorporated by cells in response to peptide, divided by the CPM incorporated by cells in medium only. An S.I. value ~. ~ ~",. . . .. . .. .
`WO 94/1 1512 2 1 4 8 ~ 1 3 Pcr/US93/ 1 loOO ~
39 i:
equal to or greater than 2 times the background level is considered "positive" and indicates that the peptide contains a T cell epitope. The results of this assay indicated that peptides Cr j II, and Cry j IIB did noit appear to contain a T cell ;epitope for this particular allergenic patient. However, additional Japanese cedar S ~ pollen allergic patients will be tested in this assay system and one or both of these peptides may contain T cell epilopes for other allergic individuals ; ~
~.":.:
~, ;:
r > ~
.~, ~',, ~;;
., W094/11512 21~871:~ pCI/US93/11000 ~
Preparation of (EBV)-transformed B Cells for Use as Antigen Presenting Cells Autologous EBV-transformed cell lines were y-irradiated with2S,000 Rad ¦
and used as antigen presenting cells in secondary proliferation assays and secondary ' bulk stimu!ations. These cell lines were also used as a control in the immuno-s fluorescence flow cytometry analysis. These EBV-transformed cell lines were made by incubating S X 106 PBL with 1 ml of B-59/8 Marmoset cell line (ATCC
CRL1612, American Type Culture Collection, Rockville, MD) conditioned medium ;in the presence of 1 llg/ml phorbol 12-myristate 13-acetate (PMA) at 37C for 60 minutes in 12 X 75 mm polypropylene round-bottom Falcon snap cap tubes (Becton o ; Dickinson Labware, Lincoln Park, NJ) . These cells were then diluted to 1 .2S X 106 cellsiml in RPMI~ 0 as described above except supplemented with 10% heat-irlactivated fetal bovine serum and cultured in 200 !11 aliquots in flat bottom culture plates until visible colonies were detected~ They were then transferred to larger wells until the cell !ines were established.
15~ Although the invention has been described with reference to its preferred embodiments, othèr embodiments, can achieve the same results. Variations and modifications to the present invention will be obvious to those skilled in the art and it is inended to cover in the appended claims all such modification and equivalents and fo!low in the true spirit and scope of this invention.
,~, .
.. ~ ~ . .
t i,, `
`~:
, , ,, . . - ` . ~ ` : : . :.
214~7~3 l~
/ c ,,.. ; ;`
SEQUENCE LISTING
i ( (1) GENERAL INFORMATION:
S
(i) APPLICANT:
(A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION
(B) STREET: 610 Lincoln Street (C) CITY: Waltham ~D) STATE: MA
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 02154 (G) TELEPHONE: (617) 466-6000 (H) TELEFAX: (617)466-6040 (ii) TITLE OF INVENTION: Allergenic Proteins and Peptides From Japanese Cedar Pollen (iii) NUMBER OF SEQUENCES: 55 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (TEXT) `: :
:~ (v) CURRENT APPLICATION DATA:
(A) APPLIC~TION NUMBER:
: (B) FILING DATE:
~vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT. INFORMATION:
(A)- NAME: Vanstone, Darlene (B) REGISTRATION NUMBER: 35,729 (C) REFERENCE/DOCKET NUMBER: IPC-033PC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 466-6000 (B) TELEFAX: (617) 466-6040 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1726 base pairs i`
(B) TYPE: nucleic acid (C) STRANDEDNESS: single ~;
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA `-(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 42..1586 WO94/11512 PCI/US93/11000 ~ ~ ~14~713 42 (xi) SEQ~NCE DESCRIPTION: SEQ ID NO:l:
TGAGTTCGAG ACAAGTATAG AAAGAATTTT CTTTTATTAA A ATG GCC ATG AAA
Met Ala Met Lys ) `
TTA ATT GCT CCA ATG GCC TTT CTG GCC ATG CAA TTG ATT ATA ATG GCG
Leu Ile Ala Pro Met Ala Phe Leu Ala Met Gln Leu Ile Ile Met Ala GCA GCA GAA GAT CAA TCT GCC CAA ATT ATG TTG GAC AGT GTT GTC GAA
~: Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp Ser Val Val Glu : 25 30 35 .
AAA TAT CTT AGA TCG AAT CGG AGT TTA AGA AAA GTT GAG CAT TCT CGT
: 197 :: Lys Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val Glu His Ser Arg CAT GAT GCT ATC AAC ATC TTC AAT GTG GAA AAG TAT GGC GCA GTA GGC
His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly : ~ 55 60 65 GAT GGA AAG CAT GAT TGC ACT GAG GCA TTT TCA ACA GCA TGG CAA GCT
: 293 Asp Gly Lys ~is Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala ~ .
: 35 GCA TGC AAA AAC CCA TCA GCA ATG TTG CTT GTG CCA GGC AGC AAG AAA
Ala Cys Lys Asn Pro Ser Ala Met Leu Leu Val Pro Gly Ser Lys Lys : TTT GTT GTA AAC AAT CTG TTC TTC AAT GGG CCA TGT CAA CCT CAC TTT
Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys Gln Pro His Phe ACT TTT AAG GTA GAT GGG ATA ATA GCT GCG TAC CAA AAT CCA GCG AGC
: Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser TGG AAG AAT AAT AGA ATA TGG TTG CAG TTT GCT AAA CTT ACA GGT TTT i ;.
:~ 485 Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys Leu Thr Gly Phe , 135 140 145 `~
ACT CTA ATG GGT AAA GGT GTA ATT GAT GGG CAA GGA AAA CAA TGG TGG ', 533 . t:~
Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly Lys Gln Trp Trp ~-150 155 160 . j.
:: 60 ~;
: GCT GGC CAA TGT AAA TGG GTC AAT GGA CGA GAA ATT TGC AAC GAT CGT
Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg 165 170 175 180 .
~-: 65 GAT AGA CCA ACA GCC ATT AAA TTC GAT TTT TCC ACG GGT CTG ATA ATC
, .
':
;
-:
. ,~' WO 94/1 1512 2 1 ~ 8 7 1 3 PCI`/US93/1 1000 r~
~. -43 ~ :
Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr Gly I.eu Ile Ile 18S 190 1~5 CAA GGA CTG AAA CTA ATG AAC AGT CCC GAA TTT CAT TTA GTT TTT GGG
Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe Hls Leu Val Phe Gly AAT TGT GAG GGA GTA AAA ATC ATC GGC ATT AGT ATT ACG GCA CCG AGA
Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile Thr Ala Pro Arg GAC AGT CCT AAC ACT GAT GGA ATT GAT ATC TTT GCA TCT AAA AAC TTT
Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala Ser Lys Asn Phe CAC TTA CAA AAG AAC ACG ATA GGA ACA GGG GAT GAC TGC GTC GCT ATA
His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp Cys Val Ala Ile GGC ACA GGG TCT TCT AAT ATT GTG ATT GAG GAT CTG ATT TGC GGT CCA
Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu Ile Cys Gly Pro GGC CAT GGA ATA AGT ATA GGA AGT CTT GGG AGG GAA AAC TCT AGA GCA
Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu Asn Ser Arg Ala GAG GTT TCA TAC GTG CAC GTA AAT GGG GCT AAA TTC ATA GAC ACA CAA
Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe Ile Asp Thr Gln AAT GGA TTA AGA ATC AAA ACA TGG CAG GGT GGT TCA GGC ATG GCA AGC
Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser Gly Met Ala Ser CAT ATA ATT TAT GAG AAT GTT GAA ATG ATA AAT TCG GAG AAC CCC ATA
His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser Glu Asn Pro Ile TTA ATA AAT CAA TTC TAC TGC ACT TCA GCT TCT GCT TGC CAA AAC CAG
Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala Cys Gln Asn Gln AGG TCT GCG GTT CAA ATC CAA GAT GTG ACA TAC AAG AAC ATA CGT GGG
Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys Asn Ile Arg Gly ~:
360 365 370 ~-ACA TCA GCA ACA GCA GCA GCA ATT CAA CTT AAG TGC AGT GAC AGT ATG
Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys Ser Asp Ser Met CCC TGC AAA GAT ATA AAG CTA AGT GAT ATA TCT TTG AAG CTT ACC TCA
WO 94/ 1 1 5 1 2 ,~ 8 ~1 3 PCl / US93/ 11 000 . :-Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu Lys Leu Thr Ser GGG AAA ATT GCT TCC TGC CTT AAT GAT AAT GCA AAT GGA TAT TTC AGT
Gly Lys Ile Ala Ser Cys Leu Asn Asp Asn Ala Asn Gly Tyr Phe Ser 495 ~10 415 4~0 GGA CAC GTC ATC CCT GCA TGC AAG AAT TTA AGT CCA AGT GCT AAG CGA ¦.
Giy His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro Ser Ala Lys Arg AAA GAA TCT AAA TCC CAT AAA CAC CCA AAA ACT GTA ATG GTT GAA AAT
Lys Glu Ser Lys Ser His Lys His Pro Lys Thr Val Met Val Glu Asn ATG CGA GCA TAT GAC AAG GGT AAC AGA ACA CGC ATA TTG TTG GGG TCG
Met Arg Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile Leu Leu Gly Ser AGG CCT CCG AAT TGT ACA AAC AAA TGT CAT GGT TGC AGT CCA TGT AAG
Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys Ser Pro Cys Lys GCC AAG TTA GTT ATT GTT CAT CGT ATT ATG CCG CAG GAG TAT TAT CCT
: Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln Glu Tyr Tyr Pro 485 490 495 500 ~:
CAG AGG TGG ATA TGC AGC TGT CAT GGC AAA ATC TAC CAT CCA TAATGAGATA
Gln Arg Trp Ile Cys Ser Cys His Gly Lys Ile Tyr Hls Pro CATTGAAACT GTATGTGCTA GTGAATATTC TTGTGGTACA ATATTAGAAC TGATATTGAA
AATAAATCAT CAATGTTTCT AAGGCATTTA TAATAGATTA TATTAATGGT TCAGCCTGGT
GCAAAAAAAA AAA
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 514 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Ala Met Lys Leu Ile Ala Pro Met Ala Phe Leu Ala Met Gln Leu Ile Ile Met Ala Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp ~` W094/11512 214S713 PCI/US93/11000 4 5 s Ser Val Val Glu Lys Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr ¦
Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala Ala Cys Lys Asn Pro Ser Ala Met Leu Leu Val Pro Gly Ser Lys Lys Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys Gln Pro His Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys . ~ Leu Thr Gly Phe Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly 145 150 155 1~0 Lys Gln Trp Trp Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile Cys Asn Asp Arg Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr ~:~ Gly Leu Ile Ile Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe His : 195 200 205 ' ~";
.~
Leu Val Phe Gly Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile :: Thr Ala Pro Arg Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala Ser Lys Asn Phe His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp Cys Val Ala Ile Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu Ile Cys Gly Pro Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu Asn Ser Arg Ala Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe 2~0 295 300 Ile Asp Thr Gln Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser 305 310 315 320 ~.
Gly Met Ala Ser His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser 325 330 335 P:~
Glu Asn Pro Ile Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala Cys Gln Asn Gln Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys Asn Ile Arg Gly Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys WO94/11512 2 1 ~87 13 PCT/US93/11000 ~
46 ~:
Ser Asp Ser Met Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu Lys Leu Thr Ser Gly Lys Ile AIa Ser Cys Leu Asn Asp Asn Ala Asn 405 410 415 ~ I
Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro 4 , , Ser Ala Lys Arg Lys Glu Ser Lys Ser His ky- His Pro Lys Thr Val 435 440 44s Met Val Glu Asn Met Arg Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile ~ .
450 455 460 :~.
: Leu Leu Gly Ser Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys 20:
: ~ Ser Pro Cys Lys Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln Glu Tyr Tyr Pro Gln Arg Trp Ile Cys Ser Cys His Gly Lys Ile Tyr s00 505 S10 :
His Pro , (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide :::
40~ (v) FRAGMENT TYPE: internal : ' ' ~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Ala Ala Cys Lys Asn Pro Ser 35 : 40 45 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE OEARACTERISTICS: ;.
(A) LENGTH: 41 amino acids (B) TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide : ~v) FRAGMENT TYPE: internal :
'` W094/llSi2 2148713 PCI/U593/11000 4 7 ~i .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Arg Lys Val Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val .
Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp Gln Lys Asn Pro ~2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE C~ARACTERISTICS:
~A) LENGTH: 36 amino acids (B~ TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr Ala Trp 20 ~ 25 30 Gln Lys Asn Pro (2) INFORMATION FOR SEQ ID NO:6:
(i) 5EQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr 1 5 10 ~-(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1410 base pairs '.-(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
WO94/1151~ 713 PCI/US93/11000 '~ ~;
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: '~
AGAAAAGTTG AGCATTCTCG TCATGATGCT ATCAACATCT TCAATGTGGA AAAGTATGGC , .
GCAGTAGGCG ATGGAAAGCA TGATTGCACT GAGGCATTTT CAACAGCATG GCAAGCTGCA~
TGCAAAAACC CATCAGCAAT GTTGCTTGTG CCAGGCAGCA AGAAATTTGT TGTAAACAAT
CTGTTCTTCA ATGGGCCATG TCAACCTCAC TTTACTTTTA AGGTAGATGG GATAATAGCT
GCGTACCAAA ATCCAGCGAG CTGGAAGAAT AATAGAATAT GGTTGCAGTT TGCTAAACTT
ACAGGTTTTA CTCTAATGGG TAAAGGTGTA ATTGATGGGC AAGGAAAACA ATGGTGGGCT
GGCCAATGTA AATGGGTCAA TGGACGAGAA ATTTGCAACG ATCGTGATAG ACCAACAGCC
ATTAAATTCG ATTTTTCCAC GGGTCTGATA ATCCAAGGAC TGAAACTAAT GAACAGTCCC
GAATTTCATT TAGTTTTTGG GAATTGTGAG GGAGTAAAAA TCATCGGCAT TAGTATTACG
GCACCGAGAG ACAGTCCTAA CACTGATGGA ATTGATATCT TTGCATCTAA AAACTTTCAC
TTACAAAAGA ACACGATAGG AACAGGGGAT GACTGCGTCG CTATAGGCAC AGGGTCTTCT
AATATTGTGA TTGAGGATCT GATTTGCGGT CCAGGCCATG GAATAAGTAT AGGAAGTCTT
GGGAGGGAAA ACTCTAGAGC AGAGGTTTCA TACGTGCACG TAAATGGGGC TAAATTCATA
GACACACAAA ATGGATTAAG AATCAAAACA TGGCAGGGTG GTTCAGGCAT GGCAAGCCAT
ATAATTTATG AGA~TGTTGA AATGATAAAT TCGGAGAACC CCATATTAAT AAATCAATTC
TACTGCACTT CAGCTTCTGC TTGCCAAAAC CAGAGGTCTG CGGTTCAAAT CCAAGATGTG
ACATACAAGA ACATACGTGG GACATCAGCA ACAGCAGCAG CAATTCAACT TAAGTGCAGT
GACAGTATGC CCTGCAAAGA TATAAAGCTA AGTGATATAT CTTTGAAGCT TACCTCAGGG
AAAATTGCTT CCTGCCTTAA TGATAATGCA AATGGATATT TCAGTGGACA CGTCATCCCT ;`
GCATGCAAGA ATTTAAGTCC AAGTGCTAAG CGAAAAGAAT CTAAATCCCA TAAACACCCA
AAAACTGTAA TGGTTGAAAA TATGCGAGCA TATGACAAGG GTAACAGAAC ACGCATATTG
TTGGGGTCGA GGCCTCCGAA TTGTACAAAC AAATGTCATG GTTGCAGTCC ATGTAAGGCC
¦ r ~
~;`` W O 94/llS12 214S7 1 ~ PCT/US93tll000 AAGTTAGTTA TTGTTCATCG TATTATGCCG CAGGAGTATT ATCCTCAGAG GTGGATATGC
AGCTGTCATG GCAAAATCTA CCATCCATAA ~ 3 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 1395 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
~5 TCTCGTCATG ATGCTATCAA CATCTTCAAT GTGGAAAAGT ATGGCGCAGT AGGCGATGGA
AAGCATGATT GCACTGAGGC ATTTTCAACA GCATGGCAAG CTGCATGCAA AAACCCATCA
GCAATGTTGC TTGTGCCAGG CAGCAAGAAA TTTGTTGTAA ACAATCTGTT CTTCAATGGG
CCATGTCAAC CTCACTTTAC TTTTAAGGTA GATGGGATAA TAGCTGCGTA CCAAAATCCA
GCGAGCTGGA AGAATAATAG AATATGGTTG CAGTTTGCTA AACTTACAGG TTTTACTCTA
ATGGGTAAAG GTGTAATTGA TGGGCAAGGA AAACAATGGT GGGCTGGCCA ATGTAAATGG
GTCAATGGAC GAGAAATTTG CAACGATCGT GATAGACCAA CAGCCATTAA ATTCGATTTT
TCCACGGGTC TGATAATCCA AGGACTGAAA CTAATGAACA GTCCCGAATT TCATTTAGTT :
TTTGGGAATT GTGAGGGAGT AAAAATCATC GGCATTAGTA TTACGGCACC GAGAGACAGT
CCTAACACTG ATGGAATTGA TATCTTTGCA TCTAAAAACT TTCACTTACA AAAGAACACG ;~
ATAGGAACAG GGGATGACTG CGTCGCTATA GGCACAGGGT CTTCTAATAT TGTGATTGAG
GATCTGATTT GCGGTCCAGG CCATGGAATA AGTATAGGAA GTCTTGGGAG GGAAAACTCT
AGAGCAGAGG TTTCATACGT GCACGTAAAT GGGGCTAAAT TCATAGACAC ACAAAATGGA
TTAAGAATCA AAACATGGCA GGGTGGTTCA GGCATGGCAA GCCATATAAT TTATGAGAAT
W0 94/11512 i~ 1 ~ 8 ~1 3 PCr/US93/11000 ~ :
GTTGAAATGA TAAATTCGGA GAACCCCATA TTAATAAATC AATTCTACTG CACTTCAGCT
TCTGCTTGCC AAAACCAGAG GTCTGCGGTT CAAATCCAAG ATGTGACATA CAAGAACATA ~ :~
CGTGGGACAT CAGCAACAGC AGCAGCAATT CAACTTAAGT GCAGTGACAG TATGCCCTGC
AAAGATATAA AGCTAAGTGA TATATCTTTG AAGCTTACCT CAGGGAAAAT TGCTTCCTGC
CTTAATGATA ATGCAAATGG ATATTTCAGT GGACACGTCA TCCCTGCATG CAAGAATTTA
AGTCCAAGTG CTAAGCGAAA AGAATCTAAA TCCCATAAAC ACCCAAAAAC TGTAATGGTT
GAAAATATGC GAGCATATGA CAAGGGTAAC AGAACACGCA TATTGTTGGG GTCGAGGCCT
CCGAATTGTA CAAACAAATG TCATGGTTGC AGTCCATGTA AGGCCAAGTT AGTTATTGTT
ATCTACCATC CATAA
.
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1479 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPO~OGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: :;
GAAGATCAAT CTGCCCAAAT TATGTTGGAC AGTGTTGTCG AAAAATATCT TAGATCGAAT
CGGAGTTTAA GAAAAGTTGA GCATTCTCGT CATGATGCTA TCAACATCTT CAATGTGGAA
AAGTATGGCG CAGTAGGCGA TGGAAAGCAT GATTGCACTG AGGCATTTTC AACAGCATGG `~
CAAGCTGCAT GCAAAAACCC ATCAGCAATG TTGCTTGTGC CAGGCAGCAA GAAATTTGTT
.GTAAACAATC TGTTCTTCAA TGGGCCATGT CAACCTCACT TTACTTTTAA GGTAGATGGG
ATAATAGCTG CGTACCAAAA TCCAGCGAGC TGGAAGAATA ATAGAATATG GTTGCAGTTT
GCTAAACTTA CAGGTTTTAC TCTAATGGGT AAAGGTGTAA TTGATGGGCA AGGAAAACAA : :
.... WO94/11512 214~71 3 PCT/US93/11000 TGGTGGGCTG GCCAATGTAA ATGGGTCAAT GGACGAGAAA TTTGCAACGA TCGTGATAGA
CCAACAGCCA TTAAATTCGA TTTTTCCACG GGTCTGATAA TCCAAGGACT GAAACTAATG
AACAGTCCCG AATTTCATTT AGTTTTTGGG AATTGTGAGG GAGTAAA~AT CATCGGCATT ' `
AGTATTACGG CACCGAGAGA CAGTCCTAAC ACTGATGGAA TTGATATCTT TGCATCTAAA
AACTTTCACT TACAAAAGAA CACGATAGGA ACAGGGGATG ACTGCGTCGC TATAGGCACA
GGGTCTTCTA ATATTGTGAT TGAGGATCTG ATTTGCGGTC CAGGCCATGG AATAAGTATA
GGAAGTCTTG GGAGGGAAAA CTCTAGAGCA GAGGTTTCAT ACGTGCACGT AAATGGGGCT
~0. 840 ` AAATTCATAG ACACACAAAA TGGATTAAGA ATCAAAACAT GGCAGGGTGG TTCAGGCATG
GCAAGCCATA TAATTTATGA GAATGTTGAA ATGATAAATT CGGAGAACCC CATATTAATA ~.
AATCAATTCT ACTGCACTTC AGCTTCTGCT TGCCAAAACC AGAGGTCTGC GGTTCAAATC
3o CAAGATGTGA CATACAAGAA CATACGTGGG ACATCAGCAA CAGCAGCAGC AATTCAACTT
AAGTGCAGTG ACAGTATGCC CTGCAAAGAT ATAAAGCTAA GTGATATATC TTTGAAGCTT ~.
~35 1140 .
ACCTCAGGGA AAATTGCTTC CTGCCTTAAT GATAATGCAA ATGGATATTT CAGTGGACAC ~
1200 .
GTCATCCCTG CATGCAAGAA TTTAAGTCCA AGTGCTAAGC GAAAAGAATC TAAATCCCAT
AAACACCCAA AAACTGTAAT GGTTGAAAAT ATGCGAGCAT~ATGACAAGGG TAACAGAACA
1320 ` ::
::
CGCATATTGT TGGGGTCGAG GCCTCCGAAT TGTACAAACA AATGTCATGG TTGCAGTCCA
TGTAAGGCCA AGTTAGTTAT TGTTCATCGT ATTATGCCGC AGGAGTATTA TCCTCAGAGG
TGGATATGCA GCTGTCATGG CAAAATCTAC CATCCATAA
~ `
~2) INFORMATION FOR SEQ ID NO:10:
~i) SEQUENCE CHARACTERISTICS: .
~A) LENGTH: 35 base pairs ~B) TYPE: nucleic acid ~-~C) STRANDEDNESS: single `~ .
~D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
`
W094/11512 2,~48rl 13 ~ PCr/US93/11000 ~- ~
~xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGGTCTAGAG GTACCGTCCG TCCGATCGAT CCATT
S
(2~ INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) ST ~NDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
AATGATCGAT GCT
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
RTAYTTYTCN ACRTTRAA
~2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
5~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
GGGTCTAGAG GTA
~ `
(2) INFORMATION FOR SEQ ID NO:14:
:
: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ~ W 0 94/11512 ~14~713 PCT/US93/llOOO
53 ~;
(v) FRAGMENT TYPE: internal ~xi) SEQUENCE DESCRIPTION: SEQ ID NO :14:
Phe Asn Val Glu Lys Tyr - ~10 (2) INFORMATION FOR SEQ ID NO:15:
~ i) SEQUENCE CHARACTERISTICS:
s-~ (A) LENGTH; 27 base pairs ~15 ~ TYPE: nucleic acid ~ (C) STRANDEDNESS: single `~: (D) TOPOLOGY: linear ii) MOLECULE TYPE: cDNA
~20 : ~
~xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
CCTGCAGTAY TTYTCNACRT TRAANAT
(2) ~INFORMATION FOR SEQ ID NO:16:
,30~ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
. ~
~40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
CCTGCAG
:~`45 ~ ~:
:: (2) INFORMATION FOR SEQ ID NO:17:
~ ~i) SEQUENCE CHARAcTERIsTIcs :~SO (A) LENGTH: 7 amino acids .
. (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ` (v) FRAGMENT TYPE: internal :~-:- ; ~ :.
~60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Ile Phe Asn Val Glu Lys Tyr 5 ~ ` ~
(2) INFORMATION FOR SEQ ID NO:18:
~`, ~ ' ;
.~ , .
W 0 94/1l512 pCT/US93/11000 .~
214~7~3 54 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH. 27 base pairs I -(B) TYPE: nucleic acid l:~
(C) STRANDEDNESS: single `:
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
CCTGCAGTAY TTYTCNACRT TRAADAT
(2) INFORMATION FOR SEQ ID NO:l9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MO~ECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
GCNATHAAYA THTTYAA
: 17 (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amlno acid (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
Ala Ile Asn Ile Phe Asn ~2) INFORMATION FOR SEQ ID NO:21:
(i) SEQOE NCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
WO 94/11512 2 1~ ~ 71 3 PCr/US93/11000 i`i GGAATTCCGC NATHAAYATH TTYAAYGT
~2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs ?
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GGAATTCC
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid ¦l ~ (D) TOPOLOGY: linear 3 (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Ala Ile Asn Ile Phe Asn Val (2) INFORMATION FOR SEQ ID NO:24:
~ (i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid . (C) STRANDEDNESS: single (D) TOPOLOGY linear ~ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
GCYTCNGTRC ARTCRTGYTT
3 20 ~i `3. ( 2) INFORMATION FOR SEQ ID NO:25: --1 60 (i) SEQUENCE CHARACTERISTICS: ~
' (A) LENGTH: 7 amino acids ~.
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide , ., Wo94/11512 21 ~713 PCr/US9~/11000 1`
(v) FRAGMENT TYPE: internal S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
Lys His Asp Cys Thr Glu Ala l 5 (2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: llnear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
~5 GGCTGCAGGT RCARTCRTGY TTNCCRTC
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs (B) TYPE: nucleic acid ~ (C) STRANDEDNESS: single ¦ 35 (D) TOPOLOGY: linear ¦ (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
GGCTGCAG
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide `
(v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Asp Gly Lys ~is Asp Cys Thr .
(2) INFORMATION FOR SEQ ID NO:29:
~W094/11512 2la~ 3 PCI/U593/1100 I
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid .
S (C) STRANDEDNESS: single (D~ TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
1:0 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
ATGTTGGACA GTGTTGTCGA A
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
,: :
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
~30: ~ :
GGGAATTCAG AA~AGTTGAG CATTCTCGT
~ (2) INFORMATION FOR SEQ ID NO:31:
j 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~:40 (D) TOPOLOGY: linear ~- (ii) MOLECULE TYPE: cDNA
~'-;
(xi) SEQOE NCE DESCRIPTION: SEQ ID NO:31:
GGGAATTC
.
, (2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs .
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~: (ii) MOLECULE TYPE: cDNA
' . 65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
W 0 94/11512 PC'r/US93/11000 ~
~ GTTCTTCAAT GGGCCATGT .
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS: ;~
(A) LENGTH: 20 base pairs - (B) TYPE: nucleic acid (C) STRANDEDNESS: single : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xl) SEQUENCE DESCRIPTION: SEQ ID NO:33:
GTGTTAGGAC TGTCTCTCGG
~2) INFORMATION FOR SEQ ID NO:34:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single :: (D) TOPOLOGY: linear ~: 30 (ii) MOLECULE TYPE: cDNA
~ .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
TGTCCAGGCC ATGGAATAAG
:
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE C~ARACTERISTICS:
(A) LENGTH: 20 base pairs , (B) TYPE: nucleic acid . (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~ 50 (ii) MOLECULE TYPE: cDNA
.~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
S5 i.
GCCTTACATG GACTGCAACC
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
-~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ~ 65 (D) TOPOLOGY: linear J.~
~' ~ ~ WOg4/11512 21~S~l~ Pcr/us93/llooo ~
(ii) MOLECULE TYPE cDNA
:' 5~ (xi) SEQUENCE DESCRIPTION SEQ ID NO 36 _ TCCACGGGTC TGATAATCCA
2~INFORMATION FOR SEQ ID NO 37 SEQUENCE CHARACTERISTICS
(A) LENGTH 20 base pairs (B)~TYPE nucleic acid 15~ (C) STRANDEDNESS single (D~TOPOLOGY linear ~ ( i i ? MOLECULE TYPE cDNA
(x~)~SEQOE NC~ DECCRIPTIO~ SEQ ID NO 37 ; AGGCAGGAAG CAATTTTCCC
~25~ 20 ~
21~NF M~TIGN FOR 53Q~ID NO~38 `(i3 SEQUENCE CHARACTERISTICS
(A) LENGTH `20 base pairs (B) TYPE ~nucleic acid (C) STRANDE NESS single ~5 ~ (D) TOPOLOGY~ linear ii) MOLECULE TYPE cDNA
(xi) SEQ OENCE DESCRIPTION SEQ ID NO 38 TACTGCACTT CAGCTTCTGC
f -''" , ~ ~ 20 ,-~45 2~INFORMATION FOR SEQ ID NO 39 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 20 base pairs ~50 (B) TYPE nuclelc acid }
(C) STRANDEDNESS single s ~ (D) TOPOLOGY linear ;~ (ii) MOLECULE TYPE cDNA
~55 ~ ;`
(xi) SEQUENCE DESCRIPTION SEQ ID NO 39 ~`-60 GGGGGTCTCC GAATTTATCA
(2) ~INFORMATION FOR SEQ ID NO 40 ~6S~ (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 20 base pairs 1` ~'-`
2 1 4 .3 7 1 3 WO 94/ 1 1 5 1 2 PCr/ ~IS93/ 1 1 000 1 . .
i~`
(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA . -(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
GGATATTTCA GTGGACACGT
(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2G base pairs ~B) TYPE: nucleic acid : (C) STRANDEDNESS: single (D) TOPOLOGY~ linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
. ~
¦ ~ 30 TATTAGAAGA CCCTGCGCCT
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid ¦ (C) STRANDEDNESS: single I (D) TOPOLOGY: linear ¦ (ii) MOLECULE TYPE: cDNA
1` .
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
CCATGTAAGG CCAAGTTAGT
(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single .
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
1, (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
: - ACACCTTTAC CCATTAGAGT
:
`~
;~ 214~713 1~
WO 94/1 1512 PCr/US93/1 1000 ~' 61 r ~: i (2) INFORM~TION FOR SEQ ID NO:44:
~ 5 (i) SEQUENCE CHARACTERISTICS:
`:~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single ` ~; (D) TOPOLOGY: linear `'` ~`'10 ~
ii) MOLECULE TYPE: cDNA
, ~
~:.15~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
CTGTCCAACA TAATTTGGGC
.: ~ 20 ~20 ~ :
(2) INFORMATION FOR SEQ ID NO:45:
~ (i) SEQUENCE CHARACTERISTICS:
;~ (A) LENGTH: 20 base pairs ~25 ~B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
CATGGCAGGG TGGTTCAGGC
~ ~ .
(2) INFORMATION FOR SEQ ID NO:46:
~ (i) SEQUENCE CHARACTERISTICS:
G~ : ~ (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid :: (C) STRANDEDNESS: single (D) TOPOLOGY: linear ~45 (ii) MOLECULE TYPE: cDNA
-50 ~xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
TAGCCCCATT TACGTGCACG
55~
~2) INFORMATION FOR SEQ ID NO:47: ` ~.
SEQUENCE CHARACTERISTICS:
:~60 ~A) LENGTH: 20 base pairs ~ B) TYPE: nucleic acid ~
: ~C) STRANDEDNESS: single (D) TOPOLOGY: linear , ~:65 (ii) MOLECULE TYPE: cDNA
:
~:
:
~ .
~;~: ....... .
W O 94J11512 PCTtUS93/11000 `~
4 8 7 1 3 62 11``
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
~: 5 TTGGGGTCGA GGCCTCCGAA
~ (2) INFORMATION FOR SEQ ID NO:48:
;~ 10 (i) SEQUENCE CXARACTERISTICS:
(A) LENGTH: 9 base pairs : (B) TYPE: nucleic acid (C) STRANDEDNESS: single : (D) TOPOLOGY: linear 1:5 (ii) MOLECULE TYPE: cDNA
t~ -~
.~ 20:~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
TAAAAUGGC
(2) INFORMATION FOR SEQ ID NO:49:
~: (i) SEQUENCE CHARACTERISTICS:
: (A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
;~35 ~ .
~:~ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
:
AACAAUGGC
: 40 9 (2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear . (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DE5CRIPTION: SEQ ID NO:50 GCCGAATTCA TGGCCATGAA ATTAATT
(2) INFORMATION FOR SEQ ID NO:51:
; (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 base pairs (B) TYPE: nucleic acid - (C) STRANDEDNESS: single ,~
2 .
WC~ 94/11512 214 8 713 PCI/US93/11000 Ir ~ `
(D) TOPOLOGY: linear ~ii) MOLECULE TYPE: cDNA
S ~ ~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5l:
GCCGAATTC t (2) INFORMATION FOR SEQ ID NO:52:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
CGGGGATCCT CATTATGGAT GGTAGAT
, ~2) INFORMATION FOR SEQ ID NO:53:
3 (i) SEQUENCE CHARACTERISTICS:
'35 ~A) LENGTH: 9 base pairs J (B) TYPE: nucleic acid ~C) STRANDEDNESS: single (D) TOPOLOGY: linear ~40 (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
~45 CGGGGATCC
~50 ( 2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid ~D) TOPOLOGY: linear ~.
(ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln ~1 t ~
WO 94111~12 21~ ~ 71 3 PCr/US93/11000 ~ ~
64 1.
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acld ~`
10(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGM$NT TYPE: internal 1~
(xi) SEQUENGE DESCRIPTION: SEQ ID NO:55:
Asn Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn
Claims (35)
1. A nucleic acid having a nucleotide sequence coding for a Japanese Cedar pollen allergen Cry j II, or at least one antigenic fragment thereof, or the functional equivalent of said nucleotide sequence.
2. A nucleic acid of claim 1 wherein said nucleotide sequence consists essentially of at least one fragment of the coding portion of the nucleotide sequence of Fig. 4 (SEQ ID NO: 1).
3. A nucleic acid of claim 2 wherein said fragment comprises bases 108 through 1586 (SEQ ID NO: 9) of the nucleotide sequence of Fig. 4 (SEQ ID NO: 1).
4. A nucleic acid of claim 1 wherein said nucleotide sequence consists essentially of the nucleotide sequence of Fig. 4 (SEQ ID NO: 1).
5. A nucleic acid of claim 1 wherein said fragment comprises bases selected from the group consisting of bases 177 through 1586 (SEQ ID NO: 7) of the nucleotide sequence of Fig. 4, and bases 192 through 1586 (SEQ ID NO: 8) of the nucleotide sequence of Fig. 4 (SEQ ID NO: 1).
6. An expression vector comprising a nucleotide sequence coding for a Japanese cedar pollen allergen Cry j II, or at least one antigenic fragment thereof, or the functional equivalent of said nucleotide sequence.
7. An expression vector of claim 6 wherein said nucleotide sequence consists essentially of at least one fragment of the coding portion of the nucleotide sequence of Fig. 4 (SEQ ID NO: 1).
8. An expression vector of claim 6 wherein said nucleotide sequence comprises bases 108 through 1586 (SEQ ID NO: 9) of the nucleotide sequence of Fig.
4.
4.
9. A host cell transformed to express a protein or peptide encoded by the nucleic acid of claim 1.
10. Isolated Cry j II protein, or at least one antigenic fragment thereof, produced in a host cell transformed with the nucleic acid of claim 1.
11. An antigenic fragment of claim 10 which does not bind immunoglobulin E
specific for a Japanese cedar pollen allergen, or if binding of said antigenic fragment to said immunoglobulin E occurs, such binding does not result in histamine release from mast cells or basophils.
specific for a Japanese cedar pollen allergen, or if binding of said antigenic fragment to said immunoglobulin E occurs, such binding does not result in histamine release from mast cells or basophils.
12. An antigenic fragment of claim 10 which binds immunoglobulin E to a substantially lesser extent than purified, native Cry j II protein binds said immunoglobulin E.
13. Isolated Cry j II protein of claim 10 wherein the host cell is E.coli.
14. A method of producing Cry j II protein, or at least one fragment thereof, comprising the steps of:
a. culturing a host cell transformed with a DNA sequence encoding Cry j II protein or fragment thereof, in an appropriate medium to produce a mixture of cells and medium containing Cry j II protein or at least one fragment thereof; and b. purifying said mixture to produce substantially pure Cry j II protein, or at least one fragment thereof.
a. culturing a host cell transformed with a DNA sequence encoding Cry j II protein or fragment thereof, in an appropriate medium to produce a mixture of cells and medium containing Cry j II protein or at least one fragment thereof; and b. purifying said mixture to produce substantially pure Cry j II protein, or at least one fragment thereof.
15. A protein preparation comprising Cry j II protein, or at least one fragmentthereof, synthesized in a host cell transformed with a nucleic acid comprising a nucleotide sequence encoding all or a portion of Cry j II.
16. A protein preparation of claim 15 wherein said at least one fragment of Cry j II is an antigenic fragment.
17. A protein preparation comprising chemically synthesized Cry j II protein, or at least one fragment thereof.
18. A protein preparation of claim 15 wherein said Cry j II protein comprises an amino acid sequence shown in Fig. 4 (SEQ ID NO: 2).
19. A protein preparation of claim 17 wherein said Cry j II protein comprises an amino acid sequence shown in Fig. 4 (SEQ ID NO: 2).
20. An isolated peptide comprising at least one T cell epitope of Cry j II.
21. An isolated peptide of claim 20 which as minimal immunoglobulin E
stimulating activity.
stimulating activity.
22. An isolated peptide of claim 20 which does not bind immunoglobulin E
specific for a Japanese cedar pollen allergen, or if binding of the peptide to said immunoglobulin E occurs, such binding does not result in histamine release from mast cells or basophils.
specific for a Japanese cedar pollen allergen, or if binding of the peptide to said immunoglobulin E occurs, such binding does not result in histamine release from mast cells or basophils.
23. An isolated peptide of claim 20 which binds immunoglobulin E to a substantially lesser extent than purified native Cry j II protein binds said immunoglobulin E.
24. Isolated Cry j II protein, or an antigenic fragment thereof, which modifies, in an individual sensitive to Japanese cedar pollen to whom it is administered, the allergic response of the individual to a Japanese cedar pollen allergen.
25. Isolated Cry j II protein or antigenic fragment of claim 24 which modifies B-cell response of the individual to a Japanese cedar pollen allergen, T-cell response of the individual to a Japanese cedar pollen allergen, or both the B-cell response and the T-cell response of the individual to a Japanese cedar pollen allergen.
26. Modified Cry j II protein or at least one modified fragment thereof, which when administered to an individual sensitive to Japanese cedar pollen, reduces the allergic response of the individual to Cry j II.
27. A therapeutic composition comprising isolated Cry j II protein, or at least one fragment thereof, and a pharmaceutically acceptable carrier or diluent.
28. A therapeutic composition of claim 27 wherein said Cry j II protein comprises an amino acid sequence shown in Fig. 4 (SEQ ID NO: 1).
29. A method of treating sensitivity to a Japanese cedar pollen allergen, or an allergen immunologically cross-reactive with a Japanese cedar pollen allergen, in an individual sensitive to said allergen, comprising administering to the individual a therapeutically effective amount of the composition of claim 27.
30. A method of detecting sensitivity in an individual to a Japanese cedar pollen allergen, comprising combining a blood sample obtained from the individual with isolated Cry j II protein, or antigenic fragment thereof, produced in a host cell transformed with the nucleic acid of claim 1 or chemically synthesized, under conditions appropriate for binding of blood components with the protein or fragment thereof, and determining the extent to which such binding occurs.
31. A method of claim 30 wherein the extent to which binding occurs is determined by assessing T cell function, T cell proliferation, B cell function, binding of the protein or fragment thereof to antibodies present in the blood or a combination thereof.
32. A monoclonal antibody, polyclonal antibody or immunoreactive fragment thereof, specifically reactive with Cry j II protein, or at least one antigenic fragment thereof.
33. Cry j II protein isolated from Japanese cedar pollen, said protein having a molecular weight of about 40 kD as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
34. A host cell transformed with a vector containing the cDNA insert of Cry j II, said host cell having ATCC deposit number 69105.
35. A recombinant DNA molecule comprising a DNA coding for a polypeptide having at least one epitope of the protein allergen, Cry j II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97517992A | 1992-11-12 | 1992-11-12 | |
US07/975,179 | 1992-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2148713A1 true CA2148713A1 (en) | 1994-05-26 |
Family
ID=25522765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002148713A Abandoned CA2148713A1 (en) | 1992-11-12 | 1993-11-12 | Allergenic proteins and peptides from japanese cedar pollen |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0669983A1 (en) |
JP (1) | JPH08505284A (en) |
AU (1) | AU5668194A (en) |
CA (1) | CA2148713A1 (en) |
NZ (1) | NZ258701A (en) |
WO (1) | WO1994011512A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4176820B2 (en) * | 1993-11-05 | 2008-11-05 | 明治乳業株式会社 | Cedar pollen allergen CryjII epitope |
JP3649460B2 (en) * | 1993-11-05 | 2005-05-18 | 明治乳業株式会社 | Japanese cedar pollen allergen Cry j II epitope |
EP0655500B1 (en) * | 1993-11-05 | 1999-05-12 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Allergenic polypeptide from Japanese cedar pollen and dna encoding it |
US6759234B1 (en) | 1994-09-02 | 2004-07-06 | Immulogic Pharmaceutical Corporation | Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response |
JPH10505356A (en) * | 1994-09-02 | 1998-05-26 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | Compositions and methods for administration to humans, peptides capable of down-regulating an antigen-specific immune response |
AU748104B2 (en) * | 1994-09-02 | 2002-05-30 | Merck Patent Gmbh | Peptide compositions capable of down regulating an antigen specific immune response |
TW438807B (en) * | 1994-09-10 | 2001-06-07 | Hayashibara Biochem Lab | Novel peptides containing T-cell epitope(s) of cedar pollen allergens, the processes therefor and the pharmaceutical uses thereof |
KR100487456B1 (en) * | 1996-03-10 | 2005-11-25 | 메이지 데어리즈 코포레이션 | Peptide-Base Immunotherapeutic Agent for Allergic Diseases |
ATE412175T1 (en) | 1996-03-21 | 2008-11-15 | Circassia Ltd | USE OF CRYPTIC PEPTIDES TO INDUCE IMMUNOLOGICAL TOLERANCE |
US7112329B1 (en) | 1996-06-14 | 2006-09-26 | Meiji Milk Products Co. Ltd. | T cell epitope peptide |
JP4176750B2 (en) * | 1996-06-14 | 2008-11-05 | 明治乳業株式会社 | T cell epitope peptide |
DE19957904A1 (en) * | 1999-12-01 | 2001-06-07 | Merck Patent Gmbh | Insect venom allergens with reduced IgE reactivity and process for their preparation |
WO2011052697A1 (en) | 2009-10-30 | 2011-05-05 | 日本製紙株式会社 | Protein having cedar pollen immunogenicity, polynucleotide for coding for said protein, and uses of said protein and polynucleotide |
PL2861240T3 (en) | 2012-06-15 | 2021-07-05 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2838800B2 (en) * | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | Desensitizer |
AU659609B2 (en) * | 1990-08-13 | 1995-05-25 | Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. | Birch pollen allergen P14 for diagnosis and therapy of allergic diseases |
-
1993
- 1993-11-12 JP JP6512408A patent/JPH08505284A/en active Pending
- 1993-11-12 EP EP94902242A patent/EP0669983A1/en not_active Withdrawn
- 1993-11-12 WO PCT/US1993/011000 patent/WO1994011512A2/en not_active Application Discontinuation
- 1993-11-12 CA CA002148713A patent/CA2148713A1/en not_active Abandoned
- 1993-11-12 AU AU56681/94A patent/AU5668194A/en not_active Abandoned
- 1993-11-12 NZ NZ258701A patent/NZ258701A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1994011512A3 (en) | 1994-07-07 |
EP0669983A1 (en) | 1995-09-06 |
AU5668194A (en) | 1994-06-08 |
NZ258701A (en) | 1996-11-26 |
JPH08505284A (en) | 1996-06-11 |
WO1994011512A2 (en) | 1994-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU678412B2 (en) | Allergenic proteins and peptides from Johnson grass pollen | |
WO1994001560A1 (en) | Allergenic proteins and peptides from japanese cedar pollen | |
JP3575802B2 (en) | Allergenic proteins and peptides from Japanese cedar pollen | |
CA2148713A1 (en) | Allergenic proteins and peptides from japanese cedar pollen | |
WO1994011512A9 (en) | Allergenic proteins and peptides from japanese cedar pollen | |
NZ263913A (en) | Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use | |
US5710126A (en) | T cell epitopes of ryegrass pollen allergen | |
US6982326B1 (en) | Allergenic proteins and peptides from Japanese cedar pollen | |
JP4102432B2 (en) | Allergenic proteins and peptides derived from cedar pollen | |
EP0714440A1 (en) | T cell epitopes of ryegrass pollen allergen | |
ES2260760T3 (en) | NUCLEIC ACIDS THAT CODIFY AN ALLERGEN CONTAINED IN DOMESTIC POWDER ACAROS (DER P III), AND ITS USES. | |
US6090386A (en) | T cell peptides of the CRX JII allergen | |
US6214358B1 (en) | Protein allergens of the species Cynodon dactylon | |
US7514083B1 (en) | Protein allergens of the species cynodon dactylon | |
WO1992016554A1 (en) | Protein allergens of the species cynodon dactylon | |
AU3438493A (en) | Allergenic proteins and peptides from japanese cedar pollen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |